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GENERAL INTRODUCTION 
Introduction to malaria 
From time immemorial malaria has been one of the most prevalent of hu-
man diseases, affecting particularly the population of tropical regions but also in 
the past those of temperate climates. Inspite of decades of efforts at its control, 
malaria continues to rank as one of the foremost infectious global diseases. Over 
two billion people, half of the world's population, are exposed to the risk of the 
disease and about 270 million acquire new infections each year (Peters 1990a). 
According to World Health Organization (WHO) malaria kills every year between 
1.4 to 2.8 million people, mostly children in Africa (TDR news 1994 ). 
Causative agent 
Malaria is caused by a protozoan parasite of genus Plasmodium. The genus 
belongs to phylum Apicomplexa (formerly Sporozoa), of the animal subkingdom 
Protozoa (Mehlhorn and Walldorf 1988). All members of the phylum are parasitic. 
Plasmodium species exhibit two types of schizogony (asexual multiplication), an 
exoerythrocytic schizogony without pigment formation and an erythrocytic 
schizogony with pigment formation, in the chordate host and a sexual stage termi-
nating in sporogony in the female mosquito host. They are found infecting mam-
mals, particularly primates and rodents, birds and reptiles. Systematic position 
of malaria parasites is as follows: 
Phylum Apicomplexa 
Class Sporozoea 
Subclass Coccidia 
Order Haemosporida 
Suborder Aconoidina 
Family Haemosporidae 
Genus Plasmodium 
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with increase in parasitemia with each cycle, until it is impeded by drugs or the 
host defence mechanisms. The gametocytes persist in the circulation for a limited 
period of days and degenerate, if not picked up by an appropriate mosquito species 
for their further development in the gut of the new host. After arrival in the 
midgut of the mosquito the mature viable male gametocyte (microgametocyte) 
undergoes an explosive transformation called exflagellation which gives rise to 8 
motile microgametes. The microgametes set themselves free in search of a female 
gamete (macrogamete), one arising out of each mature viable macrogametocyte. 
Fusion of a micro and a macrogamete in the midgut of mosquito results in the 
formation of diploid zygote. This stage transforms into an actively moving form 
called ookinete stage and penetrates the midgut wall. The successful ookinete 
lodge themselves inside the wall and round themselves up to transform into oo-
cysts. Meanwhile reduction division has occurred following recombination and 
haploid genome is restored. The oocyst undergoes repeated mitotic divisions fol-
lowed by development and differentiation and release of thousands of infective 
sporozoites into the hemolymph of the mosquito. These sporozoites find their way 
into salivary glands of the host and are ready for initiating a new infection during 
the next bite of the vertebrate host. 
Rodent malaria parasite 
The first isolation of rodent malarial parasite was reported by Vincke and 
Lips (1948) from the African tree rat, Thamnomys surdartes and was named Plas-
modium berghei. Since then numerous species and subspecies of rodent malaria 
have been discovered and described. They have been divided into two main series, 
the berghei group, consisting of P. berghei, P. yoelii and P. y. nigeriensis and other 
subspecies and the vinckei group consisting of P uinckei and P. chabaudi, which 
also have several subspecies. About two hundred different strains of P. berghei 
have been isolated from various rodent or from the natural vectors. P. berghei has 
superseded the bird malarias, P. lophurae and P gallinaceum, in the utility for 
experimental work on parasitism, immunology and chemotherapy of malaria. 
Dozens of papers on these various subjects are being published every year point-
ing out the importance of rodent malaria in scientific research and most of the 
primary screening of some 300,000 compounds developed during the past ten years 
was performed using rodent Plasmodium (Landau and Boulard 1978). 
Human malaria parasite 
P. falciparum, P. vivax, P. malariae and P. ovale are the four species of ma-
laria parasite known to infect humans. Different species predominate in different 
geographic regions, although transmission patterns can change with time. For 
example, P. vivax was (and remains) the major species transmitted in parts of 
India, but in recent years there has been resurgence off! falciparum transmission 
in these areas. In Africa, P. falciparum predominates and P. vivax is virtually 
absent (most Africans lack the complement of Duffy blood group substances that 
define susceptibility to this parasite species) (Miller et al. 1976). P. malariae the 
second most common species in Africa is also distributed in other geographic re-
gions. P. ovale is the least common species in Africa. 
Disease symptoms and pathogenicity 
Malarial paroxysms generally develop within a few days of inoculation of 
infective sporozoites. They consist typically of sequential chills, fever and sweat-
ing, sever headache, abdominal pain, nausea and vomiting. Attacks coincide with 
parasite multiplication in the red blood cells. As the parasite population in the 
blood increases, the symptoms intensify, subsiding only when infection is termi-
nated by appropriate drug treatment or controlled by the host's immune system. 
Falciparum malaria is the most dangerous form of the disease. Two important 
biological features have been identified and implicated for its lethal potential. 
First, asexual blood stage parasites can infect and develop in erythrocytes of all 
ages, so there is no intrinsic limit on the potential magnitude of the parasitemia 
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(Wyler 1993). High parasi temia results in severe hemolysis and its a t tendant 
complications. In contrast, P. uivax and P. ovale can develop only in young eryth-
rocytes (Pasvol and Wilson 1982), thus placing a relatively a strict limit on the 
maximal magni tude of the parasi temia. P. malariae is also restricted to a sub-
population of erythrocytes, probably older ones (Pasvol and Wilson 1982). An-
other distinctive feature of P. falciparum is tha t electron dense extruberances, 
called knobs, develop on the surface of erythrocytes containing ma tu re trophozoi-
tes or schizonts (Langreth et al. 1978). These knobs mediate binding of the in-
fected cells to post capillary venules, where the parasi tes undergo their terminal 
matura t ion (called deep-vascular schizogony) and where the rup tu re of schizont 
infected cells finally occurs. As a result of this sequestration, ma tu re intraeryth-
rocytic forms are rarely detected in blood smears of pat ients with falciparum ma-
laria. The combination of severe anemia (due to hemolysis of large number of 
infected erythrocytes) and microvascular congestion tha t resul ts from deep vascu-
lar schizogony gives rise to tissue hypoxia and subsequently organ dysfunction; 
the brain, kidneys and lungs are particularly susceptible. Although vivax, ovale 
and malar iae infections are not generally life threatening, they can sometimes 
cause severe, acute illness. 
D i a g n o s i s and d e t e c t i o n of malar ia paras i te 
Malar ia diagnosis is confirmed by the detection of the causative agent in 
the blood of an infected individual. Microscopic detection of the paras i te has been 
the mains tay of diagnosis in epidemiological surveys. The method is sensitive 
enough to detect a parasi temia as low as 0.002% in a thick film using as little as 
0.2 to 0.5 vil of blood (Bruce-Chwatt and Zuluera 1980). Even 20 to 40 parasi tes 
^1 of the blood can be detected (on an average 1 ^1 of blood contains over five 
million cells). For the detection of an individual case of malar ia the amount of 
information obtainable by conventional light microscopy is remarkable . It allows 
simultaneous identification of the plasmodial species and the stage of the parasi te 
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(Field et al. 1963). It also permits rapid estimation of the level of parasitemia, an 
assessment of the degree of concomitant anemia and the presence of other blood 
parasites- all within less than 30 minutes, including staining time. However, this 
technique requires competent, committed and conscientious microscopist for cor-
rect diagnosis. It has often been the experience of may malariologists that due to 
human error quite a few cases are erroneously diagnosed, this being more so dur-
ing peak malaria season and specially during the epidemiological surveys. This 
shortcoming in the use of simple, inexpensive microscopic method calls for alter-
nate approaches for detection of malaria which not only take care of this problem 
but could also tell the susceptibility status of the parasite to the antimalarial drugs. 
Utility of various serological and immunodiagnostic methods has been explored 
but they have proved to be of limited value as the detection is possible only if the 
immune response has risen to a certain level. Also sometimes it is difficult to 
differentiate between past and present infections (Bruce-Chwatt 1987). Another 
promising approach being pursued to diagnose malaria is based on the use of nucleic 
acid probes. Identification of unique characteristic nucleic acid sequences in the 
genome of parasite species and presence of these sequences in the blood samples is 
determined using complementary nucleic acid sequences, tagged either with ra-
diolabeled or non-radiolabeled compounds, as probes. Hybridization of these probes 
to the corresponding sequence of the pathogen is monitored by the signals emitted 
by the linked tags. This is a highly specific and sensitive method. This technique, 
involving synthetic oligonucleotide probes, has been successfully employed in field 
conditions in Kenya where parasitemia of 0.002% of infected erythrocytes could be 
detected in 1 ^1 of blood sample (McLaughlin et al. 1987). Most of the work on 
probe developments has been on P. falciparum. Recently Snounou et al. (1993) 
have reported the use of polymerase chain reaction (PCR) for the identification of 
the four human malaria parasite species. They used synthetic oligonucleotide 
primer pairs which were complementary to genus and species specific sequences 
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present within the small subunit ribosomal RNA genes of the four human malaria 
parasites, for the specific amplification by PCR to detect each malaria species. 
Thus the present methods of malaria parasite detection range from microscopic 
examination of blood smears, immunodiagnostic/serological approaches, DNA 
based probe hybridization to in vitro amplification of specific nucleic acid sequences 
of the pathogen. Of these, light microscopic method is the most popular and will 
continue to play an important role in confirming the malaria diagnosis even in 
near future for its sensitivity and simplicity. However, there exists a lot of scope 
for future improvements in the detection techniques. 
Malaria control 
It is certainly frustrating to observe that inspite of considerable invest-
ments in term of human efforts and money spent during the last two decades or so, 
no effective useful vaccine against human malaria has emerged and its control 
still depends on breaking any of the several links in the chain of parasite develop-
ment through man and mosquito. Vector control and chemotherapy are the two 
most important tools to control malaria. 
Vector control 
Human malaria is transmitted by various species of Anopheles mosquito. 
Malaria transmission occurs in sub-Saharan Africa, parts of Asia, many countries 
in Latin America and small transmission foci also exist in Greece, Turkey and the 
Middle East (Wyler 1993). It is well known that epidemiology of malaria in any 
region is influenced by the geographical, climatological conditions, type of vector 
species- its bionomics, flight range, density etc., strains of parasites and immuno-
logical status of the human population. Malaria, therefore, is acknowledged as an 
exclusively local phenomenon and any control programme has to be meticulously 
designed depending upon the local situation and available resources. Early at-
tempts to control malaria vectors were directed at the immature aquatic stages in 
their breeding places and involved either the use of larvicides or aimed at source 
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reduction. It might be a method of choice in some urban areas where houses may 
outnumber the breeding places but in most rural areas where the number of breed-
ing places is astronomical this is a difficult approach (Davidson 1982). Then came 
the concept of shortening the lifespan of adult mosquito to prevent the completion 
of the extrinsic cycle of the malaria parasite. By spraying the resting places of 
female mosquitoes with the residual insecticides dramatic results were achieved 
in curtailing malaria transmission in early days of malaria eradication programme 
(WHO 1971). Unfortunately, with the appearance of resistance to hydrochlorine 
insecticides and the concern voiced by the environmentalists, the necessary switch 
to use less persistent and more expensive insecticide has been forced in several 
parts of the world. This also means that the future vector control must not solely 
rely on insecticides but should always be integrated with environmental, biologi-
cal, educational and genetic methods. 
Chemotherapy 
Antimalarial drugs are employed both for curative and preventive purposes 
(WHO, 1990). The use of drugs for prevention of diseases or protection from ma-
laria is referred to as chemoprophylaxis or chemoprevention. Antifolic drugs such 
as pyrimethamine and proguanil are essentially prophylactic drugs that prevent 
the maturation of the pre-erythrocytic forms developing in hepatocytes from the 
sporozoites. Primaquine is more lethal to pre-erythrocytic stages of malaria para-
sites. Most of the therapeutic antimalarial drugs used are curative or suppressive 
due to their blood schizontocidal properties. Quinine, a natural compound and 
chloroquine, a synthetic affordable drug are the two most popular schizontocides 
which had been given spectacular curative results. But in 1960 a new and threat-
ening event occurred in the history of chemotherapy with the emergence of strains 
of P. falciparum resistant to the most widely used antimalarial therapeutic drug 
chloroquine (Maberti 1960). The menace of resistance to chloroquine is now wide-
spread. It is a cause of concern as more and more strains of parasites from differ-
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ent par t s of the world are being reported to be resis tant not only to chloroquine 
but also to some other antimalarial drugs (Peters 1989). Appearance of these polyre-
sis tant s t ra ins of malar ia parasi tes has created an increasing clinical problem 
especially in t rea tment of P. falciparum in several par ts of the world. At one time 
it was confidently presumed tha t the disease will be subjugated with accumulated 
weaponry against malaria, but experience has shown how sadly misplaced the 
judgement was. Today the existence of resistance in mosquitoes to insecticides 
and emergence of drug resistance in the parasi tes portray a grim scenario for fu-
ture management unless new, effective tools are invented to combat the menace. 
OUTLINE OF THIS STUDY 
The search for antimalarial drugs, both na tura l and synthetic, has been 
and continues to be the most challenging and, at times, rewarding exercises ever 
under taken by biologists and chemists. While most people engaged in the search 
for new drugs agree tha t a rational approach based on knowledge of the int imate 
biochemical pa thways of the target cells would be ideal as well intellectually sat-
isfying, hiost are reluctantly obliged to concede tha t up to present time, the chances 
of success following a more or less empirical search have been far greater. Spec-
tacular advances in molecular biology and biochemistry in recent years , however, 
are rapidly changing this situation. New techniques for the study of the biology of 
malar ia parasi t ism and for the cultivation of both intraerythrocytic and tissue 
stages o^ Plasmodium have opened up new avenues, not only for such fundamen-
tal studies but also for drug screening in vitro, the investigation of the modes of 
action of ant imalar ia l drugs and the mechanisms of drug resistance. It is hoped, 
therefore, the future research on antimalarial chemotherapy will hinge more on 
int imate knowledge of the basic biology of the target organism and less on 'ran-
dom' screening. In the present study basically we have evaluated erythrocytic 
schizontocidal properties of some natura l and synthetic compounds, a series of 
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progressively resistant P. falciparum lines to dihydrofolate reductase (DHFR) in-
hibitors have been selected in vitro and mutation-specific diagnostic primers have 
been successfully used to discriminate the resistant and sensitive parasites by 
polymerase chain reaction (PCR). 
In the present work a local Plasmodium falciparum isolate together vi^ ith 
one of its fastest multiplying clones have been used for studies in vitro and for in 
vivo experiments a strain of P. berghei has been employed. Chapter 1 contains a 
mini review on the antimalarial drugs, their known modes of action and mecha-
nisms of drug resistance with emphasis on antifols and chloroquine. 
The characterization of erythrocytic stages of P. falciparum parasites with 
regard to their susceptibility profile in vitro to some known natural antimalarial 
drugs (quinine and artemisinin) and commonly used synthetic drugs (chloroquine, 
amodiaquine, pyrimethamine and cycloguaniljagainst malaria has been described 
in Chapter 2. P falciparum parasites have been found to be resistant to chloro-
quine and sensitive to all other natural and synthetic drugs evaluated. 
In vitro relative chemosensitivity of erythrocytic stages of the chloroquine 
resistant P/aZciparam isolate to quinine-type compounds has been given in Chap-
ter 3. Apart from natural cinchona alkaloids, quinine and quinidine, their hydro-
gen derivatives proved to be more potent erythrocytic schizontocidal compounds. 
Some drug combinations show extremely good antimalarial property in vitro. Go-
ing by the 10^^ values of the eight preparations tested the compounds can be ar-
ranged in following order with respect to their schizontocidal activity: 
quinidine/hydroquinidine > hydroquinidine > quinine/hydroquinine > quinidine 
> hydroquinine/quinine > apoquinine > epiquinine. 
Clearly in depth investigations are required for exploiting the full antimalarial 
potentials of these cinchona derivatives or mixtures and other combinations. 
Antiplasmodium properties of cisplatin (cis-platinum (II) diammine-dichloride), 
a neoplastic drug, have been assessed using in vivo and in vitro model systems of 
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malarial parasite (Chapter 4). A well tolerated dose of 6 mg/kg body weight of the 
compound cured the mice infected with P. berghei and the amount of cisplatin re-
quired for in vitro inhibition (IC^^) of a chloroquine resistant falciparum isolate was 
lower than either chloroquine or quinine. Minimum inhibitory concentration (MIC) 
needed to prevent the multiplication of asexual blood parasites in vitro was 30 ng/ml. 
Late ring and trophozoite stages of erythrocytic cycle were most susceptible whereas 
schizont and early ring stages were least sensitive to the toxic effect of cisplatin. Smaller 
multiple doses had been the most effective in curing malaria in mice than a single 
large dose. In a few cases, mice treated with a single intraperitoneal large dose of 6 
mg/kg body weight, there was a delay in appearance of parasitemia but most of them 
recovered completely although slowly. This compound exerts its toxicity mainly by 
randomly damaging and cross-linking DNA strands as has been shown by Southern 
hybridization using a synthetic oligonucleotide probe, which is a repeat sequence in 
the falciparum genome. The report clearly demonstrates the antimalarial potentials 
of this compound and suggests a closer evaluation of this and other related compounds, 
specially in combination with antimalarial drugs to probe their synergistic proper-
ties. 
Proguanil and pyrimethamine exhibit their antimalarial virtues by prefer-
entially inhibiting the DHFR enzyme of parasites. Pyrimethamine has been de-
ployed on a much larger scale than proguanil. These drugs have been extremely 
useful in treatment of chloroquine resistant falciparum infection but the limiting 
factor has been the quick development of resistance among the parasite popula-
tion against these drugs. Pyrimethamine resistance is known to be widely distrib-
uted in all malaria endemic areas of the globe, including India. Proguanil has not 
been (extensively) used in India for over fifty years now. It should, therefore, be of 
interest to know the susceptibility of pyrimethamine resistant and sensitive lines 
of Indian origin to cycloguanil (the active metabolite of proguanil). These consid-
erations prompted us to perform a series of experiments with a view to assess the 
potential usefulness of cycloguanil in circumventing and combating the problem 
of pyrimethamine resistance in falciparum, which are presented in Chapter 5. It 
has been found that falciparum lines resistant to pyrimethamine are selected much 
faster than for cycloguanil resistance. Highly resistant pyrimethamine lines are 
predisposed for faster selection to cycloguanil resistance. Resistance acquired to 
pyrimethamine is stable. Pyrimethamine resistant parasites acquire a degree of 
cross resistance to cycloguanil and to another DHFR inhibitor, methotrexate but 
do not show any cross resistance to other groups of antimalarial drugs. Cyclogua-
nil and pyrimethamine induce the formation of gametocytes in non-gametocyte 
forming clone. There has been no synergistic activity observed between cyclogua-
nil and pyrimethamine. The deployment of triple drug combination of py-
rimethamine, cycloguanil and sulfadoxine to impede the spread of resistance should 
be seriously considered. 
Characterization of pyrimethamine resistant P. falciparum lines with a re-
petitive oligonucleotide probe and detection of pyrimethamine resistance using 
mutation-specific polymerase chain reaction has been presented in Chapter 6. In 
vitro test methods have widely been employed for determining the drug sensitiv-
ity of P. falciparum isolates but there are several limitations that affect their use-
fulness in early diagnosis of resistant falciparum infection. Resistance in P. falci-
parum, to pyrimethamine and cycloguanil is known to be caused by point 
mutation(s) in the DHFR encoding sequence of the parasite genome. Feasibility 
of alternate assay methods for diagnosis of resistance to DHFR inhibitors based 
on genetic characterization and alterations has been explored. Restriction frag-
ment length poljunorphism (RFLP) and Southern hybridization with 21-oligomer 
probe, complementary to a repeat sequence existing in falciparum genome have 
been successfully applied to demonstrate the ability of this approach to detect 
prominent genetic alterations in the genome of highly resistant parasite DNA di-
gested with Taq I or Alu I restriction enzymes. This probe shows that Hind III 
13 
restriction sites remain unaffected in pyrimethamine resistant lines. The RFLP 
studies clearly indicate that pyrimethamine causes point mutations in genome of 
the resistant falciparum parasites at places other than the DHFR encoding re-
gion. Low levels of resistance to pyrimethamine escape detection by this tech-
nique. This approach can be used to discriminate highly resistant and sensitive 
parasites but because of certain inherent shortcomings of Southern hybridization 
this method might not be employed for diagnosis of resistance. Polymerase chain 
reaction method has been explored to determine if mutation-specific primers can 
be used to diagnose pyrimethamine resistant parasites. Using the recent guide-
lines (Mullis 1994) for primer selection and consulting the falciparum DHFR gene 
sequence obtained from the databank (UNDPAVorld Bank/WHO/TDR), the selected 
primers have been optimized for the most stringent annealing temperature which 
could be employed for effective amplification and detection of pyrimethamine re-
sistance. These initial precautions led us to discriminate the sensitive and resis-
tant P. falciparum cell lines using the counter primer and the two diagnostic prim-
ers employed without compromising the sensitivity of the technique. 
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Chapter 1 
ANTIMALARIAL DRUGS, THEIR KNOWN MODE OF ACTIONS AND 
MECHANISMS OF DRUG RESISTANCE - A BRIEF REVIEW 
Abstract- Brief historical review of antimalarial drug development and deployment shows tJtat en masse drug 
deployment for chemoprophylaxis and monotherapy inevitably results in quick selection of drug resistance in 
Plasmodia. Drug combiruitions survive longer. The chemical structure, biological activity and mode of action of 
important antimalarials of the century have been discussed. Mechanisms by which parasites become resistant to 
dihydrofolate reductase (DHFR) inhibitors have been identified to specific point mutations in the DHFR 
gene of the parasite, thus altering the structure of the enzyme which avoids affinity binding of the drug. 
Advent of resistance to chloroquine, the most affordable low cost drug, is a cause of concern. Our inadequate 
knowledge about the subject is updated and highlighted for inclusion in future research agenda among other 
listed priorities. Old remedies like 'qinghaosu', quinine and other cinchona alkaloids have brought new hopes for 
the time being. 
INTRODUCTION 
Around the turn of this century, malariology enjoyed certain vogue, in-
spired largely by : a) the interest of colonial powers in places where malaria was 
rampant; b) the explorative expeditions to the tropical locations of the developing 
world; and c) the exciting discoveries of Ross, Ehrlich and others. The popularity 
and excitement in the study of malaria subsided for next few decades in favour of 
prokaryotic infectious diseases. Short supply of the main antimalarial drug of the 
time, quinine, was experienced during the two World Wars by the developed coun-
tries. This shortage in the meanwhile had instigated the efforts in malaria re-
search leading, immediately after the Second World War, to two dazzling events 
which were to determine and dominate malarial strategy for next few decades. 
The first was the success of the residual insecticides in dramatically curtailing 
transmission of malaria in many countries and the second was the development of 
more than one synthetic antimalarial drugs which became available in rapid suc-
cession. Never before had man stockpiled such powerful arsenals to rid himself of 
malaria malady, so old an adversary. This led enthusiastically in 1955 to launch-
ing of malaria eradication programmes globally by the World Health Organization 
(WHO), one of the largest international efforts to improve the health in the devel-
oping world, but the initial enthusiasm slowly faded due to several technical as 
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well as socio-economic factors and this venture finally ended in 1970 when WHO 
decided to 'throw in the towel'. During this period support for further research 
into malaria had dried up throughout the world. In the meantime casualties in-
flicted to the U.S. forces in Vietnam War by drug-resistant parasites prompted the 
developed world to know more about the cure and prevention of malaria. This not 
only revived but intensified research and funding into several aspects of biology 
of parasitism of Plasmodium (causative agent of malaria) including molecular 
biology, immunology, vaccinology and chemotherapy. The sudden surge of research 
activity on Plasmodia demanded ever increasing supplies of the parasite mate-
rial, infecting man in particular, thus stressing an urgent need to tame the para-
sites in vitro. In 1976 Professor William Trager reported (Trager and Jensen 
1976) the first successful continuous cultivation of erythrocytic stages of P. falci-
parum (causing malignant tertian human malaria) and this salutary breakthrough 
stimulated further research activity related to malaria parasites. It also provided 
a fresh impetus to monitoring of the emergence and spread of drug resistance in 
falciparum throughout the world. This article discusses the basic structure and 
biological activity of important antimalarial drugs used in the current century 
with special emphasis to chloroquine and DHFR inhibitors, their modes of action 
and mechanisms of resistance, analysis the causes leading to speedy selection of 
resistant parasites, suggests measures to impede the spread of resistance and 
future research strategies for development of new antimalarial drugs. 
Basic Chemical Structure of Antimalarials 
Known antimalarials have been variously grouped. They may be classified 
based on the following basic chemical structures (Figure 1.1): 
Pyrimidine derivatives: The amino groups at the 2 and 4 positions of the pyrimi-
dine forms the basis of synthetic antimalarials like pyrimethamine and other less 
popular compounds. 
Quinoline derivatives: Fusion of a pyridine and a benzene ring gives rise to a 
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bicyclic quinoline ring. It forms the basis of a number of synthetic antimalarial 
compounds which are derivatives of the 4 or the 8 amino substituted quinoline. 
Chloroquine, a 4-aminoquinoline and primaquine, a 8-aminoquinoline are the two 
well known examples. Some of the natural cinchona alkaloids also have quinoline 
in their structure, quinine for instance is formed by complex substitution at the 4 
position of the quinoline ring. 
Acridine derivatives: Acridine is a polycyclic compound formed by the fusion of 
two benzene rings and pyridine. Mepacrine is an antimalarial drug which is a 9-
amino acridine derivative belonging to this group. It is largely obsolete as an 
antimalarial for causing coloration of the skin and transient mental disturbances. 
Non-cyclic derivatives: A few groups of antimalarials posses non-cyclic basic struc-
ture and substitution at some positions with benzene ring derivatives. They are 
the biguanide and the sulfa compounds. The sulfa compounds may further be 
grouped into sulfones and sulfonamides. Proguanil is an antimalarial drug de-
rived from biguanide. Sulfadoxine and dapsone are the derivatives obtained from 
the modification of sulfonamide and sulfone, respectively. 
Basic Biological Activity of Antimalarials 
Antimalarial drugs can also be classified based on their predominant site of 
action on the particular stage(s) in the life cycle of malarial parasite. There are 
four species of Plasmodium {P. falciparum, P. vivax, P. ovale and P. malariae) usu-
ally known to infect man. Malaria results when the infective stages of the para-
site are injected into the bloodstream of man by an infected female Anopheles 
mosquito. The sporozoites immediately take shelter within hepatocytes of the 
host for further development. Maturation of all these intracellular protozoan 
parasites finally results in the release of pre-erythrocytic merozoites, almost si-
multaneously in P. falciparum and P. malariae, whereas in P. vivax and P. ovale 
some of the liver stage parasites may remain dormant for variable duration , for 
17 
months or years. These dormant stages are called hypnozoites, subsequently 
blossoming into pre-erythrocytic merozoites, causing relapse of malaria . The 
drugs which prevent the maturation of pre-erythrocytic stages are called tissue 
schizonticides and those acting on the hypnozoites are known as anti-relapse drugs. 
The pre-erythrocytic merozoites invade the red cells leading to the formation of 
daughter merozoites, by schizogony (asexual division), which on release invade 
the uninfected erythrocytes. The pathogenicity of malaria is chiefly due to syn-
chronized burst of erythrocytic schizonts leading to malaria symptoms, namely 
fever, shivering, hemolytic anemia and sometimes (in infection with P. falciparum) 
to cerebral malaria and death. Blood schizontocides are toxic or lethal to intraeryth-
rocytic parasites and thus releive the host of malaria symptoms. Some of the 
merozoites on entering the erythrocytes start differentiating into the gametocytes 
(sexual forms) instead of undergoing usual asexual multiplication. The mature 
gametocytes will develop further only in the female Anopheles. The drugs which 
prevent the formation or differentiation of sexual forms are termed as gametocyto-
cidal drugs, Male and female gametocytes form respective gametes which fertil-
ize in the stomach of the insect vector to form the diploid zygote. The zygote 
continues its sporogonic development from oocyst to sporozoites. The compounds 
interfering with the sporogonic cycle are recognized as sporontocidal compounds, 
thus preventing the transmission of malaria. They have also been called anti-
sporogonic chemicals. 
Mechanisms of Action and Resistance 
The main technical reasons for the failure of malaria eradication programme 
had been the development of resistance (exophilly) to residual insecticides by 
insect vectors and the emergence of drug resistance in parasites to the antima-
larials. Improvements in malaria chemotherapy should result from better under-
standing of the mechanisms that govern drug action and drug resistance. The two 
criterions of chemical structure and biological activity of antimalarials on plasmo-
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dia have been clubbed for convenience to discuss some of the known modes of 
action and resistance to antimalarial drugs. 
1. Folate Pathway Blockers 
A Mode of Action: Folate pathway blockers includes the antimetabolite drugs 
which interfere with folic acid cycle of the parasite, in one way or the other. Re-
duced folic acid derivatives are indispensable cofactors for de novo synthesis of 
pyrimidines in plasmodia. In the absence of any salvage pathway for the utiliza-
tion of exogenous pyrimidines, depletion in the pool of reduced folic acid deriva-
tives in the parasite milieu results in blocking of Plasmodium multiplication. 
The folate pathway blocker antimalarial drugs can be grouped into two broad cat-
egories, the dihydrofolate reductase (DHFR) inhibitors and the sulfa drugs 
which are structurally similar to para-aminobenzoic acid (PABA). Two commonly 
used DHFR inhibitor antimalarial drugs are pyrimethamine and proguanil whereas 
sulfonamides and sulfones are employed as antimalarials mostly in combination 
with pyrimethamine. 
Proguanil was developed in Britain during the Second World War. While 
evaluating derivatives of pyrimidine, compounds of the chloroguanil series proved 
promising, opening the pyrimidine ring further simplified the structure to bigu-
anide (Curdetal. 1945), which were to have good antiplasmodial activity. Thus progua-
nil (chloroguanide) was discovered. The efforts of British group in collaboration 
with American scientists further culminated in the development of p5Timethamine 
(Falco et al. 1951), first introduced in 1952 for routine human use. Both the drugs 
are employed for prophylaxis and suppression of malaria infection in man. They 
act on the dividing stages of the parasites but not on the dormant (hypnozoite) or 
growing sexual stages ( developing gametocytes). They have the important prop-
erties of low toxicity. Pyrimethamine has added advantages of being effective in 
much smaller doses and longer half life with slow excretion rate compared to 
proguanil. 
19 
Proguanil and pyrimethamine act as antimalarial drugs by virtue of their 
great affinity for the plasmodial enzyme DHFR (Ferone et al. 1969). The enzyme gets 
inhibited following binding of the drug. DHFR catalyzes the conversion of dihy-
drofolate to tetrahydrofolate and occupies a key position in cellular biosynthesis 
of purines, pyrimidines and certain amino acids. DHFR is present both in the 
parasite and the host cells. The basis of selective action of these drugs is their 
differential (greater) binding to the plasmodial DHFR and the extraordinary sen-
sitivity of this action to the nuclear division of the malaria parasite at the time of 
development of schizonts in erythrocytes and in the liver tissue (Schellenberg and 
Coatney 1967; Gutteridge and Trigg 1971; Inselburg and Banyal 1984; Janse et al. 
1986). The affinity of P. berghei (rodent malaria parasite) DHFR for pyrimethamine 
is 2000 fold greater than the mouse erythrocyte enzyme (Ferone et al. 1969). Progua-
nil is not active against plasmodia in vitro but one of its metabolite, cycloguanil 
is the active intermediate having chemical structure somewhat similar to that of 
pyrimethamine (Carrington et al. 1951) (Figure 1.1). The activation of proguanil to 
cycloguanil is done by the mixed function oxidase system of the hepatic microsomes 
(Armstrong and Smith 1974). It is not known if pyrimethamine and cycloguanil 
bind to the same region of the plasmodial DHFR or occupy different sites. 
Spectacular successes of sulfonamides as antibacterial drugs in 1930s led 
to the evaluation of their antiplasmodial action. In 1937 the antiplasmodial activ-
ity of some of the derivatives was recognized against human malaria (Anand 1979). 
The sulfonamides and sulfones exert activity against all actively dividing stages 
in the life cycle of plasmodia. Among the human plasmodia P. falciparum is more 
susceptible, whereas P. uiuax is less so (Bnice-Chwatt et al. 1981). The earlier devel-
oped sulfa drugs acted slowly for short duration and the need for high and poten-
tially toxic doses were responsible for their shelving, as also more reliable 4-
aminoquinoline compounds became available. However, advent of resistance to 4-
aminoquinolines has revived interest in sulfa drugs as they retain full activity 
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against chloroquine resistant parasites (Peters 1990a) and these drugs act syner-
gistically with the DHFR inhibitors (Bartelloni et al. 1967; Harinasuta et al. 1967). 
The mode of action of the sulfonamides and sulfones against plasmodia is consid-
ered analogous. Antimalarial sulfa compounds are structurally similar to para-
aminobenzoic acid and the commonly accepted view is that these drugs are com-
petitively antagonized by PABA and non-competitively by folic acid (Watkins et 
al. 1985). PABA is incorporated into the coenzyme folic acid; inhibition of folic 
acid synthesis by these drugs has been demonstrated and the enzyme involved 
was to be tetrahydropteric acid synthetase. Another study supports the view that 
altered permeability of the erythrocyte membrane might be responsible for action 
of sulfa drugs as dapsone has been demonstrated to accumulate at the surface of 
rat erythrocytes (Canedella and Jarrell 1970), leading to the reduced uptake of glucose 
in the erythrocytes and inhibition of glucose consumption by intraerythrocytic 
parasite. 
B. Mechanism of Resistance: The use of DHFR inhibitors as antimalarials has 
been curtailed because of rapid development of resistance by the parasites. Shortly 
after the release of each drug, prophylactic and therapeutic failures against Plas-
modium infections were reported (Peters 1970) from various places. Resistance to 
DHFR inhibitors by several strains of Plasmodium has subsequently become a 
major problem throughout the world. The ease with which resistance to DHFR 
inhibitors developed both in the field and laboratory suggested that single muta-
tion in the Plasmodium DHFR segment of the genome might be enough to render 
these drugs ineffective(Bishop 1962; Diggens et al. 1970; Peters 1987). The ex-
perimental evidence as to the genetic basis of resistance came from the analysis of 
a cross between pyrimethamine resistant and sensitive lines of rodent malaria 
resulting in inheritance patterns compatible with the involvement of just a single 
gene locus (Walliker et al 1975, 1976; Knowlesi et al. 1981). Kinetic studies further re-
vealed that DHFR from resistant Plasmodium binds less tightly to py-
rimethamine, as there was marked increase in inhibition constant (K.) with re-
spect to this drug (Ferone 1970; Sirawaraporn and Yuthavong 1984; Mc Cutchan et al. 1984; 
Walter 1986; Dieckman and Jung 1986), strongly suggesting the altered structure of the 
enzyme DHFR in "resistant parasites. An important feature off! falciparum DHFR 
is that the activity resides within a bifunctional protein together with thymidy-
late synthetase (TS) (Garrett et al. 1984). Another novel property of the DHFR 
from resistant parasites is that it retains its normal enzymatic function but at the 
same time inhibits binding of the drug. First complete sequence of DHFR-TS 
was published in 1987 (Bzik et al. 1987). There work showed that as in Leishmania 
there is a single intronless open reading frame that includes a junction region 
linking the DHFR and TS domains. The DHFR domain extends from the N-termi-
nus to amino acid residue 225 approximately, while the TS domain occupies roughly 
the final 290 amino acids of the protein leading to the C-terminus at residue 607. 
The junction regions thus extends from about residue 225 to residue 320. Many of 
the or postulated active site residues in both DHFR and TS are found to be con-
served in the P.falciparum molecule (Bzik et al. 1987; Cowman et al. 1988). The 
DHFR-TS gene has been shown to reside on the fourth fastest chromosome in 
several strains (Peterson et al,1988; Cowman et al,1988; Snewin et al,1989; Tanaka 
et al,1990). Ever since, structure of the DHFR gene from number of resistant 
and sensitive falciparum clones/isolates have been compared by sequencing. This 
rapid accumulation of sequencing data has been made possible by in vitro ampli-
fication of DHFR region of the genome using polymerase chain reaction (PCR). 
Analysis of sequence data of natural resistance in diverse number of geographical 
distinct isolates shows that a single point mutation (resulting in Ser. 108 toAsn. 
108 ) in the DHFR active site is perfectly linked to pyrimethamine resistance 
(Table 1.1). Two ancillary mutations Asn. 51 to He. 51 andCys. 59 toArg. 59 were 
found to be associated with increased level of resistance in association with Asn. 
108 (Cowman et al. 1988; Peterson et al. 1988; Snewin et al. 1989; Tanaka et al. 
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1990). Experimentally induced resistance in P. falciparum using mutagens in 
vitro (Banyal and Inselburg 1986) showed that amino acid changes at entirely 
different sites than that seen in naturally resistant pyrimethamine parasites 
(Inselburg et al. 1988; Tanaka et al. 1990). This clearly shows that there are 
many sites in the DHFR gene where point mutations can alter the structure of 
the enzyme, preventing or retarding drug binding, without compromising with 
catalytic functions. More studies are needed to ascertain the extent of polymor-
phism of these sites in diverse geographical isolates. 
The finding that specific changes in DHFR base pairs are linked to py-
rimethamine resistance indicated that point mutations might also be responsible 
for resistance to cycloguanil. Sequence data analysis of cycloguanil resistant 
DHFR revealed that parasites with paired Ser. 108 to Thr. 108 and Ala. 16 to Val. 
16 mutations were found to be resistant to cycloguanil but showed only a slight 
decrease in sensitivity to pyrimethamine. Parasites refractory to both the DHFR 
inhibitors had three mutations in common Cys. 59 to Arg. 59, Ser. 108 to Asn. 108 
and He. 164 to Leu. 164 ( Foote et al 1990; Peterson et al 1990). Identification of 
specific mutations in DHFR segment of genome opens up the possibility of muta-
tion specific oligonucleotide probes, using PCR, capable of differentiating sensi-
tive and resistant parasites (Zolg et al, 1990). 
Resistance to sulfas has not been widely recorded with human plasmodia. 
For many years these drugs were exclusively used in combination with DHFR 
inhibitors mainly pyrimethamine. Of late there have been reports of emergence 
of resistance to these combinations from Brazil and Southeast Asia in P. falci-
parum (Brockelman and Tan Ariya 1982). There is, of course, little doubt that 
Plasmodia resistant to the combination also are resistant to sulfas alone. 
2. Quinoline-Containing Antimalarials (QCA) They essentially include blood 
schizonticides (except for primaquine). Cinchona alkaloids (quinine) and other 4-
23 
quinolinemethanol (mefloquine); chloroquine (4-aminoquinoline), primaquine (8-
aminoquinoline), are some of the drugs dealt in this section. 
Cinchona Alkaloids : 
Quinine, one of the major alkaloid components of cinchona bark, has saved 
mankind from ravages of dreaded malaria disease for more than 350 years and 
continues to cure malaria, any malaria even today ! It acts on the multiplying 
asexual stages of the parasite but has no lethal effect on the exoerythrocytic stages, 
it is gametocytocidal for P. vivax and P. malariae but toxic only to the developing 
gametocytes of P. falciparum. Quinine toxicity to malaria parasite is based on 
concentrative uptake of the drug in infected erythrocytes leading to cessation of 
motility and haemozoin formation. It stands apart, in an era, when life cycles 
(usefulness) of drugs are mostly expressed in decades rather than centuries. 
Indiscriminate use of this drug shall definitely lead to selection of resistant strains 
of Plasmodium, as had been the case in the past with other drugs. We can not 
afford this to happen now, at the time when quinine seems to be the only effective 
drug against the multi-drug-resistant (polyresistant) malaria strains. Time de-
mands the strategies to prolong and preserve the antimalarial efficacy of cinchona 
alkaloids and derivatives. The question is how and why this drug has survived as 
an effective antimalarial for so long. If that is answered then perhaps one might 
be able to suggest ways to delay the emergence of resistance to this drug. Mostly 
crude bark was used for preparation of powder and infusion. As we know now that 
this extract from 'bark to bottle' contained not only quinine but other alkaloids as 
well in varying amounts, some of them even more potent than quinine. Even 
the 'pure' quinine salts, as quinine sulphate, available contained other cinchona 
alkaloids (Smit,1987) to the extent of 16% in 1890, 8.5% in 1970 and 6% in 1986 
(Figure 1.2). Clearly the alkaloid mixture used in the past for treatment, survived 
in retaining the antiplasmodium virtues for centuries. Even modern medicine 
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advocates drug combination over monotherapy to prolong the Ufe span of the drugs 
(Peters 1990c). Quinine is not the most effective of the four major alkaloids found 
in cinchona bark. In vitro also some of the cinchona alkaloids and synthetic 
derivatives are more potent than quinine (Nair and Bhasin 1993). It has reached 
its unique position because it just happened to be the first to be isolated and used 
in 'pure' form. Perhaps the solution to the malaria problem even today can be 
rediscovered where it was first found - in the bark of cinchona tree. Of late, 
increasing failure rates of old and new synthetic drugs has again drawn the at-
tention of research workers to the oldest natural antimalarial drug. 
Mefloquine( 4-quinolinemethanol): 
Mefloquine may be considered the third generation quinolinemethanols. 
The first generation is represented by cinchona alkaloids, the second (less known) 
by the compounds in which the cinchona side chain was modified with introduc-
tion of 2-phenyl substituent and the third by mefloquine in which the 2-phenyl 
moiety is replaced by a trifluromethyl group (Figure 1.1.). Each generation of 
quinolinemethanols brought an improvement in the therapeutic properties of the 
representative drugs. Mefloquine is well-tolerated , effective in single dose against 
P. falciparum, as its half life is for about 14 days in man, with cure rate of 100%. 
It can be used as suppressive prophylactic drug for both vivax and falciparum 
malaria. It does not have tissue schizonticidal activity and thus cannot produce 
radical cure with relapsing malaria infections. It was first synthesized in 1971 
and improved method of synthesis patented in 1978 (Sweeny, 1984) . Parasites 
become quickly resistant to the drug specially chloroquine resistant ones. Thus it 
has a limited utility for mass use as a single drug for malaria treatment . How-
ever, it can be beneficially employed in drug combinations with caution. 
Chloroquine and other 4-aminoquinolines : 
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Presence of quinoline ring in the two antimalarials, quinine and pamaquine, 
was known to the Germans by 1930. This prompted them also to explore several 
derivatives of 4-aminoquinolines, resulting in the final selection of chloroquine 
and sontaquine for further trials in North Africa. Sontaquine was preferred over 
chloroquine by the Germans for being less toxic. Supplies of this drug together 
with German research data were captured by United States forces in Tunis which 
st imulated further studies in USA on these and other 4-aminoquinolines 
(Coatney,1963; Peters,1987). Chloroquine was found by US workers to be the most 
effective among them and less toxic on volunteers than any other. So the drug 
which was synthesized in 1934 in Germany was rediscovered in USA in 1946. 
Chloroquine and other 4-aminoquinolines have been found to be highly effective 
against the asexual blood stages of all four species of malaria (prior to appearance 
of resistant strains). They produce rapid clinical cure and are excellent suppres-
sive agents. Parasitemia disappears within 48-72 hours following standard thera-
peutic regimen. They are gametocytocidal agents against all human malaria para-
sites except mature P. falciparum gametocytes. Since release this inexpensive 
drug has been widely used both for treatment and prophyleixis. Its consumption 
had been progressively increasing for instance 265,052 kg base was actually con-
sumed in 1978 and the demand rose to estimated 351,229 kg base in 1985, repre-
senting respectively 177 million and 234 million adult therapeutic doses (WHO, 
1984).By far the most enormously consumed synthetic antimalarial drug in the 
history of mankind. Naturally, therefore, the most extensively studied antima-
larial at the same time surprisingly our knowledge about the mode of action of 
this drug is far from complete. One wonders if this deplorable situation is due to 
complexity of the subject matter or absence of appropriate technology to resolve 
the knots or simply lack of more inquisitive minds to join the endeavour to unfold 
the specific mechanism of drug action. Whatever might be the case, it calls for 
periodical update about this riddle. If we knew the exact mode of action then per-
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haps one could tackle more rationally the evolution of resistance to these drugs in 
the parasites and design effective strategies to combat or contain the ever in-
creasing menace of resistance to chloroquine. We will restrict our deliberation to 
some of the recent discoveries in this field as reviewed by Ginsburg and Krugliak 
(Ginsburg and krugliak, 1992^. 
Concentration ofQCA in Parasitized Erythrocytes : 
QCA have variety of biological effects on plasmodia depending upon their 
concentrations. Chloroquine concentration of 10 ' M, for instance, is sufficient to 
bind ferriprotporphyrin IX (FP) and form toxic complex; concentration of 10"^  M or 
greater inhibits lysosomal functions and concentration of 10"^ M or greater permit 
drug binding to the major cellular constituents and , presumably, prevent their 
functioning (Mc Chesney et al 1984). Most of the discussion on QCA relates to 
chloroquine. 
Inhibition of Lysosomal Functions: 
QCA are amphiphillic weak bases and driven freely across the membranes 
towards the acid digestive vacuoles of the malaria infected erythrocytes (Aikawa 
1972). Extent of accumulation of the drug is dependent on the pH gradient of the 
lysosomal vacuole and the extracellular medium (Yayon et al. 1984). Once inside 
the acid vacuoles the QCA bases become protonated and their free permeability 
across the membranes is reduced by several folds (De Duve et al. 1974). The pro-
tonation of the influxed bases in the lysosomal compartment causes temporary 
alkalinization and is counteracted by the vacuolar proton pump (Geary et al. 1986). 
Alkalinization inhibits metabolism in the lysosomes and decline in the pH gradi-
ent decreases the drug influx. It had, therefore, been postulated that drug accu-
mulation causes increase in the vacuolar pH resulting in inhibition of the vacu-
olar enzymes. Protease inhibitor, leupeptin, causes reversible cessation of diges-
tion in the parasite whereas impedance of digestive process due to QCA is nonre-
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versible (Rosenthal et al, 1988). But there is insignificant change in the pH of 
lysosomal vacuoles at the pharmacological level of QCA to cause any inhibition of 
lysosomal functions, as has been demonstrated (Ginsburg et al, 1989). 
Interaction of QCA with Ferriprotoporphyrin IX : 
Intraerythrocytic parasite consumes internalized hemoglobin by proteoly-
sis in the lysosomes. Toxic residue FP or oxidized heme so formed is polymerized 
by the parasite into a crystalline nontoxic substance called haemozoin or malaria 
pigment. It has been proposed that chloroquine interferes with the formation of 
nontoxic compound by complexing with FP , thus lethally poisoning the parasite 
(Fitch 1983 ; Fitch 1986). These complexes not only contribute to inhibition of 
digestion through their effect on the parasite's acid cysteine protease but also can 
disrupt integrity of vesicle membranes resulting in lysis (Orjih et al. 1981; Fitch 
et al. 1982). However, QCA treated parasitized cells do not show either morpho-
logical or biochemical disruption of the vacuolar membranes which corroborates 
the finding that lytic effect of the complexes is prevented by the serum proteins 
(Zhang and Hempelmann, 1987). Also the failure to demonstrate presence of 
QCA in the necessary amounts are incompatible with this suggestion. This does 
not rule out the possible role of QCA-FP complexes in the antimalarial action. In 
fact, since they can be formed only in malaria-infected cells, they are good candi-
dates for accounting for the specific antimalarial actions. Inhibition of heme poly-
merase by QCA has been recently implicated as mode of action ( Slater and Cerami, 
1992), also QCA preventing the release of iron from the acidified host cell cytosol, 
a possible source of this trace element for the parasite has also been proposed 
(Ginsburg and Krugliak, 1992). 
Intercalation of QCA with DNA : 
Chloroquine, quinine but not mefloquine have been found to inhibit DNA 
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synthesis by intercalating with DNA but at concentrations four orders above the 
pharmacological levels of the drugs. Another serious flaw with this hypothesis is 
that chloroquine has higher affinity to GC nucleotides (Cohen and Yielding, 1965) 
but Plasmodia DNAs are AT rich (Weber, 1988), it is difficult to account for selec-
tive action of chloroquine against plasmodia. 
Mechanisms of Chloroquine Resistance: 
Advent of chloroquine resistance is one of the principal factors for the present 
global resurgence of malaria. Resistance in the parasites may develop either due 
to reduced accumulation of the drug or because of alterations in the drug target-
site of the parasite. Drug target has not yet been identified but there is ample 
evidence that resistant strains of P. falciparum accumulate less chloroquine 
(Krogstad and Schlesinger,1987). Decreased activity of vacuolar proton pump 
(Ginsburgand Krugliak, 1989 has been implicated in reduced accumulation of the 
drug in lysosomes and not due to the activity of any efflux pump. Acidotropic 
chloroquine is driven to lysosomes by pH gradient maintained by hydrogen pump-
ing into the vacuole, slowing of the pump activity causes lowering of pH gradient 
which in turn leads to reduced concentration of the drug in resistant parasites. 
Drug resistance is associated with amplification of multiple drug-resistant (mdr) 
genes and their products in cancer cells (Endicott and Ling 1989). By analogy 
with this situation two mdr genes have been identified in P. falciparum (Wilson et 
al. 1989) and one of them Pfmdr 1 is markedly homologous to human mdr gene 
(Foote et al, 1989). In cancer cells mdr gene products are involved in efflux of the 
accumulated drug but in malaria the existence of similar mdr vacuolar pumps 
seems doubtful at present, mdr products might be involved in imparting resis-
tance by some other mechanism, also amplification of these genes have not been 
found in all resistant falciparum strains. Sequencing of Pfmdrl gene showed that 
resistant isolates differ by one to four nucleotides from chloroquine sensitive genes 
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in some strains but were same in others (Foote et al. 1990). 
Resistance Reversers : 
Compounds like verapamil (Martin et al 1987), diltiazem , vinblastine 
(Ginsburg and Krugliak,1992) etc. are known to reverse drug resistance in cancer 
cells. They are similarly effective in reversing chloroquine resistance in resistant 
falciparum, mostly in vitro. A psychotropic agent, desipramine, is effective in re-
versing falciparum resistance at well tolerated dose in Aotus monkeys (Peters 
1990a). Similarly cyproheptadine and several other related antihistaminic agents 
have shown the ability to reverse chloroquine resistance against P. falciparum 
both in vitro and in vivo. However, clinical applications against malaria is still 
far from infancy. 
Primaquine (8-aminoquinoline) : 
Most widely used tissue schizontocide and antirelapse drug (for vivax and 
ovale infections) since its introduction in 1940s. Its gametocytocidal and sporonto-
cidal virtues are important operationally, since a single dose might reduce the 
transmission of drug-sensitive and resistant falciparum malaria. Clinically inef-
fective against asexual blood stages. Although primaquine is the safest available 
8-aminoquinoline it does have significant toxic effect on individuals with glucose-
6-phosphate dehydrogenase deficiency. Primaquine inhibits parasite mitochondrial 
respiration and this is probably the basis of its action. Not enough is known about 
its exact mode of action and resistance status to this drug. 
3. Artemisinin: Artemisia annua a herb of family Compositae has been used in 
malaria therapy in China for over 1000 years but its active antimalarial compo-
nent, artemisinin or 'qinghaosu' was not isolated and characterized until 1972 by 
the Chinese scientists. Artemisinin and a derivative, artemether, are capable of 
curing patients with severe malaria resistant to most other drugs. Artemether 
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has been found to be more effective in preventing deaths from malaria than intra-
venous quinine - the traditional treatment for severe malaria. It is safe and fast 
acting blood schizonticide, a potential life-saving advantage in severely ill pa-
tients. Some of its derivatives have recently been shown to possess better schizon-
tocidal and gametocytocidal properties in vitro (Mehra and Bhasin, 1993). Arte-
misinin has the structure of sesquiterpene lactone with an internal peroxide link-
age. The peroxide moiety appears to be indispensable for chemotherapeutic activ-
ity. The definitive mode of action of this series of drugs is still not known and 
resistance to these compounds can be produced in vitro (Inselburg 1985). No doubt 
this old remedy brings new hope for the time being if deployed judiciously. 
Factors contributing to the selection of drug resistant parasites 
In the following section some of the factors which are likely to play an 
important role in the emergence and propagation of drug resistance in malarial 
parasite are considered. 
Mass drug administration: Most forms of mass drug administration employ the 
medicament at subcurative doses, thus leading to the selection of less sensitive or 
resistant parasites. This is of limited importance while malaria transmission is 
interrupted or reduced to a very low level (Wernsdorfer and Kouznetsov 1980). 
However, if drug pressure is exerted whilst transmission is intensive and unabated, 
selection and subsequent propagation will be rapidly effected. This effect is most 
marked under conditions of universal drug pressure as is exerted by the use of 
medicated salt (Verdrager 1986 a,b). 
Inadequate treatment: A strong correlation between the immune status and drug 
response in areas with intensive malaria transmission has been observed espe-
cially in children of different age groups. For many years chloroquine was admin-
istered as a single dose of 10 mg/kg body weight for providing radical cure in semi-
immune subjects for instance in tropical Africa (WHO 1986). When infants and 
children not sufficiently immune were treated with the same dose the drug failed 
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to provide radical cure. The dose was thus subcurative and therefore conducive to 
the selection of resistant parasites (Gharry et al. 1988; Ramanamirija et al. 1985). 
\bctorial factors: Studies in Central and West Africa indicate that the risk of 
contracting chloroquine resistant P.falciparum is directly correlated to vector den-
sity and sporozoite rate (Brandicourt and Gentilini 1987). The propagation of 
chloroquine resistant P. falciparum was quite slow in the areas of moderate and 
low transmission where sensitive P. falciparum continues to prevail in spite of an 
early onset of chloroquine resistance in the hyper-endemic lowland regions of Mada-
gascar ( Le-Bras et al. 1987 ). 
Population mobility: Migration has been identified as a major contributory factor 
to the occurrence and spread of drug resistance (Verdrager 1986 a,b). Migration is 
an important determinant in the transportation of the infection to unaffected ar-
eas. Intensity of migration in association with a different intensity of drug use 
may also cause major differences in the prevalance of resistant infections within 
relatively small geographic areas as was shown in the example of two population 
strata in Amazonian Brazil (Kremsner et al. 1989). 
Biological advantage of resistant parasites over sensitive ones: Chloroquine resis-
tant P .falciparum differs in certain biological characteristics from chloroquine 
sensitive populations. It has proved to be more infective to Anopheles stephensi 
and also to produce large number of oocysts; an effect also observed in A. dirus 
(Sucharit et al. 1977). Chloroquine may enhance the infectivity of chloroquine 
resistant plasmodia to anophelines. This has been shown in P. herghei I A. stephensi 
model (Ramkaran and Peters 1969). A marked decrease in sensitivity to chloro-
quine has been observed in P. falciparum isolates after continous growth for long 
periods in vitro culture in the absence of drug pressure (Le Bras et al. 1980). 
Lessons from P a s t : 
History of drug resistance shows that whenever a new antimalarial was 
deployed en masse for monotherapy and chemoprophylaxis resistance to the drug 
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appeared quickly. Life span of drug combinations had been longer. Misuse of 
drugs has also contributed to the fast selection of resistant parasites, which should 
be prevented as far as possible. Antimalarials should only be deployed as one of 
the tools in an integrated malaria control programme. 'Think globally and act 
locally' should be the guiding principle for any malaria control programme. 
Future Agenda : 
The current grim situation is a cause of concern to malaria epidemiologists, 
indicating the urgent need to identify and develop alternate compounds capable of 
curing resistant malaria. If there was more information on relationship between 
in vitro antimalarial sensitivity and in vivo response to treatment, dose regimens 
of quinine could be improved. Therapeutic concentrations of quinine need to be 
defined in different countries where sensitivity of P. falciparum to the cinchona 
alkaloids varies. Quinine should not be used alone. One of the most inexpensive 
ways of searching new lead antimalarial compounds for drug development would 
be to screen the drugs which have been developed for other diseases and evaluate 
their antimalarial potentials, either alone or in combination with other drugs. 
Searching of novel drugs empirically is expensive in time and resources. Ratio-
nal drug design is feasible if modes of action of drugs is known, so its highly 
desirable to demonstrate how the proven drugs function at molecular level. Dis-
covery of the molecular mechanisms causing resistance is of utmost importance in 
order to impede, reverse or contain the advent of resistance. Search for antire-
lapse and transmission blocking drugs should be a priority. New drug combina-
tions should be explored to which emergence of resistance is extremely difficult, 
this strategy might bear fruits quickly, specially search for synergistic combina-
tions. Efforts should continue for the search of less toxic 'resistance reverser' 
combinations. Ability of some oligos to revert DHFR resistant mutants to sensi-
tive lines in vitro by site directed mutagenesis should be tried as a first step. 
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Drugs toxic to plasmodia and capable of evoking immunogenic responses against 
parasite will be of special interest. Potent new antimalarial combinations to be 
developed should be inexpensive, nontoxic and administered under strict pre-
scription to limit their misuse. There should be separate class of drugs for pro-
phylaxis. Proper drug deployment, marketing and monitoring strategies will have 
to be worked out. 
Table 1.1 Positionsof amino acid residues that are different in pj'rimetlianiinc and cycloguanil 
sensitive tu resistant isolates in the DilFR segment of the P. falciparum genome*. 
Susceptibility of the isolate Amino acid residue 
Pyrimethamine 
S 
R 
S 
HR 
R 
HR 
Cycloguanil 
S 
S 
R 
S 
R 
HR 
16 
Ala. 
Ala. 
Vai. 
Ala. 
Ala. 
Ala. 
51 
Asn. 
Asn. 
Asn. 
He. 
Asn. 
He. 
59 
Cys. 
Cys. 
Cys. 
Arg. 
Arg. 
Arg. 
108 
Ser. 
Asn. 
Thr. 
Asn. 
Asn. 
Asn. 
164 
He. 
He. 
He. 
He. 
Leu. 
Leu. 
S = sensitive , R = resistant, HR = highly resistant 
* compiled from the literature 
1 8 9 0 1970 1986 
D Qunine sulphate 
• Cinchonidine sulphate 
ESI Dihydroqunine sulphate 
Figure 1.2 Composition of'quinine' from past to present 
Chapter 2 
SUSCEPTIBILITY OF PLASMODIUM FALCIPARUM ISOLATE AND A 
CLONE TO A FEW ANTIMALARIAL DRUGS IN VITRO 
Abstract: In vitro susceptibility of a local Plasmodium falciparum isolate together with one of its fastest 
multiplying clone to some known natural antimalarial drugs (quinine and artemisinin) and commonly used 
synthetic drugs (chloroquine, amodiaquine, pyrimethamine and cycloguanil) has been performed, using the 
modified 48 hour test method. Erythrocytic stages of the parasites have been found to be resistant to chloro-
quine and sensitive to all other natural and synthetic drugs evaluated. Advantages of in vitro bioassay meth-
ods for drug susceptibility testing has been discussed. Growth rates of the parasites have been found to be 
comparable to those of the parasites maintained in cultures in non-endemic areas, implying that serum 
supplement (obtained locally) employed in the medium for cultivation has no adverse effect on growth and 
multiplication of the parasites. 
INTRODUCTION 
The efficacy of drugs against falciparum infections has traditionally been 
evaluated by observing the clearance of parasites from the blood stream following 
administration of a drug in a subject. If the parasitemia is cleared with no subse-
quent recrudescence the drug is considered effective and the infecting strain re-
garded sensitive to the administered drug. It is obvious from this type of experi-
mental data that some strains of parasites are more sensitive than others to the 
drug. Marked differences in susceptibility are sometimes observed, particularly 
in strains of diverse geographical locations. However, with the emergence of chlo-
roquine-resistant strains of falciparum in 1960s, need for defining drug resis-
tance in malaria and standardizing procedures for assessing the varied responses 
of P. falciparum to chloroquine and other antimalarials was strongly felt. Drug 
resistance in malaria is defined by WHO (1967) as the "ability of a parasite strain 
to survive and/or multiply despite the administration and absorption of a drug 
given in doses equal to or higher than those usually recommended but within the 
limits of tolerance of the subject". Although this definition can logically be ex-
tended to include all plasmodial stages, it has generally been restricted to de-
scribe the drug susceptibility of asexual forms, presumably because this stage in 
the life cycle of the parasite produces acute clinical symptoms observed during 
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the course of malaria infection. Evaluation of drug resistance procedures in vivo 
was proposed by WHO first in 1967 and then slightly modified in 1973 (WHO, 
1967, 1973 ). The obvious problems associated with in vivo determination of the 
drug susceptibility of P. falciparum has led to the development of simple in vitro 
tests which can be easily performed both in laboratory and field conditions 
(Rieckmann and Lopez Antunano 1971). The original in vitro microtest method 
has been the most successfully applied diagnostic test for chloroquine-resistance 
and was designated by the WHO as a standard test in 1979 (WHO 1979). Proce-
dure of Trager and Jensen (1976) for in vitro cultivation of falciparum stages has 
given further impetus to modify and develop methods for in vitro determination 
of susceptibility not only to chloroquine but also to other antimalarial drugs 
(Nguyen-Dinh and Payne 1980). The results of in vitro assessment in most cases 
show excellent concordance with the results of their assessment with in vivo sys-
tem. In vitro method has superseded the in vivo procedure for assessment of drug 
susceptibility in some situations. Evaluation of the drug susceptibility of P. falci-
parum is now not only confined to those locations where drug resistance is a prob-
lem but test are also carried out in all endemic areas where falciparum infections 
exist. Such susceptibility profile of local strains to antimalarials provide a baseline 
data against which subsequent changes in the susceptibility of parasites can be 
measured. Susceptibility status of local strains of P. falciparum to new drugs 
should also be determined in areas where these drugs might be used in future. 
Malaria is acknowledged as an exclusively local phenomenon and any control 
programme has to be meticulously designed taking into consideration the suscep-
tibility profile and dynamics of resistance (if known) of the local falciparum fauna 
to the antimalarial drugs. Over the last few years we have established in vitro 
cultures of several P. falciparum isolates originating from Delhi. Clones have 
been derived from some of these isolates. Susceptibility profile of some isolates 
and clones has been determined in vitro to commonly used antimalarial drugs. In 
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this section sensitivity of an isolate and a clone, which have been employed in all 
the subsequent work of the present study, to some antimalarials has been described. 
In vitro cultivation procedures and their advantages in drug susceptibilty testing 
have been discussed. 
MATERIALS AND METHODS 
Biological materials 
Parasites: The isolate FCD-4 employed in the present study was procured locally 
from a malaria infected patient reporting to a malaria clinic of malaria research 
centre (MRC), Delhi. About 2 ml of blood was drawn aseptically, with the consent 
of patient infected with P. falciparum, by venous puncture into a sterile heparin-
ized vial. The blood sample was transported to the laboratory for in vitro cultiva-
tion of erythrocytic stages within an hour. Soon after, the cultures were initiated 
in vitro using candle-jar method of Trager and Jensen (1976). Once the isolate got 
established in culture, clones were derived from it using limiting dilution method 
(Rosario 1981). Several clones were realized and a few characterized with regard 
to their multiplication ability in vitro. A clone F-56, one of the fastest growing 
clone obtained was chosen for further studies. 
Red blood cells and serum: Human erythrocytes and serum used for cultivation 
of parasites were purchased from commercial blood banks. All blood products 
used, were certified to be free from malaria, hepatitis, HIV etc. A unit of blood 
(about 350 ml) obtained in acid citrate dextrose or citrate phosphate dextrose was 
dispensed aseptically in 50 ml aliquots and stored at 4 °C . The stored blood was 
used upto four weeks. Erythrocytes of A+ blood group were used in all studies. 
For serum, 2-3 units of AB+ blood at a time were collected without any anticoagu-
lant. It was stored at 4 °C atleast overnight to retrieve maximum amount of 
serum. The serum was harvested by centrifugation of this stored coagulated blood 
and distributed in 40 ml aliquots in sterile flasks. These serum samples were 
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kept at -20 °C till further use. Prior to use the stored serum was thawed and heat 
inactivated by keeping it for 30 min at 56 "C. 
Reagents 
Medium: For one litre of medium 10.4 g of powdered RPMI-1640 with L-glutamine 
but without bicarbonate (obtained from Sigma) was dissolved in 900 ml of glass 
redistilled water. TD this 5.94 g of HEPES buffer and 40 mg of gentamicin were 
added (RP-C). The above components were thoroughly mixed with the help of a 
magnetic stirrer and the final volume adjusted to 960 ml. This medium was imme-
diately filter sterilized through 0.45n presterilized millipore filter under negative 
pressure, aseptically in a flow hood. The sterilized medium was dispensed in 100 
ml volumes into sterile screw cap bottles for storage in refrigerator. Each bottle 
was numbered and dated. The pH of the buffered medium was made to 7.2 just 
before use by adding sterilized 5% sodium bicarbonate solution at the rate of 4.2 
ml per 96 ml (RP+C) medium. The RP+C medium was supplemented with 10% 
(v\v) heat inactivated serum to be used as complete medium (RPS) for cultivation. 
Complete medium could be stored at 4 °C upto one week in closed bottles. The RP-
C was consumed within four to five weeks. 
Cryoprotectant: It was prepared by adding 70 ml glycerol to 180 ml of 4.2% sorbi-
tol in 0.9% NaCl and filter sterilized to be used as cryoprotectant solution for 
freeze-storing of parasites. 
Thioglycollate medium: Thioglycollate medium, 29.8 g (powder) was mixed in 1 
litre of glass distilled water and heated slowly so as to dissolve it completely. This 
solution was dispensed in 10 ml volumes into glass tubes with cotton plugs and 
autoclaved at 15 lbs for 20 min. Tubes were stored at 4 °C for subsequent testing of 
bacterial contamination in medium or blood products. 
Drug solutions The stock solutions concentration and methods of preparation of 
the * various drugs employed in this study are tabulated below. 
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Drug Source Concentration of Stock Solvent 
Chloroquine 
Amodiaquine 
Pyrimethamine 
Cycloguanil 
Quinine 
Artemisinin 
Sigma Chemicals 
Sigma Chemicals 
Sigma Chemicals 
ICI Pharmaceuticals* 
WHO* 
WHO* 
40 mg/ml base 
10-2 M 
10-2 M 
10-2M 
10 mg/ml 
1 mg/ml 
Water 
Water 
Lactic acid 
Ethanol 
Sulfuric acid 
DMSO 
gifts from these agencies 
Each of these stock drug solutions was filter sterilized through 0.2 mm 
cellulose acetate millipore sterile disposable syringe filter and stored at - 20 °C. 
Test or working solutions were prepared by appropriately diluting the stock solu-
tions with complete medium (RPS). All the test solutions were kept at 4 °C. 
PROCEDURES 
Maintenance of P. falciparum parasites in vitro 
Sterility test: All media, blood and glassware must be sterile for culture work. 
The glasswares were autoclaved and baked. The sterility of the glassware was 
ensured by the pressure and heat indicator tapes. To test the sterility of media 
and blood products, 1ml of test solution was mixed with the sterile thioglycoUate 
medium. The tube was incubated at 37 °C for 4 days. If thioglycoUate solution 
remained clear, the tested product was considered free of bacterial contamination. 
Red cell preparation (washed erythrocytes): Human erythrocytes obtained from 
blood bank were centrifuged at 2500 rpm for 5 min. Supernatant and buffy coat 
were aspirated out. The pellet was resuspended in 5-10 volume of RP+C medium 
and spun again to remove any residual anticoagulant. The cells were washed 
twice this way and finally the pellet of red cells was resuspended in an equal 
volume of complete medium (RPS) to give 50% cell suspension. 
Cultivation of parasites in vitro: Parasites were cultivated using the Petridish 
candle jar method of Trager and Jensen(1976). The parasite material was drawn 
into a sterile syringe from a flow vessel, in which stock cultures of parasites were 
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routinely maintained in the laboratory (Trager 1979). The material was trans-
ferred to a graduated centrifuge tube and centrifuged at 2000 rpm for 10 min. 
Supernatant was discarded and packed cells were resuspended in equal volume of 
complete medium. Thin blood smear was made from this 50% infected cell sus-
pension. The slide was fixed in methanol and stained in 5% Giemsa's stain pre-
pared in 0.067 M phosphate buffer. The slides were air dried and microscopically 
examined under oil immersion magnification (1000 X). Differential parasite count 
was made to determine the extent of dilution required, if any. Parasite material 
was diluted with 50% suspension of non-infected erythrocytes. Cultures were ini-
tiated with less than 1% of infected erythrocytes. Appropriately diluted parasite 
material of 50% cell suspension, 2 ml of which was mixed with 10 ml of complete 
medium (RPS) so as to give a final suspension or hematocrit of 8%. This material 
(about 12 ml) was dispensed in a glass Petridish (10 cm in diameter). The Petridish 
was placed in a desiccator equipped with a stopcock. The gas phase was generated 
by burning a white candle in the desiccator jar holding the Petridishes until the 
flame extinguished; the stopcock was closed immediately. The candle jar, holding 
parasite material in Petridishes, was placed at 37 °C in an incubator. The me-
dium was removed daily by gently tipping the Petridish and aspirating off the 
medium. All this was done under sterile conditions in a flowhood. The dishes were 
then replaced in the candle jar. Culture growth was routinely monitored every 48 
hour from thin blood smears stained in Giemsa solution. Differential parasite 
count was made by counting atleast 5000 erythrocytes. If parasitemia was found 
to be more than 5% subcultures were prepared. 
Cryopreservation: Cultured parasite material was periodically stored in liquid 
nitrogen for recultivation. Parasites were cryopreserved by a modified method of 
Rowe et al. (1968). Cryopreservation of parasite materialwas done when num-
ber of parasites per 100 red cells exceeded 5 in a Petridish and majority of para-
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sites were in ring stage. The parasite material was transferred to a graduated 
centrifuge tube and centrifuged at 1500 rpm for 10 min. Supernatant was dis-
carded and the packed cells mixed gently with an equal volume of cryoprotectant 
and 1ml each of this suspension was transferred into sterile, screw-capped plastic 
cryovials. These vials were immediately dipped in liquid nitrogen and stored in 
liquid nitrogen cryocan. 
Resuscitation of parasites: Cryopreserved parasites were revived by bringing the 
cryovial from liquid nitrogen to a 37 °C water bath (momentarily loosening the 
cap to vent any compressed nitrogen). On thawing, contents of the vial were trans-
ferred to a centrifuge tube, spun at 1500 rpm for 5 min, supernatant discarded 
and packed cells suspended in an equal volume of 3.5% sterile sodium chloride 
solution. The saline suspension of cells was recentrifuged to discard the saline, 
packed cells washed twice with complete medium and finally made to 50% cell 
suspension with complete medium. To this, equal volume of freshly washed unin-
fected 50% suspension of erythrocytes was mixed. The mixture was made to 4% 
hematocrit by adding complete medium supplemented with 15% heat inactivated 
pooled serum in a glass Petridish (5 cm diameter) and parasites grown by candle 
jar method. 
Susceptibility test method 
Erythrocytic schizontocidal activity of each compound at graded concentra-
tions was evaluated in vitro using the modified 48 hr test method of Nguyen-Dinh 
and Payne (1980). The parasite material was drawn from stock continuous cul-
ture, centrifuged and pelleted cells suspended in 2.5 volume of 5 % sorbitol and 
incubated at room temperature for 7 min. Mostly the ring stage parasites sur-
vive this treatment. The sorbitol treated parasites were washed thrice with RP+C 
medium. The pellet was finally resuspended in an equal volume of complete 
medium to give 50% suspension of infected erythrocytes. This infected material 
was appropriately diluted with 50% washed, uninfected erythrocytes so as to get 
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the final parasitemia of less than 1% (zero hour) to be used as seeding material 
for susceptibility tests. Aliquots of 20 ^1 of this seed material was added to each of 
the series of wells, in 24 well sterile plastic tissue culture plates, holding 480 ^1 
of complete medium with or without drug. The final erythrocyte suspension in 
these experimental wells was thus 2%. The experiment was done in duplicate for 
each drug concentration. After thoroughly shaking the multiwell plates to ensure 
resuspended and uniform settling of erythrocytes, the plates were placed in candle 
jar and incubated at 37 °C. After 24 hours of incubation, medium in each well was 
replaced with or without drug. Drug was included at same concentration as ini-
tially and plates returned to candle jar. Cultures were under continuous drug 
pressure for 48 hour, at the end of this period a thin blood film from each of the 
well holding control and drug treated parasite material was made. Slides were 
stained with 5% Giemsa solution and number of parasites counted by enumerat-
ing atleast 5000 erythrocytes. Percentage inhibition of parasites in relation to 
control was calculated. MIC, ICg,, and IC j^, values were determined from semilog 
plot of percentage inhibition against drug concentration. 
RESULTS 
In vitro cultivation of P. falciparum 
A vial each of cryopreserved material of P. falciparum isolate FCD-4 and 
clone F-56 was retrieved from the liquid nitrogen storage container to initiate in 
vitro cultures of these parasites separately. Once the parasites started multiply-
ing to an extent of atleast four fold in an erythrocytic cycle (from starting para-
sitemia of less than 1%) they were further maintained in a routine medium (RP+C) 
supplemented with 10% serum (RPS). This usually took not more than 6 days of 
culture, if properly cryopreserved material was used for resuscitation. Freeze pre-
served material when initiated into culture retained synchronous multiplication 
for first one or two schizogonic cycles and subsequently grew asynchronously. An 
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erythrocytic cycle is of about 48 hours duration. During this period intraerythro-
cytic parasites undergo morphological changes leading to the formation of ring, 
trophozoite and schizont stages. Rupture of a schizont releases merozoites, the 
only extracellular form, which reinitiates the erythrocytic cycle on invading an 
uninfected red cell. A representative Giemsa stained thin blood film preparation 
from cultured parasite material showing various asexual and sexual stages is pre-
sented in Figure 2.1. The ring stage is the youngest intraerythrocytic stage of the 
parasite occupying approximately one fifth of the red cell area. Host red cells at 
this stage were least modified with regard to morphology or membrane permeabil-
ity. A typical 'signet' ring stage occupied first 18-24 hours of an erythrocytic cycle 
before being transformed into the trophozoite stage. A growing trophozoite could 
be seen as a small round mass of blue cytoplasm with one red chromatin dot or 
area and a small clump of brown pigment. The more mature or nucleus dividing 
stage is called schizont which looks like a large trophozoite containing more than 
one chromatin dot. Each nucleus with cytoplasm surrounding it is called merozo-
ite, may be seen in a schizont. Fully formed merozoites released from a mature 
schizont can be seen in the Figure 2.2. Occasionally developing sexual stages, 
called gametocytes and often multiple infection of red cell can also be found in 
cultures. Atypical distribution of different erythrocytic stages in a culture started 
from ring stages after first and second schizogonic cycle is depicted in Table 2.1. 
Table 2.1. A differential parasite count made at the end of first and second 
schizogonic cycles of in vitro cultivated parasites in multiwell plates with starting 
hematocrit of 4%, showing typical profile of erythrocytic stages in the cultures. 
Schizogonic 
cycle 
0 hour 
First 
Second 
R* 
36 
110 
259 
T 
0 
18 
48 
FCD-4 
S 
0 
29 
86 
TP 
36 
157 
393 
%P 
0.72 
3.14 
7.86 
R 
32 
138 
414 
T 
0 
26 
87 
F-56 
S 
0 
27 
111 
TP 
32 
191 
612 
%P* 
0.64 
3.82 
12.24 
R= rings, T= trophozoites, S= schizonts, TP= total parasites, %P= % parasitemia 
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Usually a parasite produces by asexual multiplication (schizogony) 8 to 24 
merozoites. But only some of these merozoites succeed in invading and multiply-
ing further. This determines the rate of multiplication and to monitor the growth 
of parasites, thin smears were made after every 48 hours for two consecutive cycles 
from each of the well holding either FCD-4 or F-56 culture material. Parasitemia 
was enumerated from the stained slides by counting about 5000 erjrthrocytes. Mul-
tiplication factor (MF) and parasite multiplication rate (PMR) were determined 
using the following formula (Brokelman et al. 1985): 
For the first schizogonic cycle MF = N (day 2) / N (day 0) 
where N is the number of parasites per 5000 erythrocytes on the. day indicated. 
Thus the MF from day 2 to day 4 was = N (day 4) / N (day 2) 
Because multiplication is exponential (theoretically for first few cycles), a loga-
rithmic transformation was used as follows: 
Log MF = log N (day 4) - log N (day 2) 
Log MF has been referred as the parasite multiplication rate (PMR). Results re-
g£irding MF and PMR for the isolate and clone are presented in Table 2.2. 
Table 2.2 In vitro parasite multiplication as determined by multiplication factor 
(MF) and parasite multiplication rate (PMR) in multiwell tissue culture plates, 
(refer to the text for explanation of MF and PMR) 
Parasite Erythrocytic schizogonic cycle 
First Second 
MF PMR MF PMR 
FCD-4 4.36 0.64 2.5 0.4 
F-56 5.96 0.78 3.2 0.5 
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Parasites were periodically cryopreserved for subsequent use from culture 
plates having more than 7-8% parasitemia with majority of parasites in the ring 
stage. This type of freeze-stored material revived fast, mostly within 4 to 6 days of 
resuscitation cultures could be grown in a routine medium supplemented with 
10% serum. 
In vitro susceptibility to antimalarials 
The response of the parent isolate FCD-4 and one of its derived clone F-56 
to the various antimalarials evaluated in vitro were as follows: 
Chloroquine: Figure 2.3 shows the drug dose response for chloroquine in the 
isolate FCD-4 and clone F-56 after 48 hours of incubation. The ICg^  and ICg^  val-
ues of chloroquine were found to be 0.018 jAg/ml and 0.07 ng/ml for FCD-4 and 
0.015 ng/ml and 0.027 jig/ml for clone F-56. 
Amodiaquine: Susceptibility of the parasites to various concentrations of 
amodiaquine is illustrated in Figure2.4. Interpolation of the drug dose response 
curve to determine concentrations that caused 50% and 90% inhibition of parasite 
growth gave values of 6.8 x 10-» M and 5.4 x 10-« M for FCD-4 and 1.7 x 10"^  M and 
7.4 X 10'® M for clone F-56, The clone was found to be slightly more sensitive to 
this drug since complete inhibition of clonal parasites was achieved at a concen-
tration of 10'* M whereas in the isolate it was observed at 10'' M of drug concen-
tration. 
Pyrimethamine: Sensitivity of the isolate FCD-4 and clone F-56 to graded con-
centrations of pyrimethamine in vitro is presented in Figure 2.5. Drug concentra-
tion of 10"* M or more uniformly affected the morphological appearance of sch-
izonts, as seen from 96 hours Giemsa stained blood films in both the parent isolate 
FCD-4 and clone F-56. Schizonts showed fragmented chromatin dots of unequal 
size scattered over a large area. Normal merozoite formation was prevented re-
sulting in the inhibition of parasite multiplication. In control wells 7 to 8 fold 
increase in parasitemia was observed by the end of 96 hours. The IC^^ and IC^^ 
values of the drug derived from the drug dose response curve were 1.5 x lO'* M and 
4.6 X 10-» M for FCD-4 and 1.5 x 10» M and 3.6 x lO-^  M for F-56. Apparently lactic 
acid used for drug preparation at concentrations present in the test solutions had 
no effect on parasite multiplication. This confirms the finding of Richards and 
Maples (1979). 
Cycloguanil: Parasite counts made at the end of 96 hours of the experiment 
revealed that multiplication of the parent isolate FCD-4 and clone F-56 was com-
pletely inhibited in vitro at 5 x 10"* M and 5 x 10'^ ° M concentration of cycloguanil. 
Percent inhibition of parasite growth in relation to control was plotted against log 
concentration of drug to determine ICg^ , and ICg^ , values. The isolate FCD-4 and 
clone F-56 showed marked sensitivity to cycloguanil. The IC^^ , and IC^^ , values 
derived from the drug dose response curve (Figure 2.6 ) were 8.4 x 1 0 " M and 6.8 
X lO-io M for FCD-4 and 7.2 x 1 0 " M and 2.7 x 10'^ ° M for the clone F-56. Inhibitory 
effect of the drug on parasite growth was observed even at very low concentra-
tions. The morphological appearance of cycloguanil sensitive parasites was very 
similar to that observed in the case of pyrimethamine. These abnormal parasites 
appeared enlarged and contained fragmented red staining nuclear material. Good 
growth of parasite was observed in control wells at the end of 96 hours. 
Quinine: The effect of quinine on erythrocytic stages of the clone F-56 and isolate 
FCD-4 in vitro is illustrated in Figure 2.7. The IC^ ,^ ICg^  and MIC values of the 
drug for the parasites derived from the drug response curve are 0.02 v^ml, 0.052 
Hg/ml and 0.06 ng/ml for clone F-56 and 0.01 ng/ml, 0.047 ^g/ml and 0.06 ng/ml for 
the isolate FCD-4. 
Artemisinin: The response of clone F-56 to graded concentrations of artemisinin 
is presented in Table 2.3. Complete inhibition of erythrocytic multiplication was 
obtained at a concentration of 10 ng/ml of the drug. The concentrations of the drug 
that caused 50% and 90% inhibition of parasite growth with respect to control 
derived from the tabulated data (Table 2.3 ) are 0.0019 ng/ml and 0.0058 ng/ml 
46 
respectively. 
Table 2.3 In vitro susceptibility of a P. falciparum clone, F-56 to artemisinin. 
The parasites were under drug pressure for 48 hours. Starting parasitemia was 
less than 1% and hematocrit 4%. Slides were enumerated for parasitemia at the 
end of 48 hours. 
Drug concentration (tig/ml) 
0 (control) 
0.01 
0.005 
0.001 
0.0005 
0.0001 
% parasitemia 
2.66 
0 
0.37 
2.07 
2.37 
2.71 
% inhibition 
0 
100 
86.09 
22.18 
10.9 
0 
DISCUSSION 
One of the most widely used applications based on continuous cultivation of 
erythrocytic stages of falciparum malaria (Trager and Jensen 1976) has been the 
in vitro determination of susceptibility of parasites to various antimalarial drugs 
around the world, more so in endemic locations. The popularity of these methods 
is obviously because of several advantages they offer over in vivo procedures. The 
'standard' WHO Field Test (1973) for instance which is used to determine the sus-
ceptibility off! falciparum infection in the subject requires 3 days of drug admin-
istration and 7 days of follow up period to ascertain the sensitivity of infecting 
parasites. Low levels of resistance can not be detected by this in vivo procedure. 
4/ 
Modified 'extended' Field Test requiring 28 days of follow up is employed t o deter-
mine the gradation from sensitive (S) to R I, RII or R III (high) level of resistance 
to chloroquine. Prolong follow up period with precautions for preventing any re-
infection during this duration are limiting factors to carry out this test, particu-
larly in endemic locations. The in vitro methods of determining the sensitivity of 
an isolate require much less time and can be easily completed in 2 to 3 days using 
very little blood from the infected person. The response of falciparum infection to 
drug treatment may differ from one individual to another depending upon the 
immune status of the individual (Powell et al. 1964; Waliker and Lopez Antunano 
1968). The hosts immune and other factors do not affect the outcome of results in 
vitro evaluation, thus permitting a more accurate evaluation of the intrinsic in-
hibitory properties of the drug on the parasites. However, serum supplement used, 
specially those procured from endemic regions, might interfere with correct as-
sessment of the inhibitory properties of the drug, as serum from various endemic 
regions are known to contain antibodies capable of retarding the growth of cul-
tures in vitro (Chulay et al. 1981; Jensen et al. 1982). To overcome this possibility 
each serum unit should be screened for the presence of malaria specific antibodies 
or the serum used should be heat inactivated to nullify the influence of these 
serum factors on the cultures. All through the present study the latter option was 
employed. This minimized the interference of serum factors in drug response 
studies of the parasite. Another drawback with in vivo evaluation is concerning 
uncertainty of complete absorption and retention of the drug in the subject. As-
sessment of complete uptake and presence of the correct amount of the drug in the 
blood of infected person requires use of time consuming, elaborate methods like 
HPLC. Applications of in vitro techniques have thus greatly improved the overall 
efficiency and precision of drug sensitivity tests. It is now possible to process and 
evaluate large number of compounds on different strains of falciparum simulta-
neously, thus providing broader range of information with respect to susceptibil-
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ity to various drugs. This has been made possible also because these techniques 
are relatively inexpensive compared to experimental animal model systems which 
require more space, equipment and manpower. In vitro cultures have made it 
possible to study clonal populations of parasites and this will contribute towards 
better understanding of genetic analysis of drug action and considerably facilitate 
molecular/biochemical studies on the mechanism of drug action. In vitro systems 
permit study of structural-activity relationship of compounds with great precision 
and relative ease, thus allowing the selection of lead compounds with greatest 
intrinsic antimalarial activity very rapidly. Evaluation of potential drug interac-
tion for synergism, antagonism or indifference has been made simpler by in vitro 
methods, enabling the selection of favourable combinations. By employing multi-
drug resistant strains in culture it is now possible to look for compounds which 
are not cross-resistant with existing antimalarial drugs. Finally it is possible in 
vitro studies to evaluate parent compounds and known or putative metabolites of 
the parent compounds separately, especially since only small quantities of each 
are needed. There are also important limitations associated with the use of in 
vitro methods. The most frequently cited limitation is the inability to detect the 
potential antimalarial activity of those compounds which require in vivo metabo-
lism to an active state, for example the antimalarial drug proguanil which is inac-
tive in vitro system. Similarly certain compounds which require some form of host 
interaction such as enhancement of host immunity may prove to be inactive when 
assessed in vitro. Another limiting characteristic of in vitro method is the artifi-
cial time course chosen for drug exposure, which is usually at a constant level of 
concentration for a relatively short period of time. Certain drugs which have been 
identified as effective antimalarials may ultimately prove to be toxic to the host or 
might have very little safety margin. Many compounds will also prove to be in-
soluble in the media used for culturing the parasites in vitro. Others will be sub-
ject to artifacts peculiar to in vitro systems such as adherence to the glass or plas-
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tic dishes in which the experiments are carried out. The above considerations 
lead to the conclusion that though the availability of in vitro culture techniques is 
important for antimalarial drug research, they are neither a substitute nor a re-
placement for in vivo or basic biochemical methods. A well-designed drug develop-
ment programme must carefully integrate these varied approaches, recognising 
their respective advantages, limitations and their mutual potential contributions 
towards the goal of identifying and characterising useful new antimalarial drugs. 
Parasite multiplication factor in our study was comparable with the iso-
lates and clones being cultivated elsewhere even in non-endemic areas. There 
were no crisis forms observed in cultures which have been reported from some 
holoendemic regions. The presence of malaria specific antibodies in the blood have 
been implicated for the presence of crisis form (Reese et al. 1981; Jensen et al. 
1982, 1984). There had been no excessive conversion rate of asexual forms to 
sexual stages in the culture as has been the case in most endemic regions employ-
ing hyperimmune serum (Jensen et al. 1984). All these observations peculiar to 
parasite growth and multiplication in the malaria endemic regions are contrary to 
the observations made in our cultures which confirm that the blood component 
used by us for cultivation were free from most of the factors involved in generating 
these characteristics. Oduola and coworkers (1992) have also found that plasma 
from semi-immune persons is suitable for continuous cultivation and drug suscep-
tibility testing of P./b/ciporum. 
The first simple in vitro test for assessing the drug susceptibility of P. falci-
parum parasites drawn from venous blood of an infected individual was developed 
by Rieckmann et al (1968). The test relied on a basic observation that parasites 
could survive in vitro system for short duration of atleast 30 hours. This fact was 
exploited in measuring the extent to which maturation of ring forms to schizonts 
was inhibited after incubation of parasitized blood in various drug concentrations 
for a period of 24 hours. This short term culture system provided a quick and 
reliable diagnostic tool to differentiate chloroquine resistant and ^^Hi^^'esiso-
lates both in laboratory and field conditions (Rieckmann and Lopez Antunano l571; '""'* 
Valera and Shute 1975; Palmer et al. 1976; Ebisawa et al. 1976; Sucharit et al. 
1977). Usefulness of this method culminated in the development of a test kit for 
monitoring the sensitivity of P. falciparum isolates to chloroquine by the WHO 
(1979). Using this kit one could even assess the level of resistance ranging from 
sensitive to highly resistant R III forms of the parasites. This test has also been 
used for other antimalarials. The main shortcoming of this macro-method is that 
it requires about 10 ml of venous blood which is not readily given by the patient, 
more so if the subjects are children. Development of microtechnique using capil-
lary blood specimen (Rieckmann et al. 1978), which can be obtained by a finger 
prick, has made the susceptibility test easier and can be performed by drawing 
little blood from even young children. Period of incubation in the micromethod 
can be extended to 48 hours without change of medium, so that one can even ob-
serve reinvasion of the merozoites (Rieckmann 1980; Yisunsri and Rieckmann 
1980). This technique has replaced macro test specially in the field with the de-
velopment of inexpensive battery operated out door incubators (Eastham and 
Rieckmann 1981). Considering the benefits of incubating parasites under drug 
pressure for longer duration in determining the susceptibility of falciparum iso-
lates, Nguyen-Dinh and Trager (1980) described a new 48 hour test system. In-
fected red blood cells, either from cultures or from clinical specimens (Nguyen-
Dinh et al. 1981) were diluted in a 50% suspension of fresh red blood cells in 
culture medium to obtain a parasite density of 0.1%-0.8%. The resulting parasit-
ized erythrocyte suspension was then further diluted in culture medium, with or 
without drug added, to a 2% erythrocyte suspension. A similar test method of 72 
hours has been described by Kramer and Siddiqui (1981) with 5% erythrocyte 
suspension. In the present study a modified 48 hour test method of Nguyen-Dinh 
and Payne (1980) has been employed in determining the susceptibility of para-
sites to antimalarial drugs in vitro, because this test method is reliable, reproduc-
ible and results are not modified by slight variations in starting parasitemia, eryth-
rocyte suspension, blood group of the red cells used, age of the erythrocytes, inocu-
lum size etc. 
According to Nguyen-Dinh and Trager (1980) for a strain sensitive to chlo-
roquine complete inhibition of growth occurs at 0.01 |xg/ml and for a resistant 
strain at 0.1 ng/ml. From IC^^ and ICg,, values derived from the drug response 
curve it can be inferred that both the parent isolate and the clone evaluated are 
resistant to chloroquine, the isolate being more resistant since at a concentration 
of 0.06 ng/ml complete inhibition is observed in the clonal parasites whereas only 
86% inhibition was observed in the parent isolate. In control wells in which para-
sites were incubated in drug free medium good growth was obtained with 4 to 5 
fold increase in parasitemia in 48 hours, which is comparable with the growth 
observed by Nguyen-Dinh and Trager (1980). Amodiaquine and chloroquine are 
both derivatives of 4-amino-7-chloroquinoline and differ only in the nature of the 
group attached to the 4 amino position, amodiaquine has a substituted benzene 
ring at the position, while chloroquine has a branched chain aliphatic substitu-
ent. The parasites evaluated have been found to be sensitive to amodiaquine while 
extremely resistant to chloroquine. Similar observations have been made by other 
workers (Thaithong et al. 1983; Watkins et al 1984; Looareesuwan et al. 1985) in 
strains of P. falciparum from different geographical regions, and also it has been 
observed that isolates found to be resistant to chloroquine develop resistance to 
amodiaquine sooner or later (Draper et al. 1988). Response of parasites to both 
the DHFR inhibitors evaluated was found to be similar. This is perhaps expected 
since both pyrimethamine and cycloguanil are known to act by affinity binding to 
the dihydrofolate reductase of the parasite which occupies a position in the cellu-
lar biosynthesis of the malaria parasites (Ferone et al. 1969). Smalley and Brown 
(1982) estimated that parasites obtained from clinical samples growing in 10"^  M 
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pyr imethamine or more are likely to be resis tant atleast to some degree in 24 hour 
test. Concentration of 1 x 10 ® M of pyrimethamine in a 48 hour test in vitro by 
Richards and Maples (1979) has been reported to be both inhibitory and cidal. As 
the morphological criterion has been used to determine the effect of the compound 
on P. falciparum, sometimes it becomes difficult to differentiate between the cidal 
and inhibitory effect on the parasi tes in a stained slide. In order to el iminate this 
ambiguity, the parasi tes were further cultivated for next 48 hours in drug free 
medium and percentage inhibition of parasi tes calculated at 96 hours . The 10^^ 
and ICgQ values determined both at the end of 48 and 96 hour experiments clearly 
indicate tha t isolate (FCD-4) and clone (F-56) tested are highly sensitive to py-
r imethamine and cycloguanil. Information on the relationship between in vitro 
schizontocidal activity and in vivo response to t rea tment are lacking for quinine 
and artemisinin. Quinine is being used in India for emergency medicament of 
malar ia but so far no reports have emated regarding t rea tment failure with this 
drug, indicating the sensitivity of the parasi tes to quinine. Mean plasma level of 
1.5 ng/ml of quinine base is reached in a person 4 hours after ingesting a single 
dose of 300 mg of quinine (Saggers et al. 1970). Complete inhibition of paras i tes 
were obtained at much lower concentrations, clearly indicating tha t paras i tes used 
were sensitive to quinine. This experiment has also generated a baseline da ta of 
these paras i tes for quinine susceptibility. Artemisinin has not been used for ma-
laria t rea tment in India, therefore parasi tes are expected to be sensitive to this 
drug. The mean plasma level of 110 ng/ml at tained at about 7 hours in h u m a n s 
taking the curative dose of 10 mg/kg body weight (Zhao and Zhang 1985, 1986) of 
ar temisinin is much higher the concentration of the drug needed to prevent the 
multiplication of the parasi tes used in vitro, indicating tha t the paras i tes of the 
clone F-56 are sensitive to artemisinin and we have baseline values of suscepti-
bility of th is paras i te line to a drug which may be used in future for rnalaria treat-
ment. 
Figure 2.1 A typical Giemsa stained tiiin blood film made from asynchronous culture showing 
various asexual erythrocytic stages (R= ring, T= trophozoite, S= schizont) and a sexual stage (G= 
gametocyte). ( X 1200 ) 
Figure 2.2 A Giemsa stained thin blood film depicting free merozoites released from a ruptured 
schizont. 
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Figure 2.3 Drug dose response curve for chloroquine in the P. falciparum isolate FCD-4 and cl 
F-56 after 48 hours of incubation in vitro (performed in 24-well sterile plastic tissue culture plat 
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Figure 2.4 Response of the P. falciparum isolate FCD-4 and clone F-56 to various concentrations 
of amodiaquine in vitro. 
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Figure 2.5 Pyrimethamine sensitivity of the P. falciparum isolate FCD-4 and clone F-56 deter-
mined in vitro by the modified 48 hour test method. 
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Chapter 3 
CHEMOSENSITIVITY OF A CHLOROQUINE-RESISTANT P. FALCI-
PARUM ISOLATE TO QUININE-TYPE COMPOUNDS IN VITRO 
Abstract: In vitro relative chemosensitivity of erythrocytic stages of the chloroquine resistant P falciparum 
isolate to quinine-type compounds has been evaluated. Apart from natural cinchona alkaloids, quinine and 
quinidine, their hydrogen derivatives proved to be more potent erythrocytic schizontocidal compounds. Some 
drug combinations show extremely good antimalarial property in vitro. Going by the IC^ values of the eight 
preparations tested the compounds can be arranged in following order with respect to their schizontocidal 
activity: 
quinidinelhydroquinidine ^ hydroquinidine > quinine I hydroquinine > quinidine > hydroquinine I quinine > 
apoquinine > epiquinine. 
Clearly in depth investigations are required for exploiting the full antimalarial potentials of these cinchorm 
derivatives or mixtures and other combinations. 
INTRODUCTION 
The property of cinchona bark to cure fevers of diverse origin was well known 
to the natives of South America, particularly to the Peruvian and the Bolivian 
(now Ecuador) Indians, much before the recorded historical date of 1630s when 
the first European was successfully treated (presumably of malaria) by the pow-
dered bark of cinchona tree (Guerra 1977 a, b.). Causative agent of the disease 
itself was first discovered and identified by Laveran (1880). The power of hot 
infusion of the powdered bark has been widely exploited in the treatment of ma-
laria since then. Ever increasing demand of this bark, which could easily be mis-
taken for that of other trees, especially in the dried up conditions led to frauds, 
speculative and hoarding tendencies among traders in nineteenth century 
(Gramiccia 1987). This generated interest in chemical analysis of the cinchona 
bark. The curative property of the bark was assigned to alkaloid components. 
The bark of cinchona trees contains a mixture of some 10 alkaloids, but most of 
them are not crystallizable (Bruce-Chwatt et al 1981). Quinine and cinchonine 
were the first two alkaloids isolated in crystalline form in 1820 by Pelletier and 
Caventou (Hofheinz and Merkli 1984). Quininc! salt proved to be an excellent 
antimalarial drug. Although correct structure of quinine had already been sug-
gested by 1908, synthesis of this compound was acliieved by Woodward and Doering 
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MATERIALS AND METHODS 
Parasites Locally collected P. falciparum isolate FCD-4, being routinely main-
tained in the laboratory using candle-jar method of Trager and Jensen (1976) was 
employed in this study. Isolation, establishment and maintenance in vitro of this 
isolate has been described in an earlier section of this chapter. The characteriza-
tion of the isolate demonstrated that FCD-4 was resistant to chloroquine. 
Drug solutions Coded preparations of cinchona alkaloids and their derivatives 
or mixtures were kindly provided by Dr. RI. Trigg of the World Health Organiza-
tion. Detail chemical structure of these compounds is given in Figure 3.1. 
Identity of the eight preparations used in the present investigation is as follows: 
Name Abbreviations 
1. Quinine (base) Q 
» 2. Quinidine (base) Qn 
3. Apoquinine (base) AQ 
4. Hydroquinine (base) HQ 
5. Hydroquinidine (base) HQn 
e.Quinine/Hydroquinine Q/HQ 
60:40 mixture (bases) 
T.Quinidine/Hydroquinidine QnAlQn 
60:40 mixture( bases) 
8. Epiquinine/Epiquinidine sulphate EQ/EQn 
60:40 mixture 
Stock solution of each compound was made by dissolving 1000 mg of the 
substance in 61.6 ml of O.IN sulphuric acid and diluted with glass distilled water 
to 100ml. Further dilutions of the stock solutions were made with HEPES buff-
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RESULTS 
Chemosensitivity of isolate FCD-4 to each compound was initially evalu-
ated by determining the blood schizontocidal activity in duplicate at 1,3,6,10, 60, 
100, 300, 600, 1000 ng/ml concentrations of the compound. Minimum inhibitory 
concentration (MIC) required to completely eliminate parasites with EQ/EQn (mix-
ture), AQ, Q, HQ was found to be 600, 100, 60, 30 ng/ml, respectively whereas 
other preparations effectively eliminated all parasites at concentration of 10 ng/ 
ml or less. The results obtained are summarized in the Table3.1. 
Table 3.1 Estimated MIC, IC^^ , and IC^^ values of quinine and quinine-type com-
pounds assayed in vitro against a chloroquine resistant isolate FCD-4 of P. falci-
parum in 24 well sterile plastic tissue cluture plates with starting parasitemia of 
less than 1%, erythrocyte suspension of 2%. The parasites were under drug pres-
sure for 48 hours. 
Compounds 
Quinine 
Quinidine 
Apoquinine 
Hydroquinine 
Hydroquinidine 
Quinine/Hydroquinine 
Quinidine/Hydroquinidine 
Epiquinine/Epiquinidine sulphate 
*ic,„ 
11 
4 
13 
5.6 
2.5 
3.9 
2.2 
140 
*ic. 
48 
5.8 
78 
9.4 
5 
8.4 
7 
270 
*MIC 
60 
10 
100 
30 
6 
10 
10 
600 
* Concentrations are in ng/ml. 
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tive than quinine at ICg,, level. Amount of quinidine needed to completely elimi-
nate parasites in vitro is far below the non- toxic peak quinidine levels achievable 
in plasma of human subjects. Quinidine has greater systemic clearance and a 
larger total apparent volume of distribution compared with quinine (White 1987). 
Plasma concentrations during malaria treatment are therefore lower. In the 
slightly insensitive strains of P. falciparum to quinine, although mostly cases of 
the Rl-type of resistance have been recorded (Cook 1986) quinidine has been re-
discovered as more potent antimalarial than quinine. So far there has been no 
report of quinidine resistance either from field or laboratory studies. Information 
on the relationship between in vitro antimalarial sensitivity and in vivo response 
to treatment with quinidine is lacking. This information can greatly improve and 
define the dose regimens of quinidine in different parts of the world depending on 
the susceptibility of local strains, thus increasing the safety meirgin of this drug. 
Apart from natural cinchona alkaloids the synthetic hydroderivatives of quini-
dine, quinine and their combinations showed extremely good erythrocytic schiz-
ontocidal activity. Advantages of hydroquinine over quinine had also been ob-
served by other workers (Giemsa and Werner 1914). The unnatural isomers of 
dihydroquinine and dihydroquinidine, the enantiomers or mirror image com-
pounds, were shown by Brosi and colleagues (1971) to have same degree of activ-
ity as the natural isomers in P. berghei in mice. The four major alkaloids all pos-
ses significant blood schizontocidal activity but their relative potencies vary with 
the species of Plasmodium (Hofheinz and Merkli 1984). Differences in apparent 
activity of cinchona alkaloids in vivo are related to both pharmacokinetic factors 
in the host and pharmacodynemic factors in the parasite. But evaluation of 
chemosensitivity in vitro system eliminates host factors effectively. Quinine is 
evidently not the most effective cinchona alkaloids but has reached a unique posi-
tion because it just happened to be the first to be crystallized and used in 'pure' 
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Figure 3.1 Chemical structures of quinine and qunine-type compounds 
Chapter 4 
CURE WITH CISPLATIN OF MURINE MALARIA INFECTION AND INHI-
BITION IN VITRO OF A CHLOROQUINE RESISTANT P. FALCIPARUM 
ISOLATE 
Abstract: Antiplasmodiumproperties ofcisplatin (cis-platinum (I!) diammine dichloride), a neoplastic drug, 
have been assessed using in vivo and in vitro model systems of malarial parasite. A well tolerated dose of 6 
mglkg body weight of the compound cured the mice infected with P. berghei and the amount of cisplatin 
required for in vitro inhibition (IC^ of a chloroquine resistant falciparum isolate was lower than either 
chloroquine or quinine. Minimum inhibitory concentration (MIC) needed to prevent the multiplication of 
asexual blood parasites in vitro was 30 ng/ml. Late ring and trophozoite stages of erythrocytic cycle were 
most susceptible whereas schizont and early ring stages were least sensitive to the toxic effect of cisplatin. 
Smaller multiple doses had been the most effective in curing malaria in mice than a single large dose. In a few 
cases, mice treated with a single intraperitoneal large dose of 6 mglkg body weight, there was a delay in 
appearance of parasitemia but most of them recovered completely but slowly. This compound exerts its toxic-
ity mainly by randomly damaging and cross-linking DNA strands as has been shown by Southern hybridiza-
tion using a synthetic oligonucleotide probe, which is a repeat sequence in the falciparum genome. The report 
clearly demonstrates the antimalarial potentials of this compound and suggests a closer evaluation of this and 
other related compounds, specially in combination with antimalarial drugs to probe their synergistic proper-
ties. 
INTRODUCTION 
Species of Plasmodium are the causative agents of malaria in man and some 
other vertebrates. P. berghei is responsible for murine malaria in mice and P. 
falciparum causes 'malignant tertian' human malaria. Appearance and speedy 
spread of resistance in P falciparum to common synthetic antimalarial drugs 
like chloroquine (Peters 1990b; Bruce-Chwatt et al. 1981), pyrimethamine (Peters 
1984; 1990b), proguanil (Chaudhuri andChaudhuri 1949; Field and Ederson 1949; 
Peters 1990b), used for treatment are showing an increasing rate of curative 
failures (Peters 1984; Wernsdorfer 1991). The current grim situation is thus a 
cause of concern to malaria epidemiologists, indicating the urgent need to identify 
and develop alternate compounds capable of curing resistant malaria. Malaria 
pathogenicity can be diminished by administration of drugs which inhibit active 
multiplication of asexual erythrocytic parasites and cure can be achieved by effec-
tively eliminating the blood forms from the host. The parasite clearance may be 
achieved either by lethal action of the compound used for treatment and/or by its 
ability to evoke a stronger immune response against the parasite. Cisplatin has 
twin properties of being employed for neoplastic treatment (Einhorn and Williams 
1979; Rosenberg 1984) and immunomodulation (Page et al. 1977; Kleinerman and 
Zwelling 1982). Cisplatin is a coordination compound of bivalent platinum and 
was the first inorganic antineoplastic agent to enter into clinical investigations 
around 1972 (Rosenberg 1973). Some of the known properties or salient features 
of cisplatin have been enumerated as under: 
1. The drug is active against a wide variety of tumors ( Rosenberg 1973, 
1980) 
2. Inactivates transforming DNA and viruses (Munchausen 1974; Shooter 
et al. 1972) 
3. Induces filamentous growth and causes prophage induction in lysogenic 
strains of E. coli bacteria (Rosenberg 1971, 1973) 
4. The drug causes chromosomal abnormalities and toxicity (Vandenberg 
and Roberts 1975 ) 
5. Supresses graft rejection against H2 histocompatibility barrier in mice 
(Khan et al. 1972 ) 
6. Activates the immune system of the host (Rosenberg 1985) 
7. Selectively inhibits DNA synthesis (Harder and Rosenberg 1970; Howley 
and Gale 1970) 
8. Causes mutagenesis (Monti-Bragdin et al. 1975; Lecointe et al. 1977) 
TD our knowledge no work has been reported on the effect of this compound 
on malaria parasites. These considerations prompted us to assess antiplasmodial 
properties of cisplatin in vitro and in vivo. Further, in order to understand the 
mode of action of this compound, studies on stage-specific susceptibility of eryth-
rocytic parasites in vitro and interaction of cisplatin with intact or restriction en-
zyme digested P. falciparum DNA have been carried out. The later experiments 
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were performed with a view to look for changes, if any, in the number and size of 
restriction fragments generated, following incubation of P. falciparum DNA with 
cisplatin, on a Southern blot using P. falciparum specific oligonucleotide probe. 
MATERIALS AND METHODS 
Parasites Rodent malaria parasite P. berghei was obtained from National Insti-
tute of Communicable Diseases, Delhi, India and maintained in Swiss albino mice 
of 30-40 g each, by weekly mechanical passage of infected erythrocytes drawn 
from a donor mouse by cardiac prick into a sterile, heparinized S3rringe. The 
biology of these parasites has been reviewed by Killick-Kendrik (1978). Chloro-
quine resistant P. falciparum isolate FCD-4 of human origin which has been de-
scribed in earlier section, was the other parasite used in this study. 
Stock solution of cisplatin The stock solution of cis-platinum (II) diammine 
dichloride, obtained from Sigma Chemicals, USA, was prepared by dissolving 1 
mg of the compound in 60% dimethylsulfoxide (DMSO). Further dilutions were 
made with buffered RPMI-1640 culture medium. 
Collection of parasitized blood from infected donor mouse 
The strain of P. berghei was propagated in Swiss-albino mice by weekly 
mechanical passage of infected erythrocytes. The parasitized blood was drawn 
from an infected donor mouse via cardiac puncture. The infected blood was centri-
fuged at 2000 rpm for 10 min at 4 °C. The buffy coat and supernatant containing 
plasma were discarded. Packed cells were washed twice in 3.5 volumes of sterile 
0.85% NaCl. This parasitized blood was used for passaging in mice and the course 
of infection followed by examining Giemsa stained blood films made each day from 
the tail blood. 
Inoculation of test animals 
Infected blood collected from the donor mouse usually contained about 70% 
parasitemia. The infected erythrocytes were washed with sterile normal saline as 
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described above. The number of cells per 0.05 ml of infected blood was calculated 
using Neubauer cell counting chamber. Percentage peu-asitemia was determined 
from Giemsa stained thin blood films. Each mice was inoculated with 0.05 ml of 
infected blood containing 10' to 10® parasites. Infected mice were kept in an air-
conditioned room (24 °C - 26 °C). Mice were fed ad libitum with commercial pellet 
and water supplemented with 0.01% p-aminobenzoic acid. 
Erythrocytic schizontocidal activity 
In vivo susceptibility of P. berghei: Curative property of cisplatin was as-
sessed by comparing the survival times of mice untreated or treated with cisplatin 
receiving same amount of parasite inoculum in the form of infected erythrocytes 
obtained from a donor mouse. Test mice were taken in groups of five. Preliminary 
experiments were conducted in batches consisting of three mice each to arrive at 
the optimum tolerable dose of cisplatin effective in curing the mice. These pre-
liminary doses ranged from 2-12 mg/kg body weight. Each member of the test 
group was injected with 10* parasitized erythrocytes, inoculated intraperitoneally. 
The cisplatin was given intraperitoneally but eight hours later either as a single 
dose or in four equally divided doses, at 4 hour intervals each in 1 ml saline solu-
tion. Appropriate sets of control mice were maintained. The development of para-
sitemia was monitored by making Giemsa stained blood films from the cut tail 
vein of the experimental and control animals every 24 hours for a period of 60 
days. 
In vitro susceptibility of i^ falciparum: Erythrocytic schizontocidal activity 
of cisplatin on P. falciparum was determined by exposing parasites in triplicates 
to graded concentrations of cisplatin using the modified 48 hour test method 
(Nguyen-Dinh and Payne 1980). The experiments were conducted in 24-well tis-
sue culture plates by setting up microcultures with eight different concentrations, 
ranging from 1 to 1000 ng/ml. The parasite material for experiments was ob-
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tained from stock cultures and subjected to sorbitol lysis (Lambros and Vanderberg 
1979), to get synchronized ring stages. The parasitemia of the 50% cell suspen-
sion of this synchronized material was adjusted to less than 1% with uninfected 
freshly washed erythrocytes. Aliquot of 20 ju.1 of the suspension was added into 
series of wells of the test plate, each holding 480 fi\ of complete medium with or 
without drug, yielding final cell suspension of 2%. Loaded test plates were incu-
bated at 37 "C in a candle-jar for 96 hours with daily change of medium. The drug 
was included in experimental wells for first two days only. Blood smears were 
made at the end of 48 and 96 hours, stained with Giemsa. Minimum of 5000 
erythrocytes were enumerated to determine the parasitemia. Percentage reduc-
tion of parasitemia in relation to control was calculated. Fifty percent and 90% 
inhibitory concentrations (ICg^ and ICgj,, respectively) were extrapolated from semi-
log plot of varying concentrations of cisplatin against percentage inhibition of 
growth 
In vitro stage-speciflc sensitivity: 
To investigate the preferential toxicity to any specific stage of P. falciparum 
in vitro, asynchronous culture material was subjected to triple sorbitol treatment 
at 0, 40 and 47 hours interval, to obtain synchronized peirasites of 0-7 hours old 
(Lambros and Vanderberg 1979). These synchronized parasites were in early ring 
stage for another 12 hours, for next 12-24 hours of development in late ring or 
early trophozoite stage, 24-36 hours old in late trophozoite stage and during sub-
sequent 36-48 hours of growth in schizont stage of the erythrocytic schizogonic 
cycle. The synchronized stages were subjected to drug pressure for 12 hours each, 
the respective period of their residence in the specific stage. The experiments 
were conducted in triplicates in multiwell plates and slides made at the end of 
schizogonic cycle. The toxicity of cisplatin to ring, trophozoite and schizont in-
fected stages was determined by calculating the percentage inhibition of para-
sitemia in drug treated parasites to that in drug free controls. The extent of syn-
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chronization of parasites achieved is depicted elsewhere. 
Plat inat ionofDNA 
Binding of cisplatin to P. falciparum DNA, extracted from erythrocytic stages 
(Tungpradabkul and Panyim 1985) was studied by incubating 4 /u.g of DNA at 37 
°C for 24 hours with 50 or 100 ng of cisplatin in total volume of 10 /xl. The incu-
bated material was then digested with restriction enzyme Hind III at 37 °C for 2 
hours (Sambrook et al. 1989). In another set of experiment Hind III digested DNA 
material was incubated with cisplatin. Similar experiments were performed using 
Taq I. These digested samples were size fractionated on a 0.7% agarose gel along 
with control samples of uncleaved or restriction enzyme cleaved DNA not incu-
bated with cisplatin. The gel was stained with ethidium bromide and visualized 
under UV before the material was transferred on to a nylon membrane by South-
ern blotting. The membrane was then hybridized with y-'^P end labelled 21-mer 
synthetic oligonucleotide, which is known to be a repetitive sequence in P. falci-
parum genome (Mucenski et al. 1986), at 42 °C using stringent washing condi-
tions. The methods employed for the extraction of DNA, Southern transfer and 
hybridization have been described in the following chapters. The sequence of the 
oligomer used to probe the membrane was as follows : 
5'-AGGTCTTAACTTGACTAACAT-3' 
RESULTS 
The periodicity of blood schizogony of the rodent malaria parasite/* berghei 
was a quotidian cycle i.e., 22-25 hours. The mortality rate of P. berghei in the 
strain of white mice used in the present study was 100%, if untreated. The mor-
tality curve was bimodal. During the first 6 days of infection, mature erythrocytes 
were invaded, and the mouse died in a condition of shock. If the animal survived 
the first phase, many reticulocytes then occured in the blood and were preferen-
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tially invaded, anemia increased and the animal died later in a condition of an-
oxia. Parasites were observed in tail blood films of test animals within 24 hours 
after inoculation of infected blood. As seen in Figure 4.1 a & b the characteristic 
course of infection was highly asynchronous. Blood films showed the presence of 
all the different asexual blood stages of the parasite namely rings, trophozoites 
and schizonts at the same time. Reticulocytes were frequently infected with mul-
tiple parasites than mature erythrocytes. Upto 10 parasites per reticuloc3rte were 
observed. The intraerythrocytic ring forms showed red staining chromatin dot 
with a very small area of blue stained cytoplasm. The trophozoites were recogniz-
able by the presence of chromatin dot with enlarged cytoplasm containing faint 
brown-yellowish spots of haematin granules. Mature schizonts were character-
ized by 12-20 distinct merozoites and a dark brown-yellowish dot of clustered 
haematin. These schizonts in due course became more fragile and released their 
merozoites, resulting in groups of free merozoites accompanied by a free pigment 
cluster (Figure 4.1 b). Platelets and white blood corpuscles are seen in Figure 4.2. 
Ability of cisplatin to clear P. berghei infection from mice is presented in 
Table 4. Tbtal dose of 6 mg/kg body weight given in four equally divided intraperi-
toneal injections at four hour intervals effectively cured the infected mice and no 
parasitemia could be observed for sixty days in any of the treated mice. The same 
dose when given as a single intraperitoneal injection finally cured 80% of the in-
fected mice. Initially, however, in three out of five of these test animals parasite 
appearance was delayed by 11 days compared to controls and parasite population 
increased subsequently leading to death of one of the mice whereas in the other 
two mice appearance of high parasitemia was followed by slow decline with final 
disappearance of the parasites after 14 days. Four week onwards from the start 
of the experiment no parasite could be observed in these two surviving mice till 
day sixty. In all the control animals, not receiving treatment with cisplatin, healthy 
parasites appeared in circulation within 24 hours of receiving the infective inocu-
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lum and they died in less than 10 days due to high parasitemia. 
Table 4.1 Ability of cisplatin to cure P. berghei infected mice. Each of the mice received an 
intraperitonial innoculum of 1x10* parasites. The treated animals were injected intraperitoneally 
with cisplatin 8 hr later. 
Infected mice 
Dose 
Untreated 
nil 
Treated with cisplatin 
6mg/kg body weight 
as a single dose 
6mg/kg body weight 
in four equally divided 
doses at 4 hr intervals 
Mice showing 
parasitemia 
within two 
weeks of 
innoculation 
5/5 3/5 0/5 
Mice 
surviving 
till 60 days 
following 
innoculation 
0/5 4/5 5/5 
Inhibitory effect of cisplatin on multiplication of the synchronized cultures 
of P. falciparum in vitro are presented in Figure 4.3. Complete inhibition of the 
multiplication was achieved by minimum amount of 30 ng /ml of cisplatin present 
in culture medium for a duration of 48 hours. From the dose response curve ICg^ 
and ICgj, values determined after 48 hours were found to be 6.2 and 24 ng/ml, 
respectively and 3.8 and 26 ng/ml, respectively after 96 hours experiment. Abnor-
mal parasites were observed from drug treated wells at the end of 48 hours, show-
ing different degree of vacuolization or pale staining, whereas normal healthy 
parasites multiplied to about six fold in control wells in a schizogonic cycle. Most 
of the abnormal parasites in treated wells had degenerated or lysed by 96 hours. 
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The stage specific toxicity of cisplatin is given in Figure 4.4. Schizont stages 
were least susceptible to the toxic effect of the compound followed by young rings 
whereas trophozoites and old rings were most susceptible. The schizont stages 
exposed to 30 ng/ml of cisplatin in the medium resulted in only 36% growth inhi-
bition. 
Autoradiographs of the restriction enzyme digested falciparum DNA incu-
bated with or without cisplatin and probed with a synthetic repetitive oligonucle-
otide are shown in Figures 4.5 & 4.6. No hybridization band was observed in the 
lanes containing uncut DNA or digested DNA incubated with cisplatin whereas 
control lanes showed the clear presence of one or several hybridization bands. 
DISCUSSION 
One of the most inexpensive ways of searching new lead antimalarial com-
pounds for drug development could be to screen the drugs which have been devel-
oped for other diseases and evaluate their antimalarial potentials, either alone or 
in combination with other known antimalarial drugs. Cisplatin is a drug with 
high potency in treatment of a few human malignancies (Rosenberg 1985; Hosokawa 
et al. 1982; Volge et al. 1982) and is a broad spectrum anticancer drug in animals 
(Rosenberg 1985; Welsh 1971). It is believed that the drug basically enhances the 
immunogenicity of the tumor cells by exposing new antigenic sites on the tumor 
cell surface and this evokes a host of offending immune reactions directed against 
the tumors. This assumption is based on the following observations: a) Swiss 
white mice cured of advanced Sarcoma-180 tumors with therapeutic dose of cisplatin 
completely rejected all further transplants for 11 subsequent months because of 
high level of immunity generated against the tumor lasting for this period 
(Rosenberg 1973,1985). b) In the Swiss white mice cisplatin treatment produced 
nearly absolute cure of advanced Sarcoma-180 tumors with a single intraperito-
neal injection on day eight but admin i s t ra t ion of hydrocor t isone, an 
immunodepressent, on a day prior to the ii\jection of cisplatin produces only 40% 
cure by eighth day (Conran and Rosenberg 1972). P. falciparum also possesses 
genes with affinities to multiple drug-resistance (mdr) genes of human cancer cells 
(Bradely et al. 1988; Foote et al. 1989) and this particular factor provided a strong 
clue that some anticancer drugs may possess antiplasmodial properties. The re-
sults presented in this report amply demonstrate the antiplasmodial potential of 
cisplatin. Apparently non-pathogenic dose of this compound cured the malaria 
infected mice and in vitro inhibited multiplication of a chloroquine resistant falci-
parum isolate at a low concentration included in the medium. 
Toxicity to the host is an important consideration of any candidate com-
pound with potential of being employed as a drug. The amount of cisplatin used 
in this study to cure malaria infection in mice is well tolerated by the host. The 
dose of 6 mg/kgbody weight given either as a single intraperitoneal push-in iryec-
tion or in four equally divided doses at 4 hour intervals with saline did not cause 
any mortality in control mice. Other cancer workers have also reported that thera-
peutic dose of 7 mg/kg body weight of cisplatin causes less than 10% mortality in 
mice and as a single intraperitoneal injection, the administered LD^^ dose is 13 to 
14 mg of cisplatin/kg body weight (Rosenberg 1985). Slow infusion of cisplatin 
gives better results in cancer treatments (Rosenberg 1985) and also kidney toxic-
ity is ameliorated with saline hydration (Hayes et al. 1977). Present report also 
shows that 1.5 mg/kgbody weight dose of cisplatin 4 times at 4 hour intervals with 
saline is far more superior than a single dose of 6 mg/kg in treatment of mice 
malaria. This is perhaps due to longer retention of higher level of cisplatin in the 
body for extended period of time, as half life of cisplatin in mice has been reported 
to be only 20 hours and an erythrocytic schizogonic cycle of mice malaria is of 24 
hour duration. In the two mice, which received single 6 mg/kg body weight dose of 
cisplatin, appearance of parasitemia was followed by slow but complete recovery, 
this could be due to immunostimulation property of cisplatin which has been clearly 
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demonstrated in several reports (Kleinerman et al. 1980; Kleinerman and Zwelling 
1982; Bahadur et al. 1984). Cisplatin has trypanocidal activity in mice (Wysor 
1982). The preliminary result in this study clearly demonstrates the antiplasmo-
dial properties of cisplatin both in vitro and in vivo systems. Therefore, it would 
be worthwhile to investigate the antimalarial properties of this and other related 
platinum complexes with regard to their ability to cure polyresistant Plasmodium 
species. Probing additivity and synergism properties in combination with other 
antimalarial drugs having different mode of actions should also not be ignored, 
but all this needs further serious investigations. 
Amount of cisplatin required in vitro to achieve 50% inhibition of parasitemia 
in isolate FCD-4 was found to be less than either chloroquine (ICg^r: 18 ng/ml, our 
unpublished da ta ) or quinine (ICg^jsllng/ml) (Nair and Bhasin 1993). Not much 
difference in IC^^ and IC^^ values calculated from the slides made at the end of 48 
or 96 hours of the experiment suggests that there was an insignificant delayed 
mortality of the parasites due to cisplatin toxicity. Most of its lethal effect is ex-
hibited within an erythrocytic schizogonic cycle. 
Each of the synchronized asexual erythrocytic stages were subjected in vitro 
to uniform drug pressure of 12 hours with differential outcome with regard to 
parasite survival and multiplication. Intraerythrocytic merozoites in the schizont 
and the early rings are the least susceptible to toxic effects of cisplatin, perhaps in 
these stages no active DNA synthesis takes place (Inselburg and Banyal 1984) 
and the parasite plasma membrane is most intact thus retarding free entry of the 
compound into the parasite milieu. Cisplatin is known to prevent the multiplica-
tion of cancer cells by randomly inter- and intralinking of DNA strands of these 
dividing cells (Cohen et al. 1979). The most damaging outcome, therefore, are 
seen in the early and late trophozoite stages of malaria parasite, known to be 
actively involved in DNA synthesis (Inselburg and Banyal 1984). 
Molecular basis of cisplatin toxicity has been attributed to lesions in DNA 
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molecules of cancer cells leading to inter- and intrastrand DNA cross-links, fi-
nally resulting in cell death (Cohen et al 1979; Zwelling and Kohn 1979). In vitro 
binding of cisplatin can occur with any base but prefered order of binding is 
G>A>C>T (Rahn et al. 1980). We explored the interaction of cisplatin with P. 
falciparum DNA, by incubating it with intact DNA and digesting it later with 
restriction enzymes and by incubating predigested DNA with cisplatin. When these 
samples were run on agarose gel and stained with ethidium bromide, no fluores-
cence was observed in lanes containing samples incubated with cisplatin, showing 
that cisplatin prevents intercalation of ethidium bromide with DNA. Following 
blotting of these samples on to the nylon membrane and on probing with radiola-
belled 21-mer repeat sequence, no hybridization in these lanes are visible. This 
may be due to inter- and intrastrand cross linking of DNA by cisplatin, thus pre-
venting the specific binding of the probe to complementary sequences on the DNA 
which is clearly seen in the form of distinct bands in control lanes of the autorad-
iograph. Thus mode of action of this compound on Plasmodium may be similar to 
the reported mechanism of action on neoplastic cells. 
*Part of this work has been published in Jap. J. Med. Sci. Biol.(1994),47, 241-252. 
Figure 4.1 a. A Giemsa stained thin blcx)d film from P. herghei infected mouse showing different 
asexual stages of the parasite namely ring (R), trophozoite (T) and schizont (S). 
Figure 4.1 b. A Giemsa stained thin blood film from P. berghei infected mouse showing multiple 
infection of reticulocytes, a cluster of free merozoites and pigment. 

Figure 4.2 A Giemsa stained thin blood film from P. ber^hei infected mouse showing parasites, 
platelets (P) and WBC (W). 
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Figure 4.3 In vitro growth inhibition response of asexual erythrocytic stages of P. falciparum to 
different concentrations of cisplatin in 48 hour test. Slides were made at the end of 48 and 96 hours. 
Starting synchronized parasitemia was less than 1%. 
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Figure 4.4 In vitro growth inhibition of different asexual erythrocytic stages of P. falciparum to 
various concentrations in a 48 hour test. Slides were made at the end of 48 hours. Starting 
parasitemia in each case was less than 1%. 
''Igure 4.5 An autoradiogram showing hybridization bands of/! falciparum DNA with species-
pecific synthetic Y " P labelled 21-mer oligonucleotide probe. The DNA samples (4 jxg in each lane 
:xcept lane 3, which was blank) were size fractionated on 0.7% agarose gel and Southern trans-
erred on to nylon membrane for hybridization. 
Lane 1. Undigested P. falciparum DNA 
2. DNA digested with Hind III 
3. Kept blank 
4. DNA incubated with DMSO prior to digestion with Hind III 
5. DNA digested with Hind III and incubated with DMSO 
6. DNA incubated with 50 ng of cisplatin 
7. DNA digested with Hind III and incubated with 50 ng of cisplatin 
8. DNA incubated with 100 ng of cisplatin and later digested with Hind III 
9. DNA digested with Hind III and incubated with 100 ng of cisplatin 
I 2 3 4 5 6 7 8 9 
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Figure 4.6 An autoradiogram showing hybridization bands oi P. falciparum DNA with species-
specific synthetic y ^^ P labelled 21-mer oligonucleotide probe. The DNA samples (4 |xg in each lane 
except lane 3, which was blank) were size fractionated on 0.7% agarose gel and Southern trans-
ferred on to nylon membrane for hybridization. 
Liine 1. P. falciparum DNA incubated with 50 ng of cisplatin and then digested and 
then digested with Taq I 
2. DNA digested with Taq I 
3. DNA digested with Taq I and then incubated with 50 ng of cisplatin 
4. DNA incubated with DMSO prior to digestion with Taq I 
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Chapter 5 
IN VrmO SELECTION OF P. FALCIPARUM RESISTANT LINES TO DIHY-
DROFOLATE-REDUCTASE INHIBITORS, CROSS RESISTANCE AND 
OTHER RELATED STUDIES 
Abstract: Proguanil and pyrimethamine exhibit their antimalarials virtues by preferentially inhibiting the 
DHFR enzyme of parasites. Pyrimethamine has been deployed on a much larger scale than proguanil. These 
drugs have been extremely useful in treatment of chloroquine resistant falciparum infection but the limiting 
factor has been the quick development of resistance among the parasite population against these drugs. Py-
rimethamine resistance is known to be widely distributed in all malaria endemic areas of the globe, including 
India. Proguanil has not been (extensively) used in India for over fifty years now. It should, therefore, be of 
interest to know the susceptibility of pyrimethamine resistant and sensitive lines of Indian origin to cyclogua-
nil (the active metabolite of proguanil). These considerations prompted us to perform a series of experiments 
with a view to assess the potential usefulness of cycloguanil in circumventing and combating the problem of 
pyrimethamine resistance in falciparum. It has been found that falciparum lines resistant to pyrimethamine 
are selected much faster than for cycloguanil resistance. Highly resistant pyrimethamine lines are predis-
posed for faster selection to cycloguanil resistance. Resistance acquired to pyrimethamine is stable. Py-
rimethamine resistant parasites acquire a degree of cross resistance to cycloguanil and to another DHFR 
inhibitor, methotrexate but do not show any cross resistance to other groups of antimalarial drugs. Cyclogua-
nil and pyrimethamine induce the formation of gametocytes in non-gametocyte forming clone. There has been 
no synergistic activity observed between cycloguanil and pyrimethamine. The deployment of triple drug 
combination of pyrimethamine, cycloguanil and sulfadoxine to impede the spread of resistance should be 
seriously considered. 
INTRODUCTION 
Pyrimethamine and cycloguanil, the active metabolite of proguanil, are the 
two most widely used DHFR inhibitor antimalarial drugs. Soon after introduc-
tion of proguanil, reports of resistance in P. falciparum started emanating from 
endemic areas around the world (Chaudhuri and Chaudhuri 1949; Field and Edeson 
1949; Adams and Seaton 1949; Covell et al. 1949). These observations led Nicol 
(1953) to suggest that 200 mg daily dose of proguanil would be better than 100 mg. 
Since that time there have been numerous reports of the failure of daily proguanil 
prophylaxis (100 mg) to prevent the development of P. falciparum, but with very 
few well documented case histories. The real incidence of proguanil prophylactic 
resistance appears to be in doubt, but many British authorities retain a firm belief 
in continuing efficacy of this compound as a prophylactic against falciparum ma-
laria (Peters 1984a). Proguanil is not available and used in India since early 
1950s. This is mainly because of the availability of pyrimethamine which has 
74 
proved, weight for weight, to be many times more active than proguanil (Bruce-
Chwatt et al. 1981), less expensive and has a longer retention time, thus it super-
seded the use of proguanil. Pyrimethamine resistance has followed a similar 
history to that against proguanil. Since 1952 there have been many reports of 
pjn'imethamine resistance in all species of human malaria (Coatney et al. 1952; 
Wilson 1952; Young 1967; Burgess and Young 1959). There is abundant evidence 
to indicate that pyrimethamine resistance is widely distributed throughout ma-
laria endemic areas of the world (WHO 1965, 1973), so also in India (Gajanana et 
al. 1984). It will be of interest to ascertain the susceptibility of pyrimethamine 
resistant and sensitive lines from an Indian isolate to cycloguanil in vitro, the 
drug which has not been in wide use for over fifty years now in India and in the 
absence of any authentic clinical data from other endemic areas of the world with 
regard to susceptibility to cycloguanil. These observations/considerations provided 
an impetus to design the following experiments with defined objectives, with a 
view to assQss the potential usefulness of cycloguanil in circumventing and com-
bating the problem of pyrimethamine-resistance in falciparum: 
a) To evaluate the speed of selection of resistance to the two DHFR inhibitor 
antimalarial drugs by subjecting a cloned P. falciparum line in vitro to py-
rimethamine or cycloguanil pressure, b) To isolate a series of progressively resis-
tant P. falciparum lines to each of these two drugs that will be useful in the study 
of the mechanisms of evolution of resistance to DHFR inhibitors, c) To determine 
the extent of cross-resistance acquired to each of them at various stages of resis-
tance and to look susceptibility profile changes, if any, to other antimalarials, d) 
To ascertain if resistance to one drug predisposes the parasites to be selected 
faster for resistance to the other drug, e) The two DHFR inhibitors are toxic to 
the same or different stages of P falciparum, f) Synergistic or additive virtues of 
these two compounds in vitro, g) To characterize the resistant lines selected with 
regard to biological advantage, if any. 
This chapter describes the findings of aforementioned experiments. 
MATERIALS AND METHODS 
Parasites 
Isolate FCD-4 and a clone F-56 derived from this isolate were the two P. 
falciparum parasite lines used in the present study. The clone was obtained by 
limiting dilution method (Rosario 1981) from the erythrocytic stages of parasites 
cultivated continuously in vitro employing candle-jar procedure of Trager and 
Jensen(1976). The FCD-4 was isolated locally from an infected patient( Nair and 
Bhasin 1993). 
Stock solutions of drugs 
Pyrimethamine lO^^  M stock solution was prepared in 0.05% lactic acid and 
10'^ M stock of cycloguanil in 70% ethanol. Chloroquine sulphate solution con-
tained chloroquine base equivalent to 40 mg /ml. Methotrexate (amethopterin) 
10'^ M stock solution was prepared in 60% DMSO. Artemisinin (qinghaosu) Img/ 
ml of the stock solution was made in DMSO. Drugs were filter sterilized and 
stored at 4 °C. Further dilutions were made in RPMI-1640 medium prior to use. 
Stock culture of parasites 
Parasite stocks were maintained in glass Petridishes (10 cm diameter) by 
the candle jar method (Trager and Jensen 1976) in A+ human erythrocytes using 
RPMI-1640 medium supplemented with AB+ serum. Blood products were procured 
commercially. Starting parasitemia in these cultures was less than 1% and he-
matocrit 8% in a total of 12 ml erythrocyte cell suspension in each Petridish. The 
cultures were diluted every 4 or 5 day with uninfected erythrocytes to restore the 
parasitemia and hematocrit to less than 1% and 8%, respectively. 
In vitro Gametocytogenesis 
Cultures were intiated in glass Petridishes to determine the capability of 
falciparum isolate/clone to form gametocytes in vitro (Bhasin and Trager 1984). 
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Each Petridish (5 cm diameter) was seeded with 5 ml of culture material having 
8% hematocrit and less than 1% parasitemia. An initial zero hour slide of seeding 
material was made to determine the exact parasitemia and gametocytemia. The 
cultures were incubated at 37 °C in a candle-jar with daily change of medium for 
eight consecutive schizogonic cycles without addition of uninfected erythrocytes. 
Thick blood smear of 10 /il material of 60% cell suspension was made every 48 
hours. Gametocytemia was assessed by examining minimum of 100 fields. The 
gametocytes were classified as stage II to V (Hawking et al. 1971). 
Susceptibility test method 
Susceptibility of parasites to DHFR inhibitors and other antimalarials 
was determined by exposing parasites in triplicates to graded concentrations of 
each drug using the modified 48 hours test method (Nguyen-Dinh and Payne 1980). 
The experiments were conducted in 24-well tissue culture plates by setting up 
microcultures with different drug concentrations (ranging from 1 0 " to 10 ' M 
with five fold difference or less for DHFR inhibitors). The parasite material for 
experiments was obtained from stock cultures and subjected to sorbitol lysis 
(Lambros and Vanderberg 1979), to obtain synchronized ring stages. The para-
sitemia was adjusted to less than 1% with uninfected fresh erythrocytes and this 
material was made to 50% cell suspension with complete RPMI medium. Aliquots 
of 20 /il of the suspension were added into series of wells of the test plate, each 
holding 480 fi\ of complete medium with or without drug, yielding final cell sus-
pension of 2%. Loaded test plates were incubated at 37 °C in a candle-jar for 96 
hour with daily change of medium. The drug was included in experimental wells 
for first two days only. Blood smears were made at the end of 48 and 96 hours, 
stained with Giemsa. Minimum of 5000 erythrocytes were enumerated to deter-
mine parasitemia in each well. Percentage reduction of parasitemia in relation to 
control was calculated from percentage inhibition of growth. Fifty percent ,90% 
and minimum complete inhibitory concentration (ICg^, ICg^  and MIC, respectively 
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inhibition of growth obtained from triplicate wells. ; '^' . > 
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Selection for increased antifol resistance Vi^v. ~ - > B 2 _ 7 
The cloned falciparum line was subjected in vitro to severa^^^flfl^^if^i^cri^as-
ing drug pressure in multistep manner to select a series of progressively resistant 
P. falciparum lines. Small glass Petridishes holding 5 ml of drugged medium with 
starting erjrthrocytic cell suspension of 5% hematocrit and 2% parasitemia were 
incubated at 37 K3 for 48 hour, drugged medium was replenished after 24 hours. 
The drug concentration selected for exposure of the parasites, in the first-step, 
was little lower than the ICg^  of the parasites. The surviving parasites were 
allowed to multiply in the drug free medium till the parasitemia reached to about 
2%, and these parasites were re-exposed to the first-step drug concentration for 
another 48 hours followed by growth in drug free medium. This procedure contin-
ued till the 48 hours drug pressure concentration used in the first-step did not 
retard the parasite multiplication, that is atleast five fold increase in parasitemia 
could be obtained in a schizogonic cycle with starting parasitemia of around 0.5%. 
In the second-step these parasites were exposed for 96 hours to the selected con-
centration of the drug, followed by the propagation in the drug free medium until 
the parasitemia reached to around 2%. Drug was included again in the medium 
for 96 hours duration of parasite multiplication and the procedure was repeated 
till atleast five fold increase in parasitemia was achieved in the first 48 hours 
with starting parasitemia of around 0.5% in presence of drug pressure. In the 
final-step of the first round of selection the surviving parasites were grown under 
continuous drug pressure till the rate of multiplication of these parasites was equal 
to that of control parasites grown in drug free medium, for a few cycles. The 
selected parasites of first round of selection were subjected to next round of selec-
tion pressure with five fold (or less) increase in the drug concentration by the 
same multistep procedure as described for the first round. This protocol for selec-
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tion was repeated for each of the subsequent rounds. Selected parasites were peri-
odically cryopreserved (Rowe et al. 1968) in liquid nitrogen for future use. 
Cross resistance 
The derived falciparum line resistant to one of the DHFR inhibitors was 
evaluated for its sensitivity profile to the other antifol. In addition the suceptibility 
of the highly pyrimethamine-resistant line to other antimalarials and another 
DHFR inhibitor amethopterin was evaluated to determine the degree of cross re-
sistance acquired by this selected line. 
Stability of resistance 
In order to assess, if the selected resistant phenotype of the parasite cell 
line is stable or lost once the drug pressure is discontinued for an extended period 
of time during continuous cultivation, the susceptibility to pyrimethamine of these 
parasites was determined at the end of 60 weeks of continued growth in drug free 
medium and compared with that of the original resistant cell line kept under 
constant drug pressure. The parasites were cultivated in glass Petridishes hold-
ing 5 ml of erythrocyte suspension in RPMI-1640 by candle jar method, with 
dilution of cultures every 4 or 5th day by restoring the parasitemia to less than 1% 
and hematocrit to 5%. 
Stage-specific sensitivity to DHFR inhibitors 
Highly synchronized parasites of clone F-56 were employed to look for dif-
ferences in toxicity of pyrimethamine and cycloguanil, if any, to the specific stages 
of P. falciparum. Asynchronously multiplying parasites with atleast 5% parasitemia 
and containing majority of the parasites in the ring stage were used for triple 
sorbitol synchronization (Lambros and Vanderberg 1979). The culture material 
was centrifuged at 2000 rpm for 5 min, the supernatant was discarded and the 
pellet resuspended in 5 volumes of sterile 5% sorbitol in distilled water for 7 min 
at room temperature. After incubation the parasite material was centrifuged and 
the supernatant discarded. The pellet was washed thrice with RPMI medium and 
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culture was reestablished by addition of fresh uninfected erythrocytes in the me-
dium containing 10% serum supplement. At 40 hours following the first sorbitol 
treatment the parasites were treated again with 5% sorbitol in the same afore-
mentioned manner to increase the synchronization (Vial et al. 1982). Freshly 
washed erythrocytes were added to the infected cells and culture was set again. 
Seven hours later the culture material was subjected to third and final treatment 
with sorbitol , so as to obtain 0-7 hour old ring stage parasites. The pellet was 
thoroughly washed in order to avoid the influence of trace amounts of sorbitol on 
the parasites. This material was mixed with freshly washed uninfected cells to 
obtain the final parasitemia between 0.5 to 1% in 50% erythrocyte cell suspension. 
Stage-specific effect of pyrimethamine and cycloguanil was determined by 
exposing different synchronized erythrocytic stages of P. falciparum clone F-56 to 
either 1.5 x 10'® M concentration of pyrimethamine or 7.2 x 1 0 " M cycloguanil, the 
concentrations used cause 50% inhibition of parasite growth in vitro. The experi-
ments were performed in 24-well tissue culture plates. Infected erythrocyte mate-
rial in aliquots of 20 ptl with about 0.7% parasitemia was inoculated in each well. 
The experiment was divided into following five test groups: 
Group 1- as control group, parasites were cultivated in drug free medium 
Group 2- early ring stage, parasites were cutured in medium containing either 
cycloguanil or pyrimethamine from 0-12 hours and thereafter in drug free me-
dium. 
Group 3- parasites were exposed to the drug in the late ring or early trophozoite 
stage that is the parasites were cultured in medium containing drug from 12-24 
hours. 
Group 4 - parasites were exposed to the drug in trophozoite stage of their life cycle 
that is they were cultured in the presence of drug from 24 to 36 hours of the 48 
hours of life cycle. 
Group 5 - parasites were cultured in medium containing drug in the schizont stage, 
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the parasites were kept in drug free medium from 0-36 hours followed by 12 hours 
in presence of the drug. 
The experiments were done in triplicate. At the end of 48 hours thin blood 
films were made from each of the experimental wells. The slides were stained in 
Giemsa solution. Antiparasite effect of the drugs on early rings, late rings, tro-
phozoite and schizont infected erythrocytes were determined by comparing the 
percentage inhibition of parasite growth in drug treated parasites to that in drug 
free controls. 
Synergism 
Synergy, the ability of one drug to potentiate the activity of another drug 
was evaluated algebraically by determining the sum of the fractional inhibitory 
concentration (FIC) of a combination of drugs. The FIC of a drug is its effective 
concentration in combination with another drug divided by its effective concentra-
tion alone. When the sum of the FIC is < 1; it indicates synerggism; value = 1 
indicates additive effect and values > 1 indicates antagonism. To examine the 
combined effect of pyrimethamine and cycloguanil in vitro on pyrimethamine re-
sistant line derived from the clone F-56 the method of Berenbaum (1978) was 
employed. First IC^^ values for each drug when used alone was determined. The 
parasites were exposed for this purpose either to different concentrations ranging 
from 1 x 10"^  M to 8 X 10'* M of pyrimethamine or 6 x 10* M to 4 x l O ' M of 
cycloguanil in multiwell plates for 48 hours and 10^^ values were determined by 
studying the slides made at the end of 96 hours, as described elsewhere. To test 
for synergism, a reference combination of the two drugs consisting of half of the 
concentration close to IC^^ of each drug was prepared in complete RPMI medium 
and actual IC^^ of this combination was determined together with parallel deter-
mination of ICgj, values of the drugs when used alone for estimating the FIC val-
ues. 
Biological advantage of pyrimethamine resistant parasites 
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In order to asses any biological advantage acquired by the pyrimethamine 
resistant (PS-5) line selected over the parent sensitive clone F-56 with regard to 
growth in vitro, the following two experiments were performed. First, the growth 
rate of the sensitive and the resistant parasites was compared in vitro. Second, 
equal number of PS-5 and F-56 parasites were mixed, and sensitivity to py-
rimethamine of this mixed population evaluated immediately and after a year of 
continuous cultivation in drug free medium. Aliquots of the mixed parasite cul-
ture prepared at the beginning of experiment was also cryopreserved for subse-
quent resuscitation and comparison of pyrimethamine sensitivity with that of the 
mixed parasite population kept under continuous cultivation for a year. 
RESULTS 
Susceptibility profile of the parasites used: Susceptibility of jR falciparum clone F-
56 and the isolate FCD-4 to pyrimethamine, cycloguanil, and chloroquine was de-
termined in vitro. ICg^ and ICj^ values are presented in Table 5.1. 
Table 6.1 In vitro susceptibility of erythrocytic stages of P falciparum (FCD-4 
and F-66) to antimalarial drugs, determined by 48 hour test. The starting para-
sitemia was less than 1% and hematocrit 2% 
Drug 
IC«o 
Clone F-56 
i c . IC,o 
Isolate FCD-4 
IC«o 
Pyrimethamine* 1.5 3.6 1.5 4.6 
Cycloguanil* 0.072 0.27 0.084 0.68 
Chloroquine* 46.89 84.4 56.26 218.85 
Data in *= nM 
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MIC for each of these drugs respectively was found to be 5 x 10'^ M, 5 x 10-*°M and 
1.87 X l O ' M for clone F-56. MIC required for FCD-4 for pyrimethamine, cyclogua-
nil, and chloroquine was 10"®M, 4x lO^M and 1.87x 10''M, respectively. Chloro-
quine was found to be equitoxic to the clone and the parental isolate as observed 
by MIC. 
In vitro gametocytogenesis 
Isolate FCD-4 and the clone F-56 were used for gametocytogenesis. Thick 
smear of the isolate made at the end of first schizogonic cycle showed the presence 
of a few gametocytes. The number of gametocytes in the thick smears increased in 
the subsequent schizogonic cycles. However, no gametocyte formation was ob-
served in any of the smears made from the clone F-56 maintained under similar 
conditions for eight schizogonic cycles. The F-56 was confirmed to be non-game-
tocyte forming clone under in vitro conditions of continuous cultivation in drug 
free medium by performing these experiments repeatedly. The gametocytes were 
not observed even after 20 days of continuous culture without dilution. 
Selection of falciparum lines resistant to pyrimethamine 
The number of days required to select in vitro a series of increasingly py-
rimethamine resistant P. falciparum lines from the clone F-56 and the drug con-
centrations used in each cycle of the selection process are depicted in Figure 5.1 
A. It took a total of 348 days of continuous cultivation of F-56, in presence or 
absence of drug pressure, to obtain the most resistant parasites that could multi-
ply at the highest selective drug concentration of pyrimethamine (10"* M) em-
ployed. In total of seven rounds of selection there was five or twofold increase of 
drug pressure during each successive rounds. A series of progressively resistant 
cell lines from PS-1 to PS-5 were cryopreserved in between and their sensitivity to 
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pyrimethamine in vitro evaluated, shown in Table 5.2. Each successive line of the 
series was less sensitive to the preceding line by 2.4 to 8 folds as adjudged by IC g^ 
value. The parasite line PS-5 showed 2400 fold decrease in sensitivity to py-
rimethamine compared to parent clone F-56. 
Table 5.2 Sensitivity to pyrimethamine of the series of selected parasite lines 
derived in vitro. 
Selected cell line 
F-56 clone 
PS-1 
PS-2 
PS-3 
PS-4 
PS-5 
ic«, 
1.5 X 10-»M 
3.8 X 10-»M 
2.6 X 10« M 
2.1 X lO 'M 
5.1 X 10 ' M 
3.6xlO-«M 
ic^ 
3.6 X 10-»M 
2.3 X 10-» M 
9.4 X 10-8 M 
8 X 10-' M 
6.2 X 10-« M 
8 X 10-« M 
MIC 
5xlO-»M 
5xlO-8M 
5x lO- 'M 
2.7 X 10-«M 
5xlO-«M 
> 1 X 10-* M 
Selection of falciparum line resistant to cycloguanil 
To select cycloguanil resistant falciparum lines the clone F-56 was continu-
ously cultivated in vitro with or without cycloguanil pressure for a total duration 
of 351 days. Only about seventy five fold decrease in sensitivity was registered in 
the derived line during this selection. Time required to achieve each level of 
decresed sensitivity to cycloguanil is shown in Figure 5.1 B. In vitro senstivity 
studies with cycloguanil showed that IC^ ,^ ICg^  and MIC of the parasite line de-
rived at the end of selection period to cycloguanil were 5.4 x 10'^ M , 3.6 x 10-* M 
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and 5 x 10*M, respectively. 
Gametocytogenesis during selection 
An interesting observation made during the selection process was the for-
mation of gametocytes in culture by the non-gametocyte forming clone F-56 under 
drug pressure. Healthy gametocytes of various stages were observed in thick and 
thin blood films made from the cultures kept under sub-inhibitory concentrations 
of the drugs. At concentrations equal to or higher than the MIC the gametocytes 
formed were phenotypically unhealthy. Gametocyte production was very low, since 
in most of the blood films examined less than one gametocyte per 15,000 erythro-
cytes was observed. No correlation could be made between the concentration of 
drugs in culture and the number of gametocytes formed. 
Cross resistance 
The falciparum lines selected for pyrimethamine resistance in vitro acquire 
a degree of cross resistance to cycloguanil and to another potent DHFR inhibitor, 
amethopterin (methotrexate). Results of the cross resistance studies to these drugs 
are presented in Table 5.3 and 5.4. 
Table 5.3 Sensitivity to cycloguanil of the series of pyrimethamine selected para-
site lines derived in vitro. 
Selected cell line 
F-56 clone 
PS-1 
PS-2 
PS-3 
PS-4 
PS-5 
IC.0 
7 . 2 x l O " M 
6 . 2 x l O " M 
4.6 X 1 0 " M 
SxlO-^M 
7 X 10-8 M 
7.4xlO-»M 
ic,„ 
2 . 7 x l 0 i ° M 
4.9 X lO-io M 
6 X lO-i" M 
8.6 X 10-» M 
4.3 X 10-« M 
3.1xlO-''M 
MIC 
5 x l O " M 
lxlO-«M 
3.8 X 10-»M 
5 x l O « M 
8xlO-«M 
4 X 1 0 ' M 
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Table 5.4 Sensitivity of clone F-56 and the highly pyrimethamine-resistant 
selected paras i te line PS-5 to chloroquine (CQ), ar temisinin (QHS) and 
amethopterin (MTX) in vitro. 
Drug F-56 PS-5 
IC,„ IC,, MIC IC,„ IC^ MIC 
CQ* 0.011 0.027 0.06 0.017 0.035 0.06 
QHS* 0.0017 0.004 0.005 0.0015 0.0038 0.005 
MTX 2.9xl0-8M 6.9xl0-8M IxlO'M 1.5xlO-'M 2.9xlO-'M 6.9xl0-«M 
* values in ng/ml 
Selection of cycloguanil resistance in pyrimethamine resistant falci-
parum derived line (PS-5) 
Predisposition, if any, of the pyrimethamine resistant cell line to be se-
lected faster for cycloguanil resistance was evaluated by exposing highly resistant 
PS-5 line to increasing concentrations of cycloguanil in a step wise fashion in vitro 
for 40 days. During this short duration of selection there was 7.3 fold decrease in 
the sensitivity to cycloguanil. 
Stability of resistance 
There was no marked difference observed in the susceptibility to py-
rimethamine of PS-5 parasite line, determined at the start and end of sixty weeks 
of continuous cultivation without drug pressure. IC^ ,^ ICj^ of this line at the be-
ginning and at the end of this experiment were found to be 3.6 x 10"^  M, 8.8 x 10-^ M 
and 4..1 x 10-«M, 8.2 x 10-«M, respectively. 
Stage-specific sensitivity to DHFR inhibitors 
The experimental parasite material examined immediately after triple sor-
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bitol treatment consisted almost entirely of single and mutiple ring form infec-
tions and uninfected erythrocytes. The synchronised parasite stages obtained are 
shown in Figures 5.2 to 5.5. No significant lysis of uninfected erythrocytes was 
observed. 
The ICg^  value of pyrimethamine or cycloguanil was chosen to expose the 
synchronized stages of the parasites to determine the stage specific toxicity of the 
DHFR inhibitors to ring (Figure 5.2), trophozoite(Figure 5.3) and schizont(Figure 
5.4) infected stages. Percent decrease in parasitemia observed at the end of the 
schizogonic cycle was maximum when late ring or trophozoite stages were under 
drug pressure (Figure 5.6). Rings were least susceptible to DHFR inhibitors. 
Marked difference in stage specific toxicity between pyrimethamine and cyclogua-
nil was observed in group-5 where the parasites were exposed in schizont stage 
(36-48 hours) of the development. When the schizonts were exposed to these drugs 
95% of subsequent ring stage production was inhibited by cycloguanil, whereas 
56% inhibition was seen with pyrimethamine. 
Synergism 
The parasites of the highly pyrimethamine resistant line PS-5 derived from 
the clone F-56 were found to be more sensitive to pyrimethamine than to cyclogua-
nil. The IC90 values of the two drugs when evaluated alone were 8.6 x 10'^ M for 
pyrimethamine and 3.2 x 10 'M for cycloguanil. Concentration of 4x10"^ M of py-
rimethamine and 2x10' M of cycloguanil used in combination caused 90% inhibi-
tion of the parasite growth. Sum of the FIC values were close to 1 as calculated by 
the following formula of Berenbaum (1978): 
4xl0-« / 8.6xl0-« + 2x10' / 3.2x10' = 1.08 
The sum of the FIC values for some other combinations of pyrimethamine and 
cycloguanil tested also gave figures close to 1. These results show no significant 
potentiation of antimalarial activity between cycloguanil and pyrimethamine 
against the asexual erythrocytic stages of P. falciparum. The combinations of the 
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two DHFR inhibitors, pyrimethamine and cycloguanil demonstrated at best only 
an additive effect. 
Blologfical advantagfe of pyrimethamine resistant parasites 
Table 5.5 shows the multiplication ability of pyrimethamine sensitive par-
ent clone F-56 and the highly pyrimethamine resistant line PS-5 for two consecu-
tive erythrocytic schizogonic cycles in vitro. 
Table 6.6 In vitro parasite multiplication as determined by multiplication factor 
(MF) and parasite multiplication rate (PMR) in multiwell tissue culture plates. 
Starting percentage parasitemia in F-56 and PS-5 were 0.82 and 0.68, respec-
tively. 
Parasite Erythrocytic schizogonic cycle 
First Second 
MF PMR MF PMR 
F-56 5 0.75 2.86 0.45 
PS-5 5.6 0.7 2.28 0.49 
From the parasite multiplication rate (PMR) for the two consecutive schizogonic 
cycles it can be inferred that parasites of the sensitive clone and the resistant line 
have similar multiplication ability. Results of pyrimethamine sensitivity tests 
performed on mixed population of resistant and sensitive parasites at the begin-
ning and at the end of 56 weeks of continuous cultivation in drug free medium, 
show no marked change in the susceptibility of the parasites to this drug. 
o o 
DISCUSSION 
Complete inhibition of multiplication of P. falciparum strains sensitive to 
chloroquine has been reported to take place in vitro at a concentration of 10 ng/ml 
(Nguyen Dinh and Trager 1980). Based on this observation both isolate FCD-4 
and clone F-56 are chloroquine resistant, the clone being more sensitive than the 
parent isolate. Similarly the parasites capable of multiplying in a medium con-
taining l O ' M pyrimethamine (Smalley and Brown 1982) or cycloguanil (Watkins 
and Sixsmith 1984; Eriksson et al. 1989; Peterson et al. 1990) are likely to be 
resistant to this DHFR inhibitor to some extent. Amount of pyrimethamine or 
cycloguanil needed to achieve complete inhibition has been at least ten fold less 
than this concentration. Clearly, therefore, the parasites employed in this study 
are sensitive to the DHFR inhibitors. It has long been known that a single asexual 
parasite can give rise to both male and female gametocytes as well as more of 
asexual forms(Downs 1947). Some of the asexual parasites are incapable of giving 
rise to the sexual forms (Bhasin and Trager 1984). These mutants will not able to 
propagate in nature beyond the host of their origin. Another novel phenotypic 
feature of the clone F-56 is that it does not form gametocytes in drug free medium, 
whereas the parent isolate FCD-4 is a good gametocyte forming line in vitro. 
Pyrimethamine and cycloguanil are the two DHFR inhibitor antimalarial 
drugs developed but pyrimethamine has been deployed on much larger scale than 
cycloguanil because of its longer retention time and smaller dose needed for cure 
(Bruce-Chwatt 1985). These drugs have been extremely useful in treatment of 
chloroquine resistant falciparum infection but the limiting factor has been the 
quick development of resistance among the parasite population against these drugs 
(Bishop 1962; Diggens et al. 1970). The development of resistance to these inhibi-
tors has been associated in the field with heavy use of monotherapy with the 
drugs in a particular area and emergence of resistance has been observed to be 
sporadic and multifocal. The ease of development of resistance to these drugs has 
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suggested that a mutation at a single locus is likely to be involved. Analysis of 
res is tance to pyrimethamine and proguanil in experimental malar ia , P. 
gallinacium, also suggests the involvement of a single gene (Bishop 1962). Resis-
tance to pyrimethamine has been developed in P. yoelii in a single step by Diggens 
(1970) and later by Walliker et al. (1975) in P. chabaudi. Morgan (1974) obtained 
a pyrimethamine resistant line of jR yoelii from a clone of this species, demonstrat-
ing the origin of resistant mutants de novo. Cowman and Lew (1989) selected 
P3n*imethamine resistant parasites of P, chabaudi in vivo by passaging parasites 
four times through mice treated with increasing doses of the drug. Banyal and 
Inselberg (1986) have been successful in obtaining pyrimethamine resistant lines 
of P. falciparum in vitro using two different protocols. In one of the protocols, they 
exposed the sensitive strain to increasing concentration of pyrimethamine in a 
series of selection steps while in the other, they first exposed the sensitive para-
sites in vitro to a mutagenic agent, the N-methyl-nitro-N-nitrosoguanidine 
(MNNG), and then to a single high dose of pyrimethamine for selection of resis-
tant survivors. The relapse protocol adopted in the present study for selection of 
resistant lines to the two DHFR inhibitors is slow but very succesful in selecting 
parasites exhibiting a very high level of resistance to pyrimethamine atleast. The 
highest pyrimethamine resistant line obtained showed 2400 fold increase in ICg^  
value compared to the parent clone. However, for reasons unknown we did not 
succeed in deriving parasite lines showing high level of resistance to cycloguanil. 
Failure to obtain cycloguanil resistance is quite intriguing in view of the fact that 
both pyrimethamine and cycloguanil are structurally somewhat similar, both are 
potent inhibitors of the DHFR enz3rme of the Plasmodium and exert their toxic 
effect by binding to this enz3ane. This observation is attractive from application 
point of view, as the experiments here have clearly demonstrated that in vitro 
emergence of pyrimethamine resistance is much faster and stronger than cyclogua-
nil in P. falciparum. It should be of great interest to know, if under field condi-
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tions also, the emergence of resistance to pyrimethamine is faster than cyclogua-
nil in P. falciparum. No serious studies have been carried out in this regard, so 
far. It is not known whether cycloguanil and pyrimethamine share the same bind-
ing site on the DHFR enzyme, neither it is clear whether the acquisition of resis-
tance to one of the drugs necessitates concomitant resistance to the other. The 
existence of field isolates resistant to both pyrimethamine and proguanil is well 
documented, so also the presence of natural isolates sensitive to one drug and 
resistant to the other and vice versa (Schapira 1984; Watkins et al. 1984). Recent 
reports on the molecular basis of pyrimethamine resistance in P. falciparum have 
implicated an accumulation of point mutations being associated with increasing 
resistance to pyrimethamine (Foote et al. 1990). Analysis of the P. falciparum 
DHFR from different parasites reveal the structural basis of differential suscepti-
bility to these antifol drugs. Parasites harboring a pair of point mutations from 
Ala 16 to Val 16 and Ser 108 to Thr 108 are resistant to cycloguanil but not to 
pyrimethamine (Inselburg et al. 1988; Tanaka et al. 1990; Foote et al. 1990). A 
single Asn 108 mutation, on the other hand confers resistance to pyrimethamine 
with only a moderate decrease in susceptibility to cycloguanil (Cowman et al. 1988; 
Peterson et al. 1988; Snewin et al. 1989; Zolg et al. 1989). These and other related 
inferences are compiled from the studies made on parasites originating from dif-
ferent places. The moleculeir basis of resistance to cycloguanil and pyrimethamine 
of selected lines derived in the present study should provide more meaningful and 
accurate inferences to be drawn, as these lines have all originated from the same 
sensitive parent genome of the clone F-56. 
An interesting observation made during the selection of antifol resistant 
parasite lines is that the non-gametocyte forming clone occasionally formed some 
gametocytes under drug pressure. A marked increase in the number of circulating 
gametocytes in P. falciparum infected patients has been reported following treat-
ment with antimalarial drugs like pyrimethamine, proguanil and sulphadiazine 
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(Findley et al. 1946; Mackerras et al. 1947; Ramakrishnan et al. 1952; Shute and 
Maryon 1954). Increase in gametocyte production has also been observed in P. 
gallinaceum treated with sulphadiazine and proguanil, whereas no such increase 
has been recorded during treatment with chloroquine, mepacrine or pamquine 
(Bishop 1954). But these observations are based on in vivo systems and it is well 
known that the number of gametocytes produced during an infection is highly 
variable. The factors responsible for these variations have not been exactly iden-
tified. Therefore, there had always been suspicion regarding the increased num-
ber of gametocytes observed in vivo following treatment with DHFR inhibitors. 
This suspicion has been cleared by this study, as it has been amply demonstrated 
that DHFR inhibitors somehow induce the formation of gametocytes, even in a 
non-gametocyte forming clone. 
No marked cross resistance to cycloguanil has been observed in parasites 
selected for low levels of resistance to pyrimethamine. But the highest py-
rimethamine resistant line (PS-5) exhibits 1027 fold increase in cycloguanil IC^^ 
value. No cross resistance has been seen in the highest pjrrimethamine resistant 
line (PS-5) to chloroquine or artemisinin. This is also expected as both chloro-
quine and artemisinin are structurally different from pyrimethamine and have 
dissimilar mode of actions. However, there is clear evidence of cross-resistance to 
methotrexate, another DHFR inhibitor. Concentration of 1 0 ' M of methotrexate 
causes complete inhibition of pyrimethamine sensitive clone F-56 in vitro whereas 
there is only 26% inhibition of pyrimethamine resistant line PS-5. Selection of 
methotrexate resistant Leishmania parasites in vitro has shown gene amplifica-
tion leading to the overproduction of the DHFR enzyme in methotrexate resistant 
parasites (Coderre et al 1983), reminiscent of those observed in methotrexate re-
sistant mammalian cells and fibroblasts (Haber et al 1981). Reduced binding of 
methotrexate to DHFR (5 to 10 fold) in parasite extracts has also been reported in 
pyrimethamine resistant P. falciparum parasites selected in vitro ( Inselburg et 
al. 1988). Part of the explanation for the decreased sensitivity of pyrimethamine 
resistant line to methotrexate may be attributed to the altered structure of the 
DHFR during the selection process that has reduced binding capability to 
methotrexate. 
Selection of parasites exhibiting increased resistance to cycloguanil has been 
obtained relatively faster in the parasite from the parasites that have been se-
lected earlier for pjn-imethamine resistance than from the pyrimethamine sensi-
tive parasites. This demonstrates that acquisition of resistance to pyrimethamine 
predisposes parasites to become resistant faster to a related antimalarial drug 
like cycloguanil, atleast in vitro. Foote et al. (1990) postulate that factors respon-
sible for pyrimethamine resistance may be genetically linked to cycloguanil resis-
tance, since both these drugs show structural similarity and have similar mode of 
action. Cycloguanil resistance causing factors are perhaps not as actively selected 
as those of p3n*imethamine and this might be responsible for less common occur-
rence of cycloguanil resistance. 
A little studied aspect of drug resistance in malaria parasites is the capac-
ity of the resistant forms to persist in the absence of drug pressure. This aspect is 
important especially in situations where the use of a particular drug has been 
discontinued for a long period with a hope that the resistant mutant forms would 
revert to sensitive phenotype in absence of drug pressure. This thinking is based 
on an assumption that on withdrawal of drug pressure resistant genes would be at 
a disadvantage or might not be of any use to the parasite and thus would be 
selected out in favour of some specific sensitive genes. However, contradictory 
observations have been made in this regard for instance, Jensen et al. (1981) have 
observed a case of clinical drug resistant falciparum malaria acquired from an 
initially chloroquine sensitive strain. A marked decrease in the level of sensitiv-
ity to chloroquine in falciparum has been observed after a few weeks of cultivation 
by Le Bras et al. (1983). Our studies with pyrimethamine resistant parasite lines 
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cultivated in drug free medium for an extended period of time in vitro, indicate no 
appreciable change in the level of sensitivity to pyrimethamine, clearly showing 
that resistance acquired by the parasites is stable and the resistant parasites do 
not show any biological advantage of overgrowing the sensitive parasites in vitro. 
Clyde (1967) has provided epidemiological evidence to the fact that drug resis-
tance once arisen, can survive and spread in the absence of further drug treat-
ment. It has been reported pyrimethamine resistant P. falciparum in regions of 
Tanzania several years after the large scale use of the drug has ended. Further 
there are evidences that the pyrimethamine resistance has spread from its pre-
sumed place of origin into surrounding areas in which no pyrimethamine is be-
lieved to have been used (Clyde 1967). Similar findings concerning cycloguanil 
are lacking. 
The potentiating effects of pyrimethamine and sulfadiazine in treatment of 
P. falciparum infection in man has been demonstrated for the first time by Goodwin 
(1952). Drug combination of pyrimethamine and sulfadoxine (Fansidar) has been 
deployed exclusively for both therapy and prophylaxis in countries where multidrug 
resistant P. falciparum is a problem (Peters 1990c). A combination of pjrrimethamine 
and dapson is also available under the name maloprim, though less popular (Worth 
and Werbel 1984). Unfortunately, resistance to these drug combinations have be-
gun to emerge on a serious scale from various parts of the globe (Peters 1990b). In 
the present study it has been shown that there is no significant potentiating or 
synergistic antimalarial activity between cycloguanil and pyrimethamine when 
used in combination. Yeo and Rieckmann (1992) have also reported the absence of 
potentiation of antimalarial activity between cycloguanil and pyrimethamine. This, 
however, does not imply that the two drugs should not be used in combination. 
The identification of mutually exclusive point mutations in the DHFR gene encod-
ing resistance to the two most widely used DHFR inhibitors (pyrimethamine and 
cycloguanil) and the observation that more extensive multiple mutations (that are 
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less likely to arise frequently) are required for resistance to both the drugs (Foote 
et al. 1990; Peterson et al. 1990), suggests an innovative approach to the deploy-
ment of a triple drug combination of pyrimethamine, cycloguanil, sulfadoxine to 
impede the spread of resistance in P. falciparum to the DHFR inhibitor antima-
larials. The suggestion should be seriously considered for further in depth inves-
tigation. 
Figure 5.1 The pattern of selection of progressively pyrimethamine-resistant (A) 
and cycloguanil-resistant (B) P. falciparum lines obtained in vitro from the clone F-
56. The selective drug concentrations at which the parasites grew are shown. Beside 
the drug concentration, in parentheses is the number of days after the initial expo-
sure to the drug that parasites grew normally in presence of drug concentration. The 
five pyrimethamine-selected lines, PS-1 to PS-5 growing at progressively higher con-
centrations are shown. 
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Figure 5.2 A Geimsa stained thin blood film from P. falciparum synchronised culture showing 
ring stages (0-7 hours old). 
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Figure 53 A Geimsa stained thin blood film from P. falciparum synchronised culture showing 
trophozoite stages. 
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Figure 5.4 A Geimsa stained thin blood film from P. falciparum synchronised culture showing 
schizont stages. 
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Figure 5.5 Spontaneously released merozoites from a ruptured schizont in culture surrounding 
the free pigment. 
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Figure 5.6 Sensitivity to pyrimethamine and cycloguanil in vitro of different synchronised P. falci-
parum stages, rings (0-12 hours), early trophozoites (12-24 hours), trophozoites (24-36 hours) and 
schizonts (36-48 hours). 
Chapter 6 
CHARACTERIZATION OF PYRIMETHAMINE RESISTANT P. FALCIPARUM LINES 
WITH A REPETITIVE OLIGONUCLEOTIDE PROBE AND DETECTION OF RESIS-
T \ N C E USING MUTATION-SPECIFIC POLYMERASE CHAIN REACTION 
Abstract: Feasibility of assay methods for diagnosis of Plasmodium falciparum resistance to 
DHFR inhibitor antimalarials based on genetic characterization and alterations has been ex-
plored. Restriction fragment length polymorphism (RFLP) and Southern hybridization with 21-
oligomer probe, complementary to a repeat sequence existing in falciparum genome have been 
successfully applied to demonstrate the ability of this approach to detect prominent genetic alter-
ations in the genome of highly resistant parasite DNA digested with Tag I or Alu I restriction 
enzymes. The RFLP studies clearly indicate that pyrimethamine causes point mutations in ge-
nome of the resistant falciparum parasites at places other than the DHFR encoding region. Low 
levels of resistance to pyrimethamine escape detection by this technique. This approach can be 
used to discriminate highly resistant and sensitive parasites but because of certain inherent short-
comings of Southern hybridization this method might not be employed for diagnosis of resis-
tance. Polymerase chain reaction method has been explored to determine if mutation-specific 
primers can be used to diagnose pyrimethamine resistant parasites. Using the recent guidelines 
(Mullis 1994) for primer selection and consulting the falciparum DHFR gene sequence obtained 
from the databank (UNDP/World Bank/ WHO/TDR), the selected primers have been optimized 
for the most stringent annealing temperature which could be employed for effective amplification 
and detection of pyrimethamine resistance. These initial precautions led us to discriminate the 
sensitive and resistant P. falciparum cell lines using the counter primer and the two diagnostic 
primers employed without compromising the sensitivity of the technique. 
INTRODUCTION 
Point mutations, primarily within the gene sequence coding for the dihy-
drofolate reductase of P. falciparum, have been shown to impart pyrimethamine 
resistance to these parasites (Peterson et al. 1988; Cowman et al. 1988; Zolg et al. 
1989; Tanaka et al. 1990). The resistant parasites produce alterd DHFR enzyme 
which retains its biocatalytic activity but looses the characteristic affinity binding 
of pyrimethamine (Mc Cutchan et al. 1984; Walter 1986). Sequence comparison 
of DHFR gene from pyrimethamine sensitive and resistant falciparum lines indi-
cate the pivotal role of amino acid 108 in the resistance mechanism to this antifol. 
A single base exchange in position 323 of the DHFR coding region changes Thr-
108 or Ser-108 found in pyrimethamine sensitive parasites to Asn-108. Addi-
tional point mutations in the DHFR gene have been found to confer higher degree 
of resistance (Foote et al. 1990). Due to their subtle nature, point mutations are 
the most difficult to detect of all the genetic alterations by methods other than 
sequencing. The development of technologies for detection and characterization of 
these genetic alterations is having great impact in early cancer diagnosis, since 
some point mutations have been implicated in several malignancies (Carter et al. 
1992; van Mansfeld and Bos 1992; Tbminaga et al. 1992). The other area where 
the potential of these technologies hold promise is the early detection of incipient 
drug resistance, arising out of point mutations due to drug pressure, in parasite 
populations and in understanding the mechanisms of drug resistance. Methods 
currently utilized for detection and characterization of single base substitution, 
deletion or insertion, other than sequencing are: a) RNAase mismatch cleavage 
methods (Winter et al. 1985; Myers et al. 1985). b) The mismatch chemical cleav-
age (MCC) by generic denomination (Cotton et al. 1988; Montandon et al. 1989; 
Gogos et al. 1990). c) The single strand conformation polymorphism (SSCP) 
(Hayashi 1991). d) Restriction fragment length polymorphisms (RFLP). e ) Muta-
tion specific PCR. With the exception of the MCC, all these methods have been 
successfully used with total genomic or total cellular RNA. They have been greatly 
simpliHed by use of previously amplified nucleic acids in vitro by polymerase chain 
reaction (PCR). In vitro test methods have widely been used for determining the 
drug sensitivity of P falciparum isolates (Nguyein-Dinh and Payne 1980; Richards 
and Maples 1979; Yisunsri and Rieckmann 1980) but there are several limitations 
that affect their usefulness (Desjardins 1984). Feasibility of alternate assay meth-
ods based on RFLP and PCR are explored. This chapter will address the applica-
tion of the RFLP to the detection of genomic rearrangements in drug resistant 
parasites and utility of mutation specific PCR to distinguish the pyrimethamine 
sensitive and resistant parasite lines selected in vitro. 
MATERIALS AND METHODS 
Parasite cultures Parasites of the clone F56 and the five pyrimethamine 
resistant lines (PS-1 to PS-5) derived from it were each seperately grown in large 
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glass Petridishes (10 cm diameter) using candle jar method (Trager and Jensen 
1976). When parasitemia in these cultures reached 5-6%, the cells were pelleted, 
washed once with HEPES buffered RPMI-1640 medium, snap frozen in liquid ni-
trogen and stored below 0 °C till DNA was extracted. Before freezing, a cell count 
was made in a haemoc3rtometer and total parasite count was estimated in each 
sample. 
Requirements for extraction of parasite DNA 
RNAase A (lOmg/ml): Pancreatic RNAase was dissolved at a concentration of 10 
mg/ml in 10 mM Tris.Cl (pH7.5), 15mM NaCl. Solution was heated to 100 "C for 15 
min, allowed to cool slowly at room temperature, dispensed in aliquots and stored 
at -20 °C. 
DNA extraction buffer: It consisted of the following reagents-
lOmM Tris.Cl (pH 8.0) 
O.IM EDTA (pH 8.0) 
20 /Ltg/ml Pancreatic RNAase A 
0.5% SDS 
Proteinase K (20mg/ml): Stock solution of proteinase K was prepared at a con-
centration of 20 mg/ml in water and stored at -20 "C. 
Phenol: Liquified phenol stored at -20 °C was melted at 68 °C, mixed with 
hydroxyquinoline (final concentration 0.1% ) and equilibrated with O.IM Tris.Cl 
(pH 8.0). It was stored in a dark bottle under a layer of O.IM Tris.Cl (pH 8.0) 
containing 0.2% p-mercaptoethanol at 4 °C. 
Ctiloroform: It was used in combination with isoamylalcohol in the ratio of 24:1. 
TE buffer (pH 7.5): It had the following composition 
lOmM Tris.Cl (pH 7.5) 
ImM EDTA (pH 8.0) 
The buffer was sterilized by autoclaving and stored at room temperature. 
TBE buffer (5X): One litre of 5X TBE was prepared by mixing 54 g Tris base. 
27.5 g boric acid and 20 ml of 0.5 M EDTA (pH 8.0) in water. 
Extraction of parasite DNA: The frozen samples (containing about 10^° para-
sites ) were thawed, mixed with two volumes of 1% cold acetic acid and centri-
fuged at 6000 rpm for 20 min at 4 °C. Supernatant which contained most of the 
haemoglobin was removed and the pellet was resuspended in two volumes of 1% 
triton X-100. It was again spun at 6000 rpm for 20 min at 4 °C and supernatant 
discarded. The resulting pellet of parasites was washed twice with 0.85% NaCl 
(pH 7.4). The washed parasite pellet was again resuspended in DNA extraction 
buffer in a volume equal to that of the original frozen sample and incubated at 37 
°C for 1 hour with intermittent shaking. Proteinase K at a final concentration of 
100 fig/nd was added to the above mixture, mixed gently and incubated overnight 
at 37 °C. DNA was extracted with an equal volume of phenol once, 
phenol:chloroform (1:1) twice, chloroform:isoamylalcohol (24:1) once and chloro-
form once. To the aqueous phase of the final extraction step was added 0.2 volume 
of 10 mM ammonium acetate and 2.5 volume of cold absolute alcohol (ethanol). 
This was left overnight at -20 "C for DNA to precipitate. DNA was pelleted by 
centrifugation at 12,000 rpm for 30 min at 4 "C and supernatant carefully re-
moved. The pellet was washed with cold 70% ethanol and dissolved in 200 fil of TE 
buffer (pH 7.5). Amount of DNA was estimated spectrophotometrically at optical 
density 260 nm and its purity determined from ratio of OD^^gJOD^^. The presence 
of contaminating RNA and sheared DNA, if any, was checked by running the 
samples on a mini agarose gel. 
Components of Southern hybridization and oligonucleotide probe labelling 
The stock solutions and buffers were prepared in glass redistilled water according 
to the protocols of Sambrook et al. (1989) 
SSC(20X): Sodium chloride and sodium citrate were dissolved in water to get 
final concentration of 3M and 0.3M, respectively. The pH of the solution was ad-
justed to 7.0 with NaOH. 
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STE buffer (pH 7.5): It consisted of the following reagents 
100 mM NaCl 
10inMTris.Cl(pH7.5) 
1 mM EDTA (pH 8.0) 
The buffer was sterilized by autoclaving and stored at room temperature. 
Sephadex G-50 : Sephadex G-50 slurry was made by mixing 3 g of it with 300 ml 
of STE solution and the suspension was autoclaved to hydrate the beads. 
Denhardt's solution (lOOX): 2 g each of Ficoll, polyvinylpyrrolidone ( PVP-40, 
Sigma ) and BSA was dissolved in 100 ml of distilled water and stored at -20°C. 
Sodium phosphate buffer (1 M, pH 7.2 ): It was prepared by mixing 28 ml of 
IM NaHjPO^ solution and 72 ml of IM Na^HPO^ solution. 
Pre-hybridization buffer: The composition of the buffer was as follows 
5 X S S C 
5% (w/v) Dextran sulfate 
0.05M Sodium phosphate buffer (pH 7,2) 
5X Denhardt's solution 
0.0025M EDTA 
0.4% SDS 
It was stored in aliquots at -20°C. 
Salmon sperm DNA (5 mg/ml): It was dissolved at a concentration of 5 mg/ml in 
water and stirred continuously to get complete dissolution. DNA was sheared by 
repeatedly passing it through a syringe with 18 gauge needle and stored in aliquots 
at -20°C. 
Loading dye (6X): It had the following composition 
0.25% Bromophenol blue 
0.25% Xylene cyanol FF 
40% (w/v) Sucrose in water 
Restriction enzymes and their buffers: The following 10 X restriction en-
zyme buffers were prepared for use with the respective restriction enzymes 
Be^t^rigtion ?nZYm? Composition of 10 X buffer 
Alu I 10 mM Tris.Cl (pH 7.0) 
10 mM MgCl^ 
I m M D T T 
Hind III 50 mM NaCl 
10 mM Tris.Cl (pH 7.9) 
10 mM MgCl^ 
I m M D T T 
Taq I 100 mM NaCl 
10 mM Tris.Cl (pH 8.4) 
10 mM MgClj 
10 mM p-mercaptoethanol 
BSA was added at a final 
concentration of 100 fig/ml in IX 
reaction mixture 
Bacteriophage T^ polynucleotide kinase (PNK) buffer: PNK, lOX buffer 
was made of the following composition 
500 mM Tris.Cl (pH 7.5) 
100 mM MgClj 
50mMDTT 
1 mM EDTA (pH 8.0) 
1 mM Spermidine HCl 
RFLP using Southern hybridization 
Restriction digestion ofDNA: DNA about 4 ng each from the clone F-56 and the 
pyrimethamine resistant lines was individually digested with 20 units of either 
Hind III, Alu I or Taq I restriction endonuclease in an appropriate buffer in a total 
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volume of 20 \d. Restriction digestion reaction was carried for three hours. Reac-
tion mix containing Taq I was incubated at 65 °C while others at 37 °C. Following 
incubation the microfuge tubes containing Hind III or Alu I were transferred to a 
65 °C water bath for 10 min and kept in ice for 5 min. 
Preparation of Southern blots: The entire volume of each restriction digestion (20 
\i\) was mixed with 4 ^1 of 6 X loading dye, loaded on a 0.8% agarose gel made in 
0.5 X TBE buffer and electrophoresed in the same buffer overnight at 40 volts till 
the tracking bromophenol dye had travelled 20 cm from the well. Gel was stained 
in 1 ng/nil ethidium bromide solution for 30 min, visualised under UV light and 
photographed with a polaroid camera. DNA was transferred to a nylon membrane 
by Southern's capillary method as follows: 
Size fractionated DNA was depurinated by incubating the gel in 0.25 N HCl 
solution at room temperature with gentle agitation for 15 min. Acid solution was 
decanted and replaced with 0.4 N NaOH solution and gel incubated with constant 
agitation for 30 min. Gel was then neutralised in 12 mM Tris, 6 mM sodium ac-
etate, 0.3 mM EDTA solution (pH 7.5) for 30 min with gentle shaking of the gel. 
Gene screen membrane cut to the size of gel was wetted with distilled water by 
capillary action and immersed in transfer buffer (10 X SSC) for 15 min. Apiece of 
Whatman 3MM paper was wrapped around a stack of three glass plates and placed 
inside a large baking dish. The dish was filled with transfer buffer (10 X SSC) 
until the level of liquid reached almost to the top of glass plates. Gel was removed 
from the neutralising solution, inverted and placed on the glass support kept in 
baking dish. All the edges of the gel were covered with a thin strip of parafilm to 
prevent liquid from flowing directly from reservoir to paper towels placed on top of 
the gel. Wet nylon membrane was then placed on the gel. Two pieces of Whatman 
3MM paper cut to the size of gel were dipped in 2 X SSC and placed on top of the 
membrane. Care was taken that no air bubble was trapped between any of the 
layers in the entire set-up. A stack of paper towels (5 cm high), just smaller than 
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the size of Whatman paper was placed on top of Whatman paper. Placed a glass 
plate on top of the stack and weighed it down with a 500 g weight. The transfer of 
DNA was allowed to proceed for 20-24 hours with periodic replacement of wet 
paper towels with dried ones. Membrane was carefully removed after the transfer 
and soaked in 6 X SSC for 5 min before being dried at room temperature. Gel was 
restained in ethidium bromide solution (lug/ml) and viewed under UV lamp to 
check the efficiency of transfer. Air dried membrane was sandwiched between two 
sheets of dry 3MM Whatman paper and baked in vacuum oven at 80 °C for 2 hours. 
End labelling of synthetic oligonucleotide employed as a probe 
The synthetic 21-mer deoxynucleotide which was obtained as lyophilized powder 
had the following sequence: 
5'- AGGTCTTAACTTGACTAACAT -3' 
It was dissolved in 500 fi\ of sterile distilled water, vortexed and centrifuged to 
remove the remaining resin. The aqueous phase containing dissolved oligonucle-
otide was extracted once with phenol:chloroform (1:1) and once with chloroform. 
0.1 volume of O.IM MgCl^ and 2 volumes of ethanol were added to aqueous phase 
of chloroform extraction and left overnight in -20 °C freezer for oligo- precipita-
tion. Oligomer was recovered by centrifuging at 14,000 rpm for 30 min at 4 **C in 
a microfuge. The pellet was washed twice with 70% ethanol and finally dissolved 
in 200 ^1 of sterile distilled water and quantitated spectrophotometrically. About 
15 pM (0.1/xg) of oligonucleotide was labelled at 5' end with 10 fiCi of (y-'^P) ATP 
(specific activity 3000 Ci/mmol) using 20 units of T^ polynucleotide kinase (PNK) 
in PNK buffer in a reaction volume of 50 fxl at 37 °C for 1 hour. The reaction was 
terminated by adding 2 /il of 0.5 M EDTA. 
Separation of labelled oligo probe from unincorporated nucleotides 
The oligo probe was separated from unincorporated nucleotides using Sephadex 
G-50 spun columns. The spun column was prepared as follows. Bottom of a 1ml 
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disposable S3n"inge was plugged with autoclaved glass wool. Sephadex G-50 slurry, 
equilibrated in STE was inserted into a centrifuge tube, containing at the bottom 
an epperndorf tube with its lid cut off and this set-up was centrifuged at 3,000 
rpm for 5 min. Eluate from centrifuge tube was drained out, more of slurry was 
added into syringe and this was repeated 2-3 times till the post-spin bed volume of 
0.9 ml was obtained. 100 fxl of STE was then added into syringe and spun at the 
same speed (3000 rpm) for the same time. This was repeated once more. The 
eppendorf tube in centrifuge was replaced with a fresh one. The column, when not 
needed immediately, was stored at 4 °C after wrapping the mouth of syringe with 
parafilm. End labelled probe was made to 100 /u,l volume by adding STE solution. 
100 /il of labelled probe was loaded on to each of the spun column and centrifuged 
at 3000 rpm for 5 min. The eluate was collected in an eppendorf tube and syringe 
was safely disposed off in a radioactive waste container, l/nl of this purified probe 
was taken in an eppendorf tube and placed in a scintillation vial for Cerenkov 
counting in a scintillation counter (Beckman Instruments Inc.). The specific activ-
ity of probe was calculated by following formula. 
The specific activity of probe = (CPM for l/itl sample) x (counting efficiency 
factor) X (volume of end labelled probe in /il) x 10 
When not used immediately, the labelled probe was stored in a lead container in 
-20 °C freezer and was used within 4-5 days. 
Hybridization on the Southern blot 
Prehybridization: Each of the Southern blotted nylon membrane was individu-
ally placed in heat sealable plastic bag. Prehybridization buffer (80 fi\ buffer/ cm^ 
area of membrane) was added into the bag. Salmon sperm DNA was denatured by 
boiling for 10 min and added into the bag (50 fig salmon sperm DNA/ml 
prehybridization buffer). It was thoroughly mixed and the bag was sealed after 
removing all air bubbles. Membrane was prehybridized by keeping the bag in a 
waterbath set at 65 °C for 3-5 hours. 
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Hybridization: Labelled oligomer probe was boiled for 10 min and quickly cooled 
on ice for 10 min. One corner of the bag was cut open and probe was added. Bag 
was resealed after removing air bubbles and hybridized overnight at 40 "C in a 
waterbath with constant and slow shaking. 
Post-hybridization washing of membrane: Membrane was removed from the bag 
and incubated in a solution of 2X SSC, 0.1% SDS at room temperature for 8 min 
with constant shaking and this step was repeated once more. The above solution 
was replaced with prewarmed (40 °C) solution of 0.5X SSC, 0.1% SDS and incu-
bated in a shaker water bath at 40 "C for 15 min. This was repeated with fresh 
prewarmed solution of 0.5X SSC, 0.1% SDS. Membrane was then washed twice 
with 2X SSC at room temperature with constant shaking for 8 min each. 
After the final wash, membrane was placed on a sheet of prewet (with dis-
tilled water) Whatman 3 mm paper, covered with cling film (Saran wrap) and 
exposed to X-ray film (Kodak XOMAT AR) for desired duration of time, using in-
tensifying screens at -70 °C. X-ray film was developed by immersing it in devel-
oper (20% Kodak GBX) for 1 min, rinsed briefly in water, immersed in fixer (20% 
Kodak GBX) for 3min and finally rinsed in running tap water for 5 min. X-ray 
film was dried and photographed. 
Polymerase chain reaction (Mullis 1986; Saiki et al. 1988) 
The technique: This is a technique used for specific in vitro amplification of 
nucleic acid segment that is bracketed between two regions of known sequences. 
The hallmarks of this method include specificity, sensitivity and speed beside be-
ing straightforward. The specificity of the amplification results from the require-
ment of DNA pol3rmerases for a primer (a short stretch of synthetic nucleotides) 
that is extended only when annealed to a complementary target sequence. In 
presence of dNTPs, the annealed primers are extended from 5' to 3' end and the 
target DNA strand is copied from 3' end by the DNA polymerase during this exten-
sion step. The copying is halted by raising the temperature to 94 °C, causing 
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separation of all double stranded molecules. This denaturation step is followed by 
annealing step in a typical cycle of the polymerase chain reaction wherein the 
reactants are cooled to 37 - 55 °C, the temperature which favours the annealing of 
the primers to template DNA. Raising the temperature again to 72 °C stimulates 
the heat resistant Taq polymerase to copy the target DNA by extending the an-
nealed primers. Number of copies of the target DNA increases in an exponential 
fashion with each subsequent cycle. Usually 30 cycles are carried out giving an 
amplification level of 10*. 
Components of the polymerase chain reaction: 
lOX reaction buffer 
The reaction buffer had the following composition: 
100 mM Tris-HCl pH 8.3 
500 mM KCl 
15 mM MgClj 
0.01% (w/v) gelatin (Sigma, Cat. No. G2500, St. Louis, MO) 
Deoxynucleotide triphosphates (mix) 
Stock solution of each of the following dNTPs was prepared in water (pH 7.0) 
dATP 10 mM 
dCTP 10 mM 
dGTP 10 mM 
dTTP 10 mM 
Each of the dNTP was included at a final concentration of 200 yM in the reaction 
mix. 
Template DNA 
Dilutions of the template DNA from the stock were made in 10 nM Tris.Cl pH 8.0, 
ImM EDTA pH 8.0 solution. About 70 ng of template DNA was included in each 
reaction mix. 
Primers employed for the polymerase chain reaction 
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i . Control primers 
Bacteriophage lambda DNA was used as control DNA template. Oligonucleotides 
used as primers in the amplification of a segment of X DNA were 
Primer Map position Sequence 
Control primer 1 7131-7135 5/-GATGAGTTCGTGTCCGTACACTGG-3/ 
Control primer 2 7606-7630 5'-GGTTATCGAAATCAGCCACAGCGCC-3/ 
From map positions, these two primers should amplify 500 nucleotide target seg-
ment of the X DNA. 
2. Mutation specific primers 
Mutation specific primers employed to discriminate pyrimethamine sensitive and 
resistant P. falciparum lines by polymerase chain reaction were: 
Primer Type Map position Sequence 
SP Detects the Ser 108 codon 323-337 5'-GAATGCTTTCCCAGC-3/ 
of pyrimethamine sensitive 
parasites 
DRl Detects the Asn-108 codon 323-337 5'-GAATGCTTTCCCAGT-3/ 
. of pyrimethamine resistant 
parasites 
CP Counterprimer used with 1-21 5'-ATGATGGAACAAGTCTGCGAC-3' 
SP and DRl 
These oligonucleotide primers were synthesized at the Keystone laboratories and 
were derived from the DHFR coding sequence of the P. falciparum genome (Bzik et 
al. 1987). Additional primers evaluated for amplification with the above 
counterprimer (CP) were: 
DR2 Detects the Thr-108 codon 323-337 5/-GAATGCTTTCCCAGG-3/ 
of cycloguanil resistant 
parasites 
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DP A distant primer present 
both in sensitive and 
resistant lines 
1154-1169 5/-CACCTACTCCCGTTCG-3/ 
Taq DNA polymerase 
The enzyme was used at a concentration of 2.5 units/lOO/xl reaction mix. 
Equipments 
1. Thermal cycler, Perkin Elmer Cetus DNA Thermal Cycler Model 480. 
2. Electrophoresis apparatus to characterize amplification products en agarose 
gels. 
3. Transilluminator with polaroid camera 
Mutation specific polymerase chain reaction The components of the ampli-
fication reactions were mixed in the following order in a sterile 0.5 ml microfuge 
tube ; 
Components 
Autoclaved redistilled water 
lOX Reaction buffer 
dATP 
dCTP 
dGTP 
dTTP 
Primer 1(CP) 
Primer 2 (SP,DR1, 
DR2 or DP) 
Template DNA 
Volume 
SOiLtl 
10^1 
2 All 
2/il 
2 Ml 
2ix\ 
1/nl 
Ifil 
Final concentration 
IX 
200/LtM 
200/ iM 
200/nM 
200)LtM 
500 ng 
500 ng 
Depending on the cone, 
of the stock 
Made the final volume to 100 /il with water 
70 ng 
Positive control for PCR Whole bacteriophage lambda DNA was used as a 
positive control template DNA. The positive control reaction 
following components: 
Components 
Autoclaved redistilled water 
lOX Reaction buffer 
dATP 
dCTP 
dGTP 
dTTP 
Control primer 1 
Control primer 2 
Control template 
(1:10 dilution) 
Total mix 
Vo^ ^me 
62)Lil 
lOjLll 
2/xl 
2;iil 
2^1 
2/il 
5/il 
5/il 
lOjtil 
100 ul 
Fina 
mix consisted of the 
.1 concentration 
IX 
200/LtM 
200;tiM 
200/LiM 
200 ^M 
1.0 MM 
1.0/nM 
Ing 
Overlaid the reaction mixture with 50 fi\ of light mineral oil to prevent evapo-
ration of the sample during repeated cycles of heating and cooling. The reaction 
mixture was heated for 5 min at 94 °C to denature the DNA completely. While the 
reaction was still at 94 "C, 0.5 /xl (5 units/^il; Perkin Elmer Cetus N801-0046 ) of 
Taq DNA polymerase was added. The amplification reaction was carried out as 
described below. Typical conditions for denaturation, annealing and polymeriza-
tion were standardized and used as follows: 
Cycle Denaturation Annealing^ Polymerization 
First cycle 5 min at 94 °C 45 sec at 58 °C 2 min at 72 °C 
Subsequent cycles 45 sec at 94 "C 45 sec at 58 °C 1 min at 72 °C 
Last cycle 45 sec at 94 °C 45 sec at 58 °C 8 min at 72 "C 
The duration of the ramp temperature was 30, 30 and 45 seconds between 
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each denaturation, annealing and polymerization step of a cycle, respectively. Am-
plification was carried for a total of 28 cycles. 
Analysis of PCR products: Following amplification the amplified product from the 
reaction mixture was examined by gel electrophoresis. 10 /il sample of the ampli-
fied DNA was drawn from each of the microfuge tube and mixed with 2 fil of 6X 
loading dye. The samples were then loaded on an agarose gel (1.5 %) made in 0.5X 
TBE buffer containing ethidium bromide (0.5 jug/ml) and electrophoresed in the 
same buffer at 60 volts till the tracking bromophenol dye travelled a distance of 
atleast 40 to 45 mm from the well. The gel was visualized in dark under UV illu-
mination and photographed. 
RESULTS 
Extraction of falciparum DNA 
DNA extracted from the parasites was found to be of high molecular weight 
and examination of various samples on the agarose gel stained with ethidium 
bromide revealed that there was no visible shearing of the DNA samples isolated. 
Quality of the DNA samples obtained was further assessed by determining the OD 
ratio of each sample at 260 and 280 nm. The OD g^p/ODggg was found to be close to 
1.8 in each case. This purified DNA was employed for all further work. 
Restriction digestion of DNA 
Four microgram DNA each from the clone F-56 and the pyrimethamine se-
lected lines were individually digested with either Hind III, Alu I or Taq I restric-
tion enzyme. The digested material was size fractionated on a 0.8% agarose gel. 
The gels were stained with ethidium bromide and photographed. Lane 1 of Figure 
6.1 shows the uncut F-56 DNA as clear single band without smear or contaminat-
ing RNA. The F-56 DNA digested with Hind III, Alu I and Taq I for three hours 
were loaded in lane 2,3 and 5, respectively. The lane 4 shows the DNA digested for 
one hour with Thq I and Hind III cut lambda DNA showing discrete bands is seen 
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in lane 6. Presence of smears in lanes 2 to 5 shows that the DNA used was suscep-
tible to the digestion by all the enzymes used. Digestion was more extensive in 
three hours of incubation. Alu I generated smaller fragments than the other en-
zymes. 
RFLP analysis Autoradiograms showing specific hybridization of blot trans-
ferred DNA molecules onto nylon membrane to the radiolabelled oligomer probe is 
seen in the form of prominent dark bands or smears (Figures 6.2 to 6.4 ). Alu I 
digested DNA from pyrimethamine selected lines PS-5, PS-4, PS-3, PS-2 and sen-
sitive clone F-56 were loaded in the gel lanes 1, 2, 3, 4 and 5, respectively of the 
autoradiogram (Figure 6.2). Comparison of the band profile of the most resistant 
line (PS-5) with the sensitive parent clone F-56 shows the presence of additional 
bands in resistant line. Arrangement of DNA bands looks almost alike in Figure 
6.3 of the Hind III digested DNA of resistant and sensitive cell lines. Consider-
able difference in the hybridization patterns can be seen in Taq I digested DNA 
obtained from sensitive and resistant lines probed with the repeat oligomer. Sev-
eral new bands made their appearances in the most resistant cell line which were 
conspicuous by their absence in the genome of sensitive F-56 clone and other se-
lected lines. 
Mutation specific polymerase chain reaction 
Mutation specific PCR is the variation of the basic PCR theme. It is a method 
for determining whether previously characterized point mutations are present in 
a target sequence. The assay is based on the observation that efficient amplifica-
tion under stringent PCR conditions occurs only when there is a perfect match 
between the target DNA and the 3' terminous of the diagnostic primer. A single 
nucleotide change can thus be detected by a PCR primer having 3' terminal nucle-
otide complementary to the mutation. As shown below the fully complementary 
primer I will be extended by Taq polymerase while primer II mismatched at the 3'' 
terminus will not be extended: 
I l l 
ATG CAT ATT GCG TCG TCC > Matched primer I 
TAG GTA TAA CGC AGO AGG GCA TTG ACG CTA ATT GGA CTG A (target DNA) 
ATG CAT ATT GCG TCG TCC ^X-> Mismatched primer II 
TAC GTA TAA CGC AGC AGT GCA TTG ACG CTA ATT GGA CTG A (target DNA) 
Two diagnostic primers and one common primer are needed for the detec-
tion of each point mutation; one diagnostic primer complementary at the 3' termi-
nal nucleotide to the wild-t3T)e sequence, the other complementary to the mutated 
sequence. 
Design of mutation-specific primers 
The mutation-specific primer assayed to detect the presence of Ser 108 (codon 
AGC), located in the DHFR-TS gene of the pyrimethamine sensitive parasites, 
was a 15-mer oligonucleotide and ended with cytosine base at the 3^  annealing 
position 323, which is the central nucleotide of the 108 serine codon AGC. The SP 
primer 5/-GAATGCTTTCCCAGC-3/ is fully complementary to the wild type py-
rimethamine sensitive DHFR gene segment. The primer used to locate aspar-
agine (Asn) codon AAC of resistant parasites was similar to the SP primer except 
' that it had th3rmine base terminus at 3' end (DR-1 primer). Another drug resis-
tant diagnostic primer DR-2 had guanine base at 3^  terminus and amplifies the 
target DNA if threonine codon (ACC) was present, found in the cycloguanil resis-
tant parasites at 323 position of the DHFR gene. All these mutation specific 
primers when used in combination with a 21-mer oligonucleotide counter primer 
(CP) annealing with the starting portion of DHFR coding sequence results in am-
plification of 337 base pair fragment by PCR. A distant 16-mer primer (DP) span-
ning between 1154-1169 nucleotides of the DHFR coding region present both in 
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sensitive and pyrimethamine resistant parasites had also been used in combina-
tion with the CP for amplification. 
Detection limit of a 15-mer primer 
Taking variable amounts of target DNA from F-56, ranging between 0.001 
ng to 100 ng with a 10 fold difference, an experiment was performed to estimate 
the minimum amount of the DNA required for amplification with a pair of prim-
ers, the SP a 15-mer and the CP a 21-mer , so as to have a visible fluorescence on 
an agarose gel on loading 10 |il aliquot of the total 50 ,^1 of the ampUfied product 
obtained after 30 cycles of PCR. A typical time and temperature profile of the 
cycle was 45 sec at 94 °C, 45 sec at 58 °C and 1 min at 72 °C. As seen in the Figure 
6.5 even 1 pg of the target DNA was sufficient to give a clear fluorescent band on 
loading only 20 % of the amplified product. 
Amplification of X control DNA template 
Amplification conditions employed efficiently amplified a specific 500 base 
pair target segment bracketed between a pair of control primers 1 and 2 from the 
48.5 kb X genome as seen in lane 3 of Figure 6.8, for instance. 
Detection of pyrimethamine resistance with mutation specific primers 
A series of experiments were performed to determine the most stringent an-
nealing temperature that can be used at which the mutation specific primers were 
able to prime the enzymatic amplification and at the same time discriminate the point 
mutation at position 323 of the DHFR coding region of the pjrrimethamine resistant 
and sensitive parasites. The annealing temperature was increased by 1 °C in each 
experiment, beginning from initial annealing temperature of 45 °C. Effective ampli-
fication and discrimination was obtained at an annealing temperature of 58 "C. 
Using the primer pair CP and SP, which form perfect match for wild type Ser 
codon (AGC) at the position 323 of the DHFR coding region, efficient amplification 
was found in the microfuge tubes containing target DNA F-56, PS-1 and PS-2 
amplification product shown in lanes 4, 5 and 6, respectively of Figure 6.6. No 
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amplification whatsoever was seen in lanes 6, 7 and 8 which contained the target 
DNA derived from PS-3, PS-4 and PS-5 pyrimethamine selected lines. This pair of 
primers can clearly, therefore, discriminate between sensitive F-56, PS-1 and PS-
2 lines from the resistant PS-3, PS-4 and PS-5 lines without any ambiguity. Simi-
larly by employing CP and DR-1 pair of primer in each tube containing target 
DNA from either F-56, PS-l, PS-2, PS-3, PS-4 or PS-5 lines of P. falciparum, enor-
mous amplification of target DNA obtained from PS-3, PS-4 and PS-5 py-
rimethamine resistant lines as can be observed in lanes 6,7,8 of Figure 6.7, re-
spectively. This pair of primer can not amplify the DNA from sensitive lines (F-56, 
PS-1, PS-2) but is very efficient in amplifying DNA from pyrimethamine resistant 
lines (PS-3, PS-4, PS-5). The expected specific amplification of the target DNA 
was monitored by the molecular weight of the amplified product by running paral-
lel controls. The two pairs of primers (one common and the two diagnostic) used 
had been found to be very effective in discriminating the target DNA obtained 
from pyrimethamine sensitive and in vitro selected resistant cell lines. In an-
other set of experiment Figure 6.8 using different sets of primers (even multi-
plex), target DNA etc. the utility of CP and SP pair was reconfirmed, in amplify-
ing only the p3a'imethamine sensitive target DNA only whereas all the other primer 
and target DNA combinations failed to show the amplified product. The primer 
pair CP and DR-2 failed to amplify the target DNA obtained from F-56 or any of 
the selected parasite lines. 
DISCUSSION 
Genetic characterization of microorganisms is being performed increasingly 
at the DNA level. The molecular biology approach generally used for an isolate or 
clone individualization which may be phenotypically alike is the typing of vari-
able number of tandem repeat loci by restriction fragment length polymorphism. 
How far this and other methods are valid and practical to detect drug resistance 
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resulting from point mutations in P. falciparum ? The methods currently in use to 
detect and characterize single base change in a gene are: a) Mismatch cleavage 
by RNAase, This method is based on the ability of pancreatic ribonuclease to 
recognize and cleave single base mismatches in RNA:RNA (Winter et al. 1985) 
and RNA:DNA heteroduplexes (Myers et al. 1985). The method is performed by 
hybridization of the target sequence to a labelled complementary riboprobe, diges-
tion with RNase A and analysis of the resistant products by polyacrylamide elec-
trophoresis in denaturing gels. Mutations are detected and localized by the pres-
ence and size of the RNA fragments generated by cleavage at the mismatches. 
Single nucleotide mismatches in DNA heteroduplexes are also recognized by this 
approach, b) Similarly mismatch chemical cleavage (MCC) provides another strat-
egy to detect single base mismatch in DNA heteroduplexes by generic denomina-
tion (Cotton et al. 1988; Montandon et al. 1989; Gogos et al. 1990). c) The single 
strand conformation polymorphism (SSCP) is another method based on the differ-
ences in the secondary structure of ssDNA molecule differing in single nucleotide, 
which are frequently reflected in an alteration of their electrophoretic mobility 
(Hayashi 1990). MCC or SSCP methods can detect mutations but can not charac-
terize them. Although the characterization of mutations can be achieved with 
RNase A mismatch cleavage method by using batteries of mutant riboprobes (Win-
ter et al. 1985; Forrester et al 1987), these methods are complicated and cumber-
some. RFLP has its own limitations, which include requirements of sufficient 
quantity of high molecular weight DNA (50 ng) and isotopically labelled probes to 
obtain high level of sensitivity of detection. RFLP is also laborious as well as time 
consuming. PCR based methods prove to be useful and practical when nature 
and/or position of the mutation is known. Mutation specific PCR is the method for 
determining whether previously characterized mutations are present in a target 
sequence. The assay is based on the observation that efficient amplification un-
der stringent PCR conditions occurs only when there is a perfect match between 
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the target DNA and the 3' terminus of the diagnostic primer. A single nucleotide 
change can thus be detected by a PCR primer having 3' terminal nucleotide comple-
mentary to the mutation. Two diagnostic PCR primers and one common primer 
are required for each point mutation to be tested; one diagnostic primer comple-
mentary at the 3' terminal nucleotide to the wild-type sequence, the other comple-
mentary to the mutated sequence. 
In this study the procedure adopted to extract DNA (Tungpradubkul and 
Patiyim. 1985) from, paraaitea yielded pure DNA with high molecular weighty since 
it was easily susceptible to restriction digestions with the various enzymes and no 
smear was observed in lanes loaded with uncut DNA on an agarose gel. Alu I 
restriction enzyme produced several smaller fragments which were seen as smear 
at the farther end of the gel, suggesting the presence of many Alu I sites (AG|CT) 
in the P. falciparum genome. Like most other eukaryotic genomes, no discrete 
fragments are visible in Hind III, Alu I or Taq I digested total DNA on agarose gel, 
indicating that these enzymes have innumerable restriction sites in the falciparum 
DNA. It is very difficult to differentiate the smear-fragment profile of py-
rimethamine sensitive and various resistant P. falciparum lines, more so if the 
point mutations are responsible for resistant phenotype. 
RFLP and Southern blot hybridization have been successfully applied to 
detect point mutations in ras genes using total genomic DNA (Feinberg et al. 1983; 
Santos et al. 1984; Kraus et al. 1984). The genomic organization of P. falciparum 
has been studied by the Southern blot hybridization with repetitive DNA probes 
(Bhasin et al. 1985; Oquendo et al. 1986; Fucharoen et al. 1988). These probes 
have been very useful in genotyping of isolates and clones. P. falciparum genome 
contains about 10% of repetitive sequences (Hough-Evans 1982) of which more 
than 1% is constituted by a 21 base pair repeat (Aslund et al 1985). The comple-
mentary 21-mer oligonucleotide sequence has been employed as a probe to look for 
alterations in the genomic organization of pyrimethamine resistant cell lines se-
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lected in vitro from sensitive F-56 parent clone. RFLP on the blots will be visible 
only if the point mutations create or destroy a restriction site. Comparison of 
band profile of Hind III digested total DNA from sensitive and various py-
rimethamine resistant selected falciparum lines do not show any marked differ-
ence, prompting us to infer that most of the Hind III sites (AiAGCTT) in the falci-
parum genome remain unaffected. Also Hind III digested DNA probed with 21-
mer probe can not be used to detect genomic rearrangements occurring due point 
mutations caused by pyrimethamine pressure. However, clear differences are ob-
served in the hybridization patterns of DNA, from sensitive and most resistant 
lines, digested with Alu I or Taq I suggesting that the 21-mer probe can be used to 
compare the genomic rearrangement of pyrimethamine sensitive and the resis-
tant cell lines. This also indicates that Alu I and Taq I sites in the falciparum 
genome are definitely affected by the pyrimethamine pressure on the parasites. 
From these observations it can be inferred that pyrimethamine does not specifi-
cally act and affect the DHFR gene only. This method obviously can not be used 
for detection of point mutations in the DHFR gene using total genome, but shows 
alterations taking place at the Alu 1 and Taq I sites in the genome of pyrimethamine 
resistant falciparum lines. These alterations in the band profile are prominent 
only in the most resistant cell lines. This technique can more fruitfully be em-
ployed by first amplifying the DHFR coding sequence from the total genome and 
subsequently monitoring the RFLP in selected/mutated lines. 
Previous studies of the effect of primer-template mismatches on mutation-
specific PCR have yielded conflicting data (Wu et al. 1989; Newton et al. 1989; 
Ehlen and Dubeau 1989; Kwok et al. 1990; Okayama et al. 1989; Peterson 1993). 
Some studies revealed that certain mismatches at 3^  terminus could be detected, 
but others reported that all the 3' mismatches produced significant decrease in the 
amplified product. A thorough comparison of these studies is complicated by the 
use of different template and primers, as well as the different reaction conditions 
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specially the annealing temperatures employed. Therefore, it is necessary to opti-
mize the annealing temperature with a set of primers in order to obtain reproduc-
ible results. Using the guidelines (Mullis et al. 1994) for primer selection and 
consulting the falciparum DHFR gene sequence obtained from the databank 
(UNDP/World Bank/WHO/TDR), the selected primers were optimized for the most 
stringent annealing temperature which could be employed for effective amplifica-
tion and detection of resistance. These initial precautions in selecting the primers 
led us to discriminate the sensitive and resistant P. falciparum cell lines using the 
counter primer and the two diagnostic primers employed without compromising 
the sensitivity of the technique. The primers used are specific for detecting the 
P3rrimethamine resistance, resulting due to base exchange at 323 base of the DHFR 
coding sequence. Another diagnostic primer (DR-2) which detects cycloguanil re-
sistance failed to amplify the pyrimethamine resistant target DNA, amply demon-
strating the usefulness of these primer pairs. Utility of these primers to discrimi-
nate pyrimethamine sensitive and resistant isolates from field has yet to be deter-
mined so also the RFLP studies on the PCR amplified DHFR sequence. 
Figure 6.1 Ethidium bromide stained 0.8 % agarose gel containing 4 [xg of DNA from clone F-56 
digested with restriction enzymes and electrophoresed overnight at 30 volts 
Lane 1. Undigested DNA 
2. DNA digested with//iW/// 
3. DNA digested with A/«/ 
4. DNA digested with Taq I for 1 hour 
5. DNA digested with Taq I for 3 hours 
6. X DNA digested with//iW/// 
2 3 
/^ 
Figure 6.2 An autoradiogram of Southern blot hybridized with synthetic end labelled oligonucle-
otide. 4 ng of P. falciparum DNA from the clone F-56 and pyrimethamine selected lines digested 
with A/u /, size fractionated electrophoretically and Southern transferred on to a nylon membrane. 
Lanel. PS-5 DNA 
2. PS-4DNA 
3. PS-3DNA 
4. PS-2DNA 
5. F-56 DNA 
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Figure 63 An autoradiogram of Southern blot hybridized with synthetic end labelled oligonucle-
otide. 4 ng of/! falciparum DNA from the clone F-56 and pyrimethamine selected lines digested 
with Hind III, size fractionated electroohoreticallv and Southern transferred on to a nylon mem-
brane. 
Lanel. PS-5 DNA 
2. PS-4DNA 
3. PS-3 DNA 
4. PS-2DNA 
5. F-56 DNA 
Figure 6.4 An autoradiogram of Southern blot hybridized with synthetic end labelled oligonucle-
otide. 4 ^g of P. falciparum DNA from the clone F-56 and pyrimethamine selected lines digested 
with Tag I, size fractionated electrophoretically and Southern transferred on to a nylon membrane. 
Lanel. F-56 DNA 
2. PS-1 DNA 
3. PS-2DNA 
4. PS-3DNA 
5. PS-4DNA 
6. PS-5 DNA 
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Figure 6.5 Sensitivity of primer pairs used for in vitro amplification of target DN A using PCR. The 
starting P. falcipaum target DNA (for amplification of a DHFR segment) ranged from 0.001 to 100 
ng-
Lanel.F-56DNA100ng 
Lane 2. F-56 DNA 50 ng 
Lane 3. F-56 DNA 10 ng 
Lane 4. F-56 DNA 1.0 ng 
Lane 5. F-56 DNA 0.1 ng 
Lane 6. F-56 DNA 0.01 ng 
Une 6. F-56 DNA 0.001 ng 
Figure 6.6 Amplification of target DNA obtained from pyrimethamine sensitive clone and py-
rimethamine selected P. falciparum lines using sensitive primer (SP) and counter primer (CP). 
Lane 1. X DNA - control 
Lane 2. blank 
Lane 3. Amplification of F-56 DNA using counter primer (CP) and 
distant primer (DP)- control 
Lane 4. F-56 DNA 
Lane 5. PS-1 DNA 
Une 6. PS-2 DNA 
Une 7. PS-3 DNA 
Une 8. PS-4 DNA 
Une 9. PS-5 DNA 
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Figure 6.7 Amplification of target DNA obtained fi-om pyrimethamine resistant P. falciparum 
selected lines using mutation-specific pyrimethamine-resistant primer (DR-1) and counter primer 
(CP). 
Lane 1. >^  DNA - control 
Lane 2. blank 
Lane 3. Amplification of F-56 DNA using counter primer (CP) and 
distant primer (DP)- control 
Une4. F-56 DNA 
Lane 5. PS-1 DNA 
Une6 . PS-2 DNA 
Lane 7. PS-3 DNA 
Une8 . PS-4 DNA 
Lane 9. PS-5 DNA 
Figure 6.8 Diagnostic ability of sensitive primer (SP) and counter primer (CP) to amplify DNA 
only from pryrimethanie sensitive P. falciparum. 
Lane \. blank 
Lane 2. control-1 (F-56 DNA without Taq polymerase) 
Lane 3. X DNA - control, with X specific primer pair 
Une 4. F-56 DNA with SP and CP 
Une 5. F-56 DNA with DR-1 and CP 
Lane 6. F-56 DNA with DR-2 and CP 
Une 7. F-56 DNA with SP, DR-1 and CP 
Lane 8. F-56 DNA without primers, control 
Lane 9. No target DNA for amplification 
Lane 10. PS-5 DNA with SP and CP 
Lane 11. F-56 DNA with SP only 
Lane 12. F-56 DNA with CP only 
Lane 13. X DNA with SP and CP 
Lane 14. Human DNA with SP and CP 
I 2 3 4 5 6 7 8 9 
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